{
 "standard": "Dated record of government action relevant to practising physicians, 1 January 2026 through 16 August 2026, newest first. Each entry names its instrument, the body that acted, its action type, exactly one lifecycle state, the date, the primary source it was read at, and the date of that reading. Allegations are marked as allegations; proposals are marked as proposals.",
 "window": "1 January – 30 August 2026",
 "compiled": "2026-09-01",
 "approved": true,
 "approvalLine": "Reviewed and approved for publication by Kanwar Partap Singh Gill, MD — 17 August 2026",
 "records": [
  {
   "id": "medi-cal-eligibility-timeline-2026-2027",
   "date": "2026-10-01",
   "sort": "2026-10-01a",
   "jurisdiction": "California",
   "body": "Department of Health Care Services",
   "vertical": "medi-cal",
   "actionType": "ELIGIBILITY CHANGE",
   "lifecycle": "PROPOSED",
   "effectiveDate": "2027-01-01",
   "title": "Medi-Cal immigration-status reclassification and community-engagement requirements",
   "instrument": "Federal Medicaid changes as implemented in California; DHCS Medi-Cal Changes notice",
   "what": "From October 2026 the federal government changes how it classifies certain immigration statuses, affecting whether some adults keep federally funded full-scope Medi-Cal; those affected receive state-funded full-scope Medi-Cal through 30 June 2027. From 1 January 2027 community-engagement requirements begin for adults aged 19 to 64 covered through ACA expansion: 80 hours a month of work, job training, volunteering or community service, at least half-time school, a qualifying mix, or earnings of at least $580 a month. Counties notify affected members and determine exemptions. Members enrolled in full-scope Medi-Cal before 1 January 2026 keep coverage regardless of status while otherwise eligible.",
   "effect": "The October change moves a funding source rather than ending coverage, and saying so accurately matters more than any other patient communication in this ledger — fear of losing coverage causes disengagement before any rule reaches the patient. The January requirement is administered by notice, so the people who lose coverage will predominantly be people who were eligible and did not receive, understand or return a letter. Keeping contact information current is the intervention.",
   "limits": "Children under 19, pregnant members through one year postpartum, and foster or former foster youth under 26 remain eligible to apply for full-scope Medi-Cal regardless of immigration status. Federal implementation of community-engagement requirements is being litigated; a requirement enjoined is not a requirement in force. Nothing here is an eligibility determination for any individual.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "DHCS — Medi-Cal Changes",
     "url": "https://www.dhcs.ca.gov/medi-cal/updates/medi-cal-changes/"
    },
    {
     "label": "DHCS — Immigration Status and Changes to Medi-Cal Eligibility",
     "url": "https://www.dhcs.ca.gov/immigration-status-and-changes-to-medi-cal-eligibility/"
    }
   ],
   "related": [
    "/policy/immigrant-eligibility-rules-and-chilling-effects-on-care/",
    "/policy/medi-cal-in-plain-language/",
    "/policy/childrens-coverage-continuity/",
    "/policy/language-access-healthcare-infrastructure/"
   ]
  },
  {
   "id": "ab1956-signed-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28z",
   "jurisdiction": "California",
   "body": "Governor of California",
   "actionType": "ENACTMENT",
   "lifecycle": "ENACTED",
   "title": "AB 1956 signed: boys and young men named a focus population for the Office of Suicide Prevention",
   "instrument": "Assembly Bill 1956 (Valencia, 2025–2026 Reg. Sess.), approved by the Governor 28 August 2026; amends Health and Safety Code § 131300",
   "what": "The bill authorises the Office of Suicide Prevention, in activities focused on youth, to pay special attention to boys, and adds young men to the statutory list of highest-risk groups on which the office may focus. It requires the office, on or before 1 July 2028, to report to the Legislature on strategies for implementing those activities. The Governor's announcement places the signature in the line of a July 2025 executive order directing a coordinated state response to the position of boys and men.",
   "effect": "This is the first California statute to name boys and men as a suicide-prevention focus population. For a family physician the practical consequence is upstream: state prevention material, outreach design and data reporting will increasingly be organised around a demographic that presents late and asks for help least.",
   "limits": "The statute is permissive — the office may focus on these groups. It creates no clinical duty, no standard of care, no screening mandate and no appropriation. The chapter number and the operative date are not stated here because the chaptered text has not been read.",
   "desks": [
    "weekly",
    "policy"
   ],
   "verifiedOn": "2026-08-30",
   "sources": [
    {
     "label": "Governor of California — signing announcement, 28 August 2026",
     "url": "https://www.gov.ca.gov/2026/08/28/governor-newsom-signs-bipartisan-measure-to-strengthen-suicide-prevention-efforts-for-boys-young-men/"
    },
    {
     "label": "LegInfo — AB 1956 bill text",
     "url": "https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202520260AB1956"
    }
   ],
   "related": [
    "/patient-education/mental-health-and-primary-care/",
    "/patient-education/depression-screening-what-to-expect/",
    "/patient-education/mens-preventive-care-essential-health-screenings/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "dea-earley-dds-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28y",
   "jurisdiction": "United States",
   "body": "DEA",
   "actionType": "FINAL ADMINISTRATIVE DECISION",
   "lifecycle": "FINAL — EFFECTIVE 28 SEPTEMBER 2026",
   "title": "DEA revokes a dentist's registration for want of state authority — effective 28 September",
   "instrument": "Thomas Earley, D.D.S.; Decision and Order, 91 Fed. Reg. 55624 (28 August 2026) (FR Doc. 2026-17592); Order to Show Cause issued 7 April 2026; 21 U.S.C. §§ 824(a), 824(a)(3), 823(g)(1)",
   "what": "DEA issued an Order to Show Cause on 7 April 2026 proposing revocation of Certificate of Registration No. AE2384636 on the ground that the registrant was without authority to prescribe, administer, dispense or otherwise handle controlled substances in Ohio, the state of registration. The Agency held that a person must be a licensed health professional authorised to prescribe in Ohio to handle controlled substances there, revoked the registration under § 824(a), and denied any pending application to renew or modify it and any other pending application for additional registration in Ohio. The order is effective 28 September 2026.",
   "effect": "State licensure is the foundation of a federal registration, not a parallel credential. Lose the state authority and the DEA registration follows, without any separate finding about prescribing conduct. Any physician or dentist whose state licence lapses, is surrendered or is restricted should assume the federal registration is in play.",
   "limits": "An administrative registration decision. It is not a criminal conviction, not a civil judgment, and not a finding that any particular prescription was improper.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-30",
   "sources": [
    {
     "label": "Federal Register — Thomas Earley, D.D.S.; Decision and Order (28 Aug 2026)",
     "url": "https://www.federalregister.gov/documents/2026/08/28/2026-17592/thomas-earley-dds-decision-and-order"
    },
    {
     "label": "GovInfo — 91 FR 55624 (PDF)",
     "url": "https://www.govinfo.gov/content/pkg/FR-2026-08-28/pdf/2026-17592.pdf"
    }
   ],
   "related": [
    "/policy/controlled-substance-prescribing-and-registration/",
    "/policy/licensure-discipline-and-federal-consequences/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "dea-atlantic-treatment-center-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28x",
   "jurisdiction": "United States",
   "body": "DEA",
   "actionType": "FINAL ADMINISTRATIVE DECISION",
   "lifecycle": "FINAL",
   "title": "DEA: immediate suspension in December, revocation decision published in August — Atlantic Treatment Center",
   "instrument": "Atlantic Treatment Center, LLC; Decision and Order, 91 Fed. Reg. 55620 (28 August 2026) (FR Doc. 2026-17594); Order to Show Cause and Immediate Suspension of Registration issued 17 December 2025; 21 U.S.C. § 824(d)",
   "what": "DEA issued an Order to Show Cause and Immediate Suspension of Registration to the Pompano Beach, Florida registrant on 17 December 2025, suspending registration No. RA0645400 under § 824(d) on the allegation that continued registration was an imminent danger to the public health or safety, and proposing revocation. In the published decision the Agency found that lack of state authority to practise pharmacy in Florida is an additional, independent basis for revocation.",
   "effect": "Two distinct mechanisms sit in one matter. An immediate suspension is an interim measure available before any hearing; the independent state-authority ground is what makes the outcome nearly automatic once a state licence is gone. Reading only the headline collapses eight months of process into a single event.",
   "limits": "An administrative decision on a registration. Not a criminal proceeding and not a judicial finding of harm to any patient.",
   "desks": [
    "enforcement"
   ],
   "verifiedOn": "2026-08-30",
   "sources": [
    {
     "label": "Federal Register — Atlantic Treatment Center, LLC; Decision and Order (28 Aug 2026)",
     "url": "https://www.federalregister.gov/documents/2026/08/28/2026-17594/atlantic-treatment-center-llc-decision-and-order"
    },
    {
     "label": "GovInfo — 91 FR 55620 (PDF)",
     "url": "https://www.govinfo.gov/content/pkg/FR-2026-08-28/pdf/2026-17594.pdf"
    }
   ],
   "related": [
    "/policy/controlled-substance-prescribing-and-registration/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "dea-kump-md-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28w",
   "jurisdiction": "United States",
   "body": "DEA",
   "actionType": "FINAL ADMINISTRATIVE DECISION",
   "lifecycle": "FINAL",
   "title": "DEA publishes a physician registration decision opened by immediate suspension in December 2025",
   "instrument": "Leila Kump, M.D.; Decision and Order, 91 Fed. Reg. 55615 et seq. (28 August 2026) (FR Doc. 2026-17555); Order to Show Cause and Immediate Suspension of Registration issued 10 December 2025; 21 U.S.C. § 824(d)",
   "what": "DEA issued an Order to Show Cause and Immediate Suspension of Registration to the Great Falls, Virginia registrant on 10 December 2025, suspending registration No. FK6611013 under § 824(d) on the allegation that continued registration was an imminent danger to the public health or safety, and proposing revocation. The Decision and Order was published in the Federal Register of 28 August 2026.",
   "effect": "Three registration decisions were published on one day, which is what a normal week of DEA adjudication looks like. The visible enforcement news cycle is a small fraction of the administrative record that actually governs a prescriber's federal authority.",
   "limits": "The ordered disposition and its effective date are not stated here: only the opening allegations and the publication of the decision were read. Not a criminal proceeding.",
   "desks": [
    "enforcement"
   ],
   "verifiedOn": "2026-08-30",
   "verifyBeforePublication": [
    "Ordered disposition and effective date from the full text of FR Doc. 2026-17555"
   ],
   "sources": [
    {
     "label": "GovInfo — 91 FR 55615 (PDF), Federal Register of 28 August 2026",
     "url": "https://www.govinfo.gov/content/pkg/FR-2026-08-28/pdf/2026-17589.pdf"
    }
   ],
   "related": [
    "/policy/controlled-substance-prescribing-and-registration/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "cms-lab-program-integrity-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28v",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROGRAM-INTEGRITY CAMPAIGN",
   "lifecycle": "CURRENT",
   "title": "CMS says its actions stopped more than $1.6 billion in potentially improper Medicare laboratory payments",
   "instrument": "CMS newsroom announcement, 28 August 2026 — laboratory program-integrity actions including provider revocations",
   "what": "CMS states that its enforcement actions have stopped more than $1.6 billion in potentially improper Medicare laboratory payments, with 157 laboratory providers revoked, and describes a set of mechanisms spanning payment suspension, overpayment recoupment and law-enforcement referral.",
   "effect": "Medicare fraud enforcement is not one act. Revocation, suspension, overpayment recovery, claim denial, referral, civil settlement and criminal prosecution are seven different legal events with different burdens and different consequences, and a $1.6 billion headline is a sum across several of them.",
   "limits": "The agency headline uses the word fraudulent; the body of the release says potentially improper. These are administrative actions, not 157 criminal convictions, and not one judicial fraud adjudication. Component figures are not stated here pending CMS's own breakdown.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "CMS newsroom",
     "url": "https://www.cms.gov/about-cms/contact/newsroom"
    }
   ],
   "related": [
    "/policy/laboratory-governance-and-payment-integrity/",
    "/policy/medicare-program-integrity/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "fda-mimrylo-rusfertide-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28u",
   "jurisdiction": "United States",
   "body": "FDA",
   "actionType": "MARKETING AUTHORISATION",
   "lifecycle": "APPROVED",
   "title": "FDA approves Mimrylo (rusfertide) for polycythemia vera — the first approved treatment designed around hepcidin mimicry",
   "instrument": "FDA approval, 28 August 2026 — rusfertide, for adults with polycythemia vera not adequately controlled on existing therapy",
   "what": "In VERIFY, 76.9 per cent of treated patients required no phlebotomy in weeks 20–32, against 32.9 per cent on placebo.",
   "effect": "A mechanism borrowed from iron regulation displaces a procedure. Phlebotomy avoidance is a patient-experience endpoint that also carries real clinical meaning.",
   "limits": "Approved for an inadequately controlled population, not as first-line therapy. Not an accelerated approval.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "FDA — first drug of its kind for polycythemia vera",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
    }
   ],
   "related": [
    "/policy/rare-disease-drug-development/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "hhs-ocr-five-medical-schools-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28t",
   "jurisdiction": "United States",
   "body": "HHS · Office for Civil Rights",
   "actionType": "COMPLIANCE REVIEW OPENED",
   "lifecycle": "UNDER REVIEW — NO MERITS DETERMINATION",
   "title": "HHS OCR opens compliance reviews of five medical schools under Title VI and ACA § 1557",
   "instrument": "HHS Office for Civil Rights announcement, 28 August 2026 — compliance reviews under Title VI and Section 1557 of the Affordable Care Act",
   "what": "OCR opened compliance reviews of five medical schools to determine whether their practices violate federal nondiscrimination law, stating expressly that it has reached no conclusions on the merits.",
   "effect": "Opening a review is the first stage of a five-stage sequence and establishes nothing about the institutions reviewed. Read alongside the DOJ finding of the previous day, the pair is a clean illustration of two different legal states arriving in the same news cycle.",
   "limits": "No merits determination exists. The named schools are not published here — the announcement was read, the school-by-school detail was not.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "verifyBeforePublication": [
    "Names of the five schools from the announcement or docket"
   ],
   "sources": [
    {
     "label": "HHS OCR — compliance reviews of five medical schools",
     "url": "https://www.hhs.gov/press-room/hhs-office-civil-rights-launches-compliance-reviews-five-medical-schools-potential-title-vi-section-1557-violations.html"
    }
   ],
   "related": [
    "/policy/medical-education-and-civil-rights-enforcement/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "bundibugyo-two-state-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28s",
   "jurisdiction": "Global",
   "body": "WHO · Africa CDC · ECDC",
   "actionType": "OUTBREAK STATE CHANGE",
   "lifecycle": "PHEIC CONTINUES — DRC ACTIVE · UGANDA DECLARED OVER",
   "title": "Bundibugyo Ebola: the DRC outbreak expands while Uganda's is declared over",
   "instrument": "WHO IHR Emergency Committee assessment 28 August 2026; joint WHO AFRO / Africa CDC release dated 27 August 2026 declaring the Uganda outbreak over; DRC ministry figures relayed by ECDC, updated 28 August 2026",
   "what": "The outbreak has expanded to 60 of 151 health zones across six DRC provinces, with 5,794 confirmed cases and 2,786 deaths through 26 August 2026. WHO and Africa CDC announced the end of Uganda's outbreak in a joint release dated 27 August. DRC launched a frontline-worker Ervebo campaign in Kisangani on 27 August.",
   "effect": "One pathogen, two opposite national states, one continuing international emergency. A single active/closed flag across both countries would be false in both directions.",
   "limits": "A PHEIC is not a pandemic. Ervebo's protection against Bundibugyo virus has not been established; its use in a frontline campaign is not evidence of efficacy against this species.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "ECDC — Ebola outbreak, Democratic Republic of the Congo and Uganda",
     "url": "https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda"
    },
    {
     "label": "World Health Organization",
     "url": "https://www.who.int/"
    }
   ],
   "related": [
    "/policy/pheic-declarations-and-national-powers/",
    "/policy/quarantine-and-isolation/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "walmart-csa-settlement-2026",
   "date": "2026-08-28",
   "sort": "2026-08-28r",
   "jurisdiction": "United States",
   "body": "DOJ · DEA",
   "actionType": "CIVIL SETTLEMENT — CSA",
   "lifecycle": "SETTLED — NO LIABILITY DETERMINED",
   "title": "Walmart agrees to a $50 million settlement over allegations its pharmacies filled invalid controlled-substance prescriptions",
   "instrument": "Controlled Substances Act civil settlement announced 28 August 2026, with a memorandum of agreement with DEA governing future dispensing; alleged conduct from 2013",
   "what": "DOJ and DEA announced a $50 million settlement resolving allegations that Walmart pharmacies filled thousands of invalid controlled-substance prescriptions since 2013, together with a forward-looking DEA memorandum of agreement on dispensing practice.",
   "effect": "Two obligations sit in one announcement and should never be merged: money paid to resolve historic allegations, and prospective compliance duties that bind future conduct. The second is what actually changes a pharmacy counter.",
   "limits": "No admission of liability; the resolved claims are allegations.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "DOJ — Walmart agrees to pay $50 million",
     "url": "https://www.justice.gov/opa/pr/walmart-agrees-pay-50-million-illegally-filling-unlawful-opioid-prescriptions"
    }
   ],
   "related": [
    "/policy/pharmacy-compliance-and-controlled-substances/",
    "/policy/opioid-policy/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "villages-health-fca-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27z",
   "jurisdiction": "United States",
   "body": "DOJ",
   "actionType": "CIVIL SETTLEMENT — FCA",
   "lifecycle": "SETTLED — NO LIABILITY DETERMINED",
   "title": "The Villages Health System agrees to a $541.5 million False Claims Act settlement over self-disclosed Medicare Advantage coding allegations",
   "instrument": "False Claims Act settlement agreement, announced by the Department of Justice 27 August 2026; conduct period 2020–2024",
   "what": "The Villages Health System agreed to pay $541.5 million to resolve allegations that it submitted unsupported diagnosis codes for Medicare Advantage risk adjustment between 2020 and 2024. The conduct was self-disclosed; DOJ credited the disclosure and cooperation in the resolution.",
   "effect": "Risk-adjustment coding is where Medicare Advantage payment is actually set, and a self-disclosure of this size changes the compliance calculus for every group that codes for a plan. The lesson is about the disclosure decision, not the dollar figure.",
   "limits": "The claims resolved are allegations only. There has been no determination of liability, and a settlement is not an admission.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "DOJ — Villages Health System LLC agrees to $541.5M settlement",
     "url": "https://www.justice.gov/opa/pr/villages-health-system-llc-agrees-5415m-settlement-resolve-false-claims-act-allegations"
    }
   ],
   "related": [
    "/policy/medicare-advantage-risk-coding-integrity/",
    "/policy/false-claims-act-and-physicians/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "fda-lisraya-brepocitinib-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27y",
   "jurisdiction": "United States",
   "body": "FDA",
   "actionType": "MARKETING AUTHORISATION",
   "lifecycle": "APPROVED",
   "title": "FDA approves Lisraya (brepocitinib), the first oral therapy indicated for adult dermatomyositis",
   "instrument": "FDA approval, 27 August 2026 — brepocitinib 30 mg once daily",
   "what": "In a 241-patient phase 3 trial the Total Improvement Score was 46.5 against 31.2 on placebo at week 52.",
   "effect": "A rare autoimmune disease with no approved oral option acquires one; the interesting policy question is how a composite improvement score becomes a labelled endpoint.",
   "limits": "An approval for a stated indication in adults. Not an accelerated approval.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "FDA — first oral drug indicated to treat dermatomyositis in adults",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults"
    }
   ],
   "related": [
    "/policy/rare-disease-drug-development/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "doj-gwu-title-vi-finding-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27x",
   "jurisdiction": "United States",
   "body": "DOJ · Civil Rights Division",
   "actionType": "AGENCY FINDING",
   "lifecycle": "CONTESTED — NO COURT JUDGMENT",
   "title": "DOJ finds a medical school intentionally discriminated by race in admissions — an agency finding, not a judgment",
   "instrument": "Department of Justice Civil Rights Division finding under Title VI of the Civil Rights Act, announced 27 August 2026; admissions cycles 2024–2025",
   "what": "DOJ announced its finding that George Washington University's medical school intentionally discriminated on the basis of race in its 2024–2025 admissions, citing Title VI and Students for Fair Admissions. DOJ states that settlement negotiations follow and that suit may follow if they fail. The university disputes the conclusions.",
   "effect": "REVIEW → AGENCY FINDING → SETTLEMENT OR LITIGATION → COURT JUDGMENT → APPEAL. These stages are not interchangeable, and only the fourth binds anyone.",
   "limits": "An executive-branch determination, contested by the recipient. Not a court judgment and not a finding of liability.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "DOJ — finding regarding George Washington University medical school",
     "url": "https://www.justice.gov/opa/pr/justice-department-finds-george-washington-university-medical-school-discriminates-based"
    }
   ],
   "related": [
    "/policy/medical-education-and-civil-rights-enforcement/",
    "/policy/complaint-is-not-finding/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "azul-vision-hipaa-roa-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27w",
   "jurisdiction": "United States · California provider",
   "body": "HHS · Office for Civil Rights",
   "actionType": "AGENCY INVESTIGATIVE DETERMINATION → SETTLEMENT",
   "lifecycle": "SETTLED — NO JUDICIAL ADJUDICATION",
   "title": "OCR's 55th Right of Access action: a California eye-care group settles for $50,000 after a two-year records delay",
   "instrument": "HIPAA Right of Access settlement and two-year corrective action plan, announced 27 August 2026; resolution agreement signed August 2026",
   "what": "Azul Vision, operating 31 California eye-care clinics, agreed to pay $50,000 and to a two-year corrective action plan after a January 2023 records request went unfulfilled until January 2025. OCR states that its investigation determined the practice failed to provide timely access to protected health information within 30 days, and that the matter resolved as a potential Privacy Rule violation.",
   "effect": "The precise state is neither 'no finding' nor 'a HIPAA violation was found by a court'. It is an agency investigative determination resolved by settlement — a category the enforcement taxonomy needs in its own right.",
   "limits": "A settlement of a potential violation. No judicial adjudication and no admission.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "HHS OCR — settlement with Azul Vision",
     "url": "https://www.hhs.gov/press-room/hhs-ocr-settles-hipaa-investigation-with-azul-vision.html"
    }
   ],
   "related": [
    "/patient-education/understanding-medical-privacy-rights/",
    "/policy/hipaa-right-of-access/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "title-x-23-state-suit-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27v",
   "jurisdiction": "United States",
   "body": "State attorneys general · D. Md.",
   "actionType": "LITIGATION — COMPLAINT FILED",
   "lifecycle": "COMPLAINT FILED — NO COURT HOLDING",
   "title": "Twenty-three states including California sue HHS over new Title X funding conditions",
   "instrument": "Complaint filed in the United States District Court for the District of Maryland, 27 August 2026",
   "what": "The states ask the court to declare the new Title X funding conditions unlawful and to block their enforcement.",
   "effect": "Grant conditions are becoming the operative instrument of federal health policy, and the courtroom is where their limits are being set.",
   "limits": "A filed complaint. The characterisations are the plaintiffs' claims; no merits ruling exists. The docket number has not been read and is not stated. This record is kept in the litigation layer, not the enforcement ledger.",
   "desks": [
    "weekly",
    "litigation"
   ],
   "verifiedOn": "2026-08-29",
   "verifyBeforePublication": [
    "Docket number"
   ],
   "sources": [
    {
     "label": "California Attorney General — lawsuit challenging Title X conditions",
     "url": "https://oag.ca.gov/news/press-releases/attorney-general-bonta-files-lawsuit-challenging-trump-administration%E2%80%99s-1"
    }
   ],
   "related": [
    "/policy/federal-grant-conditions-and-clinical-practice/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "fda-screwworm-eua-cluster-2026",
   "date": "2026-08-27",
   "sort": "2026-08-27u",
   "jurisdiction": "United States",
   "body": "FDA · Center for Veterinary Medicine",
   "actionType": "EMERGENCY USE AUTHORISATION",
   "lifecycle": "AUTHORISED",
   "title": "A third New World screwworm veterinary emergency authorisation in three weeks",
   "instrument": "FDA veterinary emergency use authorisation, 27 August 2026 — ivermectin injection for prevention of New World screwworm in cattle under specified conditions",
   "what": "The authorisation sits in a cluster of animal-drug emergency actions addressing New World screwworm.",
   "effect": "The individual authorisation matters less than the pattern: veterinary emergency powers are being used at scale as an agricultural-security instrument, with zoonotic and public-health relevance downstream.",
   "limits": "An emergency authorisation for animal use under stated conditions. It is not an approval, and it establishes nothing about human health.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "FDA — press announcements index, read at fda.gov",
     "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements"
    }
   ],
   "related": [
    "/policy/one-health-and-zoonotic-surveillance/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "fda-rasonque-daraxonrasib-2026",
   "date": "2026-08-26",
   "sort": "2026-08-26z",
   "jurisdiction": "United States",
   "body": "FDA",
   "actionType": "MARKETING AUTHORISATION",
   "lifecycle": "APPROVED",
   "title": "FDA approves Rasonque (daraxonrasib), the first RAS-targeted therapy for metastatic pancreatic adenocarcinoma",
   "instrument": "FDA approval, 26 August 2026 — daraxonrasib, 300 mg once daily; reviewed under Project Orbis",
   "what": "Median overall survival was 13.2 months against 6.7 months for chemotherapy in RASolute 302.",
   "effect": "A first-in-class approval in a cancer where the survival curve has barely moved in twenty years.",
   "limits": "A standard approval on survival data — not an accelerated approval. Priority Review, Breakthrough or Orphan designation does not make an approval accelerated.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "FDA — daraxonrasib approval notice",
     "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma"
    }
   ],
   "related": [
    "/policy/surrogate-endpoints-and-approval-pathways/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "dermtech-fca-bankruptcy-2026",
   "date": "2026-08-26",
   "sort": "2026-08-26y",
   "jurisdiction": "United States",
   "body": "DOJ",
   "actionType": "CIVIL SETTLEMENT — FCA",
   "lifecycle": "SETTLED — NO LIABILITY DETERMINED",
   "title": "DermTech settles allegations it billed Medicare for skin-cancer tests with known quality-control failures",
   "instrument": "False Claims Act settlement announced 26 August 2026, effected through an allowed unsecured Chapter 11 claim of $5,038,011",
   "what": "DermTech, now liquidating in Chapter 11, settled allegations that it billed Medicare for melanoma tests despite known quality-control failures. The United States receives an allowed unsecured bankruptcy claim of $5,038,011.",
   "effect": "This is where laboratory quality stops being only a CLIA and patient-safety question and becomes a payment-integrity question: a test that cannot reliably support a clinical decision cannot reliably support a claim.",
   "limits": "Allegations resolved by settlement, not adjudicated. Actual recovery depends on the bankruptcy estate.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "DOJ — DermTech Inc. to pay $5M to resolve allegations",
     "url": "https://www.justice.gov/opa/pr/dermtech-inc-pay-5m-resolve-allegations-it-submitted-false-claims-medicare-unreliable-skin"
    }
   ],
   "related": [
    "/policy/laboratory-governance-and-payment-integrity/",
    "/policy/evidence-quality-in-diagnostics/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "nica-v-kennedy-5th-cir-2026",
   "date": "2026-08-26",
   "sort": "2026-08-26x",
   "jurisdiction": "United States",
   "body": "U.S. Court of Appeals for the Fifth Circuit",
   "actionType": "LITIGATION — APPELLATE DECISION",
   "lifecycle": "APPELLATE DECISION — NOT FINAL",
   "title": "Fifth Circuit affirms the government's judgment upholding the Medicare Drug Price Negotiation Program",
   "instrument": "National Infusion Center Association v. Kennedy, No. 25-50661 (5th Cir. 26 August 2026) (Southwick, J.) — slip opinion",
   "what": "The panel affirmed summary judgment for the government. It rejected the nondelegation challenge on an intelligible-principle reading, held the § 5000D excise not a punitive fine for Excessive Fines Clause purposes notwithstanding its Anti-Injunction Act analysis, and found no protected property or liberty interest, Medicare participation being voluntary.",
   "effect": "The constitutional attack on the negotiation program has now failed at the appellate level on every theory presented. What remains is as-applied litigation about particular prices and particular manufacturers.",
   "limits": "Read from the slip opinion. Rehearing and certiorari remain available; the decision is not final. A ruling on facial challenges is not a ruling that every application is lawful.",
   "desks": [
    "weekly",
    "litigation"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "Slip opinion — National Infusion Center Association v. Kennedy, No. 25-50661",
     "url": "https://storage.courtlistener.com/pdf/2026/08/26/natl_infusion_center_v._kennedy.pdf"
    }
   ],
   "related": [
    "/policy/medicare-drug-price-negotiation/",
    "/policy/administrative-law-after-loper-bright/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "ftc-ascension-amsurg-final-order-2026",
   "date": "2026-08-25",
   "sort": "2026-08-25z",
   "jurisdiction": "United States",
   "body": "FTC",
   "actionType": "FINAL CONSENT ORDER",
   "lifecycle": "FINAL",
   "title": "FTC finalises the Ascension–AmSurg consent order: seven surgery centres divested, ten years of prior notice",
   "instrument": "In the Matter of Ascension Health Alliance / AmSurg LLC, FTC Docket No. C-4832 — final Decision and Order approved 25 August 2026 following the public comment period; Commission vote 2–0",
   "what": "The final order requires Ascension to divest seven AmSurg ambulatory surgery centres across the Nashville, Panama City, Tulsa, Waco and Wichita metropolitan areas — six to SC Affiliates and the Panama City centre to a physician group that already held a minority stake. It requires transition assistance, protection of confidential information, maintenance of the divested assets until transfer, non-interference with employment relationships, and a monitor to oversee compliance. For ten years Ascension must give the Commission prior notice of any acquisition of an ambulatory surgical centre in the metropolitan areas around the divested facilities.",
   "effect": "The Commission did not stop the transaction; it priced it. The interesting term is the ten-year prior-notice obligation, which converts a one-off merger review into a decade of supervised expansion in named markets — the mechanism by which antitrust reaches outpatient consolidation without litigating each deal.",
   "limits": "A consent order settles allegations. It is not a judicial finding that the acquisition violated the antitrust laws, and no admission is implied. The complaint's competition allegations remain allegations.",
   "desks": [
    "enforcement",
    "policy"
   ],
   "verifiedOn": "2026-08-30",
   "sources": [
    {
     "label": "FTC — final consent order in Ascension Health–AmSurg deal (25 Aug 2026)",
     "url": "https://www.ftc.gov/news-events/news/press-releases/2026/08/ftc-approves-final-consent-order-ascension-health-amsurg-deal"
    }
   ],
   "related": [
    "/policy/health-system-consolidation/",
    "/policy/private-equity-in-medicine/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "fda-ketone-glucose-wearable-2026",
   "date": "2026-08-25",
   "sort": "2026-08-25y",
   "jurisdiction": "United States",
   "body": "FDA",
   "actionType": "DEVICE AUTHORISATION",
   "lifecycle": "AUTHORISED",
   "title": "FDA authorises the first wearable that continuously monitors both ketones and glucose",
   "instrument": "FDA marketing authorisation, 25 August 2026 — continuous dual glucose and ketone monitoring system",
   "what": "FDA describes the device as the first in the United States to monitor ketones continuously, and the first anywhere to monitor glucose and ketones together in one wearable, authorised for people aged two years and older with diabetes.",
   "effect": "Continuous ketone data changes the home management of diabetic ketoacidosis risk from an episodic test to a monitored trend — and moves another clinical judgement into a consumer device.",
   "limits": "An authorisation for a stated intended use. Not a clearance of any particular treatment algorithm, and not evidence that continuous ketone monitoring improves outcomes.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "FDA — news and events index, read at fda.gov",
     "url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements"
    }
   ],
   "related": [
    "/patient-education/home-glucose-monitoring/",
    "/policy/remote-patient-monitoring-and-the-evidence-gap/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "russia-orders-696n-434n-540n-2026",
   "date": "2026-08-24",
   "sort": "2026-08-24z",
   "jurisdiction": "Russia",
   "body": "Ministry of Health",
   "actionType": "REGULATION",
   "lifecycle": "PUBLISHED — EFFECTIVE ON STATED DATES",
   "title": "Three Russian health-ministry orders verified by official publication number — including radiology rules that expressly permit registered AI devices",
   "instrument": "Order 696н (adult dental-care procedure, effective 1 October 2026; publication card 0001202608240014, registration № 87933); Order 434н (position nomenclature, effective 1 September 2026; 0001202605300020); Order 540н (radiology rules expressly permitting registered AI-based medical devices, effective 1 September 2026)",
   "what": "Each instrument is recorded by its official publication object rather than by any summary of it.",
   "effect": "A national radiology procedure that names registered AI devices as permitted equipment is a different regulatory instrument from guidance about AI, and it is the kind of change that is invisible in English-language coverage.",
   "limits": "Recorded by publication number. A reported paediatric-oncology postponement is not published: its circulating order number collides with a 2025 obstetrics instrument. No Russian rule becomes binding law here on the strength of an explainer, a search result or a translation.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "pravo.gov.ru — official publication card 0001202608240014",
     "url": "http://publication.pravo.gov.ru/document/0001202608240014"
    }
   ],
   "related": [
    "/policy/global-ai-standards/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "ab2575-ordered-third-reading-2026",
   "date": "2026-08-24",
   "sort": "2026-08-24y",
   "jurisdiction": "California",
   "body": "Legislature",
   "actionType": "LEGISLATIVE ACTION",
   "lifecycle": "ACTIVE — THIRD READING PENDING",
   "title": "AB 2575 (health care AI, Ortega): ordered to Senate third reading after the Appropriations suspense vote",
   "instrument": "AB 2575 (2025–2026 Reg. Sess.): 13 August 2026 Senate Appropriations — do pass as amended (5–2) from the suspense file; 24 August read second time and ordered to third reading",
   "what": "The bill would require health facilities using clinical decision support software to make an inventory available to clinicians on request from 1 July 2027, and would bar an AI-tool defendant from asserting a clinician's non-adherence to the tool as a defence.",
   "effect": "Of the two same-captioned California AI bills, this is the one that reaches the clinician's own liability position.",
   "limits": "Two competing accounts of 28 August floor activity have been reported to this desk — one of a passage refusal with reconsideration granted, one of a further amendment that day. Neither was located in an official chamber history read here, and neither is published. This record does not state that the text was frozen on 21 August and does not state that the bill failed.",
   "desks": [
    "weekly",
    "policy"
   ],
   "verifiedOn": "2026-08-30",
   "verifyBeforePublication": [
    "Senate Daily Journal, 27–28 August 2026"
   ],
   "sources": [
    {
     "label": "LegiScan — AB 2575 action history",
     "url": "https://legiscan.com/CA/bill/AB2575/2025"
    }
   ],
   "related": [
    "/intelligence/medical-board-august-2026/",
    "/intelligence/california-legislature-2026/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "coopersurgical-inca-cpap-early-alert-2026",
   "date": "2026-08-24",
   "sort": "2026-08-24a",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "SAFETY ALERT",
   "lifecycle": "CURRENT",
   "title": "FDA Early Alert: CooperSurgical INCA neonatal nasal CPAP sets — loose cannula connection; do not use affected lots",
   "instrument": "FDA Early Alert — Ventilator Issue from CooperSurgical; customer letter 11 August 2026",
   "what": "Specific lots of the INCA Neonatal Nasal CPAP Complete Set and Replacement Set may exhibit a loose connection between the flexible tubing and the nasal cannula, which can cause loss of CPAP pressure, reduced treatment effectiveness and decreased oxygenation until the connection is restored. Instruction: do not use affected product; cease use and distribution and return to CooperSurgical; if the loose connection is recognized during use, replace the tubing or the CPAP device. No serious injuries or deaths reported as of 11 August.",
   "limits": "An Early Alert is FDA reviewing a potentially high-risk device issue — not a final recall classification and not a finding of harm.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-25",
   "sources": [
    {
     "label": "FDA — Early Alert: ventilator issue from CooperSurgical",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-ventilator-issue-coopersurgical"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/medical-device-recalls-how-the-system-works/"
   ],
   "record": "/weekly/#updates-0825"
  },
  {
   "id": "ca-end-of-session-dates-2026",
   "date": "2026-08-21",
   "sort": "2026-08-21z",
   "jurisdiction": "California",
   "body": "Legislature",
   "actionType": "FIXED DATE",
   "lifecycle": "CURRENT",
   "title": "California end-of-session mechanics: the four dates that decide every tracked bill",
   "instrument": "Published legislative calendar, 2025–2026 Regular Session",
   "what": "Floor amendments ordinarily closed 21 August; each house must pass bills by 31 August; the Governor acts on qualifying bills by 30 September; enactment by 2 October carries the ordinary 1 January 2027 effective date.",
   "effect": "These are engine dates, held once and read by every bill record, rather than four sentences repeated in twenty articles.",
   "limits": "A calendar rule generates expected transitions. It never overrides an observed, sourced chamber action, and a passed gubernatorial deadline never implies a signature or a veto.",
   "desks": [
    "weekly",
    "policy"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "California State Senate — legislative calendar",
     "url": "https://www.senate.ca.gov/calendar"
    }
   ],
   "related": [
    "/intelligence/california-legislature-2026/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "fda-ge-portrait-software-early-alert-2026",
   "date": "2026-08-21",
   "sort": "2026-08-21b",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "SAFETY ALERT",
   "lifecycle": "CURRENT",
   "title": "FDA Early Alert: GE HealthCare Portrait Core Services software can drop monitored patients during updates",
   "instrument": "FDA Early Alert — Portrait Core Services software issue from GE HealthCare",
   "what": "During the software-update process, monitored patients can be discharged or removed from the monitoring system, and alarm settings can revert to factory defaults. Mitigation: provide alternative monitoring during updates. Equipment not ordered out of use; no serious injuries or deaths reported as of the source record.",
   "limits": "An Early Alert is not a recall classification and not a finding of harm. The issue described is update-process behavior, not a cybersecurity intrusion.",
   "desks": [
    "weekly",
    "ai"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "FDA — medical device recalls and Early Alerts (Portrait Core Services, GE HealthCare)",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts"
    }
   ],
   "related": [
    "/policy/connected-device-cybersecurity-and-software-risk/",
    "/intelligence/ai-specialty-impact-atlas/"
   ],
   "record": "/weekly/2026-08-24/#fda-ge-portrait-software-early-alert-2026"
  },
  {
   "id": "medi-cal-rx-early-refill-2026",
   "date": "2026-08-21",
   "sort": "2026-08-21a",
   "jurisdiction": "California",
   "body": "Department of Health Care Services — Medi-Cal Rx",
   "actionType": "BENEFIT POLICY CHANGE",
   "lifecycle": "EFFECTIVE",
   "effectiveDate": "2026-08-21",
   "title": "Medi-Cal Rx early-refill thresholds change for members 21 and older",
   "instrument": "Medi-Cal Rx provider alert, Updates to the Early Refill Policy (July 2026)",
   "what": "From 21 August 2026 Medi-Cal Rx applies revised early-refill thresholds to members aged 21 and older. A refill is blocked where the member has not used at least 75 per cent of the previous fill of the same medication by name, strength and formulation — 90 per cent for opioids — or where cumulative early fills exceed a 20-day supply of that same medication across a 180-day period. Non-conforming claims deny with Reject Code 88, DUR Reject Error, reason-for-service code ER, overutilisation, and are subject to override limits. A vacation-supply override using submission clarification code 03 is available once per 365 days.",
   "effect": "This is a point-of-sale change, so the physician learns about it from a patient whose pharmacy has refused a refill, not from a notice. The 90-per-cent opioid threshold is stricter than the 75-per-cent general rule, which matters most for patients on stable chronic opioid therapy travelling or transitioning between facilities, and the once-per-year vacation override is a limited remedy that is consumed the first time it is used.",
   "limits": "The change alters refill timing thresholds and claim adjudication only. It does not change coverage, formulary status, quantity limits or prior-authorisation criteria for any drug, and it does not apply to members under 21.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "Medi-Cal Rx — Coming Soon: Updates to the Early Refill Policy (PDF)",
     "url": "https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/2026/07_A_Coming_Soon_Updates_Early_Refill_Policy.pdf"
    },
    {
     "label": "DHCS — Pharmacy benefits frequently asked questions",
     "url": "https://www.dhcs.ca.gov/providers-partners/pharmacy-benefits-division-and-vision-care-program/pharmacy-benefits-frequently-asked-questions/"
    }
   ],
   "related": [
    "/policy/medi-cal-dental-vision-pharmacy-and-medical-benefits/",
    "/policy/medi-cal-in-plain-language/",
    "/patient-education/medication-adherence-guide/",
    "/patient-education/safe-medication-storage-disposal/",
    "/patient-education/opioid-safety-overdose-recognition-naloxone/",
    "/patient-education/medication-safety-during-travel/"
   ],
   "events": [
    {
     "on": "2026-08-21",
     "state": "EFFECTIVE — OPERATIONAL",
     "note": "Effective date reached as scheduled; recorded 24 August 2026."
    }
   ]
  },
  {
   "id": "who-icg-ervebo-allocation-drc-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20f",
   "jurisdiction": "Global",
   "body": "WHO · Africa CDC · International Coordinating Group on Vaccine Provision",
   "actionType": "VACCINE ALLOCATION",
   "lifecycle": "CURRENT",
   "title": "70,000 Ervebo doses released to the DRC — 50,000 for frontline workers, 20,000 for a Phase 3 trial against Bundibugyo",
   "instrument": "WHO/Africa CDC joint release, 20 August 2026: ICG initial release of 70,000 Ervebo doses to the DRC government (ICG decision communicated Monday 17 August, on a DRC request made the prior week)",
   "what": "The allocation comprises 50,000 doses for frontline and health workers in line with current SAGE recommendations and 20,000 doses for a Phase 3 clinical trial to understand the vaccine’s impact on Bundibugyo virus. Ervebo is licensed for Ebola disease caused by Zaire ebolavirus; WHO states it is not known whether Ervebo is protective against Bundibugyo virus in humans — which is what the trial arm exists to test.",
   "limits": "An allocation is a supply decision, not an efficacy finding: no vaccine is licensed against Bundibugyo virus, and this record states no outbreak case figures — WHO’s dated epidemiological numbers belong to their own source documents.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "WHO — news release, 20 August 2026",
     "url": "https://www.who.int/news/item/20-08-2026-who-and-africa-cdc-welcome-the-allocation-of-ebola-vaccines-to-the-democratic-republic-of-the-congo"
    },
    {
     "label": "Africa CDC — joint release",
     "url": "https://africacdc.org/news-item/who-and-africa-cdc-welcome-the-allocation-of-ebola-vaccines-to-the-democratic-republic-of-the-congo/"
    }
   ],
   "related": [
    "/weekly/2026-08-19/#health-canada-bundibugyo-mrna-trial-2026"
   ],
   "record": "/weekly/#updates-0824"
  },
  {
   "id": "mhra-fingolimod-zentiva-class2-recall-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20e",
   "jurisdiction": "United Kingdom",
   "body": "MHRA",
   "actionType": "RECALL — CLASS 2 MEDICINES RECALL",
   "lifecycle": "CURRENT",
   "title": "Class 2 recall: one batch of Fingolimod Zentiva 0.5 mg capsules, for potential metal-particle contamination",
   "instrument": "Class 2 Medicines Recall EL(26)A/37, issued 20 August 2026: Zentiva Pharma UK Limited, Fingolimod Zentiva 0.5 mg Capsules, batch BN 4L01372H",
   "what": "One batch is recalled as a precautionary measure for a potential risk of metal-particle contamination identified in shelf-life testing. MHRA states the particles, if present, are small and pose a low risk to safety or efficacy; no reports of harm for the batch. Pharmacies: stop supplying, quarantine and return. Patients with the affected batch should contact their pharmacy and not stop fingolimod — a multiple-sclerosis disease-modifying therapy — without speaking to a healthcare professional.",
   "limits": "A precautionary batch recall is not a finding of patient harm and not an action against the medicine’s authorisation. Other fingolimod products and batches are unaffected on this record.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "GOV.UK — Class 2 Medicines Recall EL(26)A/37, 20 August 2026",
     "url": "https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zentiva-pharma-uk-limited-fingolimod-zentiva-0-dot-5-mg-capsules-el-26-a-slash-37"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "record": "/weekly/#updates-0824"
  },
  {
   "id": "doj-war-room-medicaid-transport-indictment-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20d",
   "jurisdiction": "United States",
   "body": "DOJ · U.S. Attorney's Office, S.D. New York",
   "actionType": "CRIMINAL CHARGES — INDICTMENT UNSEALED",
   "lifecycle": "ALLEGATION",
   "title": "“War Room” indictment: $12 million in alleged Medicaid transportation claims built on GPS-spoofed rides that never happened",
   "instrument": "Nine-count indictment unsealed 20 August 2026 (S.D.N.Y.): Louis Trejo, Kenneth Garner, Harold Stevenson, Erihk Belis — racketeering, violence in aid of racketeering, firearms, fraud, narcotics and money-laundering offenses",
   "what": "Per DOJ: 2023–2025, the defendants allegedly recruited Medicaid patients at Bronx and Manhattan methadone clinics, logged rides in driver ride-tracking apps without providing transportation, used a GPS-spoofing application to fabricate pickup and drop-off coordinates, paid patients recurring kickbacks in cash and drugs including fentanyl and heroin, and passed the fake data to collusive transportation companies that billed Medicaid at least $12 million. Three defendants arrested 20 August; one remained at large.",
   "limits": "An indictment is an allegation; every defendant is presumed innocent unless and until proven guilty. Nothing here is a finding about Medicaid transportation as a benefit.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "DOJ — USAO S.D.N.Y., 20 August 2026",
     "url": "https://www.justice.gov/usao-sdny/pr/four-members-war-room-charged-connection-12-million-medicaid-fraud-scheme"
    }
   ],
   "related": [
    "/enforcement/",
    "/policy/fraud-waste-and-abuse-the-enforcement-architecture/"
   ],
   "record": "/enforcement/#chron-2026"
  },
  {
   "id": "doj-richardson-telemedicine-sentencing-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20c",
   "jurisdiction": "United States",
   "body": "U.S. Attorney's Office, District of Massachusetts",
   "actionType": "CRIMINAL SENTENCING",
   "lifecycle": "ADJUDICATED",
   "title": "Former telemedicine-company owner sentenced to two years for $110 million Medicare DME scheme",
   "instrument": "Sentencing announced 20 August 2026: Steven Richardson (Expansion Media; Hybrid Management Group), two years in prison, two years supervised release; guilty plea April 2024 to one count of conspiracy to commit health care fraud",
   "what": "Per DOJ: March 2016–January 2023, per-order payments from telemarketers targeting Medicare beneficiaries; doctors and nurses recruited through medical staffing companies signed prepopulated DME orders, typically without any contact with the beneficiary; signed orders sold to DME suppliers who billed Medicare on false, kickback-tainted documentation.",
   "limits": "Adjudicated as to this defendant, by guilty plea. Establishes nothing about any other person or company, and is not a finding about telemedicine as a modality.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "DOJ — USAO District of Massachusetts, 20 August 2026",
     "url": "https://www.justice.gov/usao-ma/pr/former-owner-telemedicine-companies-sentenced-two-years-prison-110-million-medicare"
    }
   ],
   "related": [
    "/enforcement/",
    "/policy/fraud-waste-and-abuse-the-enforcement-architecture/"
   ],
   "record": "/weekly/2026-08-24/#doj-richardson-telemedicine-sentencing-2026"
  },
  {
   "id": "medline-breathing-circuit-early-alert-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20b",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "SAFETY ALERT",
   "lifecycle": "CURRENT",
   "title": "FDA Early Alert: Medline Hudson RCI neonatal/infant heated-wire breathing circuits — remove and destroy",
   "instrument": "FDA Early Alert — Breathing Circuit Issue from Medline; Medline recall initiated 13 July 2026, customer letters 13 and 27 July and 5 August",
   "what": "Sporadic failures at the heated-wire connector (pigtail) at the Neptune humidifier: discoloration, melting, smoke, burning odor or other localized thermal damage. Humidifier safety features cut power to heated wires on electrical abnormality; gas flow continues. Instruction: quarantine and destroy affected lots. Medline reports no known serious health consequences.",
   "limits": "Not, on the record read, a final FDA recall classification; no injury finding stated. The 0.011% occurrence rate is the manufacturer’s reported figure.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "FDA — Early Alert: breathing circuit issue, Medline",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-breathing-circuit-issue-medline"
    },
    {
     "label": "FDA — Medline company announcement (posted as a public service)",
     "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medline-industries-lp-issues-nationwide-recall-hudson-rci-neonatalinfant-heated-wire-breathing"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "record": "/weekly/2026-08-24/#medline-breathing-circuit-early-alert-2026"
  },
  {
   "id": "calrx-school-albuterol-initiative-2026",
   "date": "2026-08-20",
   "sort": "2026-08-20a",
   "jurisdiction": "California",
   "body": "Governor's Office · CalRx · CDPH",
   "actionType": "PROGRAM LAUNCH",
   "lifecycle": "CURRENT",
   "title": "CalRx School Albuterol Access Initiative announced: free emergency albuterol for ~10,000 TK–12 schools",
   "instrument": "School Albuterol Access Initiative, announced 20 August 2026; CalRx partnership with Amneal Pharmaceuticals under the CDPH statewide albuterol standing order; funded in the 2025–26 state budget",
   "what": "Public and charter TK–12 schools receive an annual emergency stock — two 90-mcg-per-actuation albuterol metered-dose inhalers and 25 single-use disposable spacers — at no cost for three years; private schools may purchase at $9.50 per inhaler and $93.75 per 25-pack of spacers. Product ships under the CDPH standing order rather than individual prescriptions; free training runs through the California School Nurses Organization.",
   "limits": "A standing order is a population-level authorization for emergency stock, not individual prescribing advice and not a change to any child’s treatment plan. Enrollment, shipment timing and uptake are implementation facts that follow the announcement.",
   "desks": [
    "weekly",
    "california"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "Governor of California — announcement, 20 August 2026",
     "url": "https://www.gov.ca.gov/2026/08/20/california-sends-free-life-saving-asthma-inhalers-to-all-schools/"
    },
    {
     "label": "CalRx — School Albuterol Access Initiative",
     "url": "https://calrx.ca.gov/albuterol"
    },
    {
     "label": "CDPH — standing orders",
     "url": "https://standingorders.cdph.ca.gov/"
    }
   ],
   "related": [
    "/patient-education/understanding-asthma-guide-to-managing-your-breath/",
    "/patient-education/air-quality-respiratory-health-fresno-central-vall/"
   ],
   "record": "/weekly/2026-08-24/#calrx-school-albuterol-initiative-2026"
  },
  {
   "id": "genglycos-gsdia-accelerated-approval-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19z",
   "jurisdiction": "United States",
   "body": "FDA · Center for Biologics Evaluation and Research",
   "actionType": "ACCELERATED APPROVAL",
   "lifecycle": "APPROVED",
   "title": "First therapy for glycogen storage disease type Ia: accelerated approval of Genglycos",
   "instrument": "Accelerated approval of Genglycos (pariglasgene brecaparvovec-opnr), Ultragenyx Pharmaceutical, announced 19 August 2026",
   "what": "Indicated to reduce daily cornstarch intake as an adjunct to nutritional management in patients 8 years and older with GSDIa; first approved treatment for the condition. RMAT and Fast Track designations; rare pediatric disease priority review voucher. Approval rests on a surrogate endpoint (cornstarch reduction); continued approval may be contingent on confirmatory trials.",
   "limits": "Accelerated approval is not verified clinical benefit. The approval does not state that the therapy prevents hypoglycemic events, extends life, or ends dietary management.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "FDA — press announcement, 19 August 2026",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia"
    }
   ],
   "related": [
    "/policy/accelerated-approval-and-confirmatory-trials/",
    "/patient-education/hypoglycemia-awareness/"
   ],
   "record": "/weekly/2026-08-24/#genglycos-gsdia-accelerated-approval-2026"
  },
  {
   "id": "fda-robotic-blood-draw-authorization-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19y",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "MARKETING AUTHORIZATION",
   "lifecycle": "CURRENT",
   "title": "FDA authorizes a first-of-its-kind robotic blood-draw device (recorded at index level)",
   "instrument": "CDRH announcements index entry: “FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device”",
   "what": "Recorded at the level read: the index entry and its title. Authorization pathway, device name, manufacturer, indications and limitations live in the underlying announcement and are not restated until read directly.",
   "limits": "An index entry establishes that the authorization was announced and its stated first-of-kind character — nothing about pathway, performance data or conditions of use.",
   "desks": [
    "weekly",
    "ai"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "FDA — CDRH news and updates index",
     "url": "https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-new-news-and-updates"
    }
   ],
   "related": [
    "/intelligence/ai-specialty-impact-atlas/"
   ],
   "record": "/weekly/2026-08-24/#fda-robotic-blood-draw-authorization-2026"
  },
  {
   "id": "fda-commissioner-nomination-overton-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19i",
   "jurisdiction": "United States",
   "body": "The White House",
   "actionType": "NOMINATION",
   "lifecycle": "PROPOSED",
   "title": "The President names a nominee to lead FDA; the Senate decides whether she takes office",
   "instrument": "Presidential announcement, 19 August 2026, on the President's Truth Social account: White House aide Heidi Overton named to lead the Food and Drug Administration, subject to Senate confirmation",
   "what": "The President announced the naming of White House aide Heidi Overton to lead FDA — the office previously held by Marty Makary, who left the agency in May 2026. The announcement was made on the President's Truth Social account on 19 August, as reported by RAPS Regulatory Focus; the nomination is subject to confirmation by the Senate.",
   "effect": "Nothing at the agency changes on an announcement: dockets, guidance, reviews and enforcement continue under existing leadership until the Senate acts. What the announcement fixes is the question the confirmation process will put on the public record — the nominee's positions on the agency's open files, from AI regulation to abbreviated approval pathways.",
   "limits": "An announced nomination confers no office. It becomes a formal nomination when transmitted to the Senate and takes effect only on confirmation. This record asserts nothing about the nominee's views or prospects, and no agency decision reads differently because of it.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "RAPS Regulatory Focus — Regulatory News, 19 August 2026 (report of the announcement)",
     "url": "https://www.raps.org/resource-library-search.html"
    }
   ],
   "related": [
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/accelerated-approval-and-confirmatory-trials/"
   ]
  },
  {
   "id": "oig-louisiana-parity-pa-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19c",
   "jurisdiction": "United States",
   "body": "HHS Office of Inspector General",
   "actionType": "AUDIT / OVERSIGHT FINDING",
   "lifecycle": "CURRENT",
   "title": "OIG’s third state prior-authorisation audit finds Louisiana’s MCO generally complied",
   "instrument": "HHS-OIG audit A-06-24-02000: Louisiana Healthcare Connections generally complied with federal and state process requirements when denying prior authorization requests",
   "what": "A third state joins the OIG’s Medicaid managed-care prior-authorisation audit series — and this one cuts the other way. Where the Kansas and New York audits found state oversight failures, OIG’s Louisiana audit found the managed-care organisation generally complied with federal and state process requirements when denying prior-authorisation requests. The report appears on OIG’s own index; the index page does not carry its issue date, which is therefore not restated here.",
   "effect": "The series now has a spread — two states with findings, one generally compliant — which is what makes it an audit program rather than an indictment. For physicians the operational meaning is unchanged: process compliance is what these audits test, not whether any individual denial was clinically right.",
   "limits": "An audit finding is not a fraud finding, and a generally-complied finding is not a clean bill for prior authorisation as a practice: it establishes that sampled denials followed required process. It says nothing about denial rates, clinical appropriateness, or any other state or plan.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "HHS-OIG — What’s New index (A-06-24-02000)",
     "url": "https://oig.hhs.gov/newsroom/whats-new/index.asp"
    },
    {
     "label": "HHS-OIG — managed care oversight strategy",
     "url": "https://oig.hhs.gov/reports/featured/managed-care/"
    }
   ],
   "related": [
    "/policy/prior-authorization-a-patient-and-physician-guide/",
    "/policy/cg-inspectors-general-and-gao-in-health-oversight/",
    "/policy/claim-denials-and-the-appeals-ladder/"
   ]
  },
  {
   "id": "pasatru-fop-approval-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19c",
   "jurisdiction": "United States",
   "body": "FDA · Center for Drug Evaluation and Research",
   "actionType": "APPROVAL",
   "lifecycle": "APPROVED",
   "title": "Second treatment for fibrodysplasia ossificans progressiva: FDA approves Pasatru (garetosmab-grts)",
   "instrument": "FDA approval of Pasatru (garetosmab-grts), Regeneron, announced 19 August 2026: to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups in adults with FOP",
   "what": "Second drug approved for FOP, per FDA. Dosing: 10 mg/kg IV over 60 minutes every four weeks; may be decreased to 3 mg/kg if not tolerated. Trial: 2 new HO lesions among 23 patients (10 mg/kg) and 1 among 19 (3 mg/kg) vs 19 among 21 on placebo; clinician-assessed flare-ups over 56 weeks 9 vs 53 vs 66. Warning for fetal harm; effective contraception during treatment and for 6 months after the last dose.",
   "limits": "Approved for adults; FDA states it is not known whether the drug is safe and effective in children. “First and only” framing in company material describes the flare-up endpoint, not the disease: FDA characterizes Pasatru as the second FOP treatment.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-25",
   "sources": [
    {
     "label": "FDA — FDA Approves Second Treatment for Fibrodysplasia Ossificans Progressiva",
     "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva"
    }
   ],
   "related": [
    "/policy/accelerated-approval-and-confirmatory-trials/"
   ],
   "record": "/weekly/#updates-0825"
  },
  {
   "id": "fda-pfdd-chronic-wounds-2026",
   "date": "2026-08-19",
   "sort": "2026-08-19b",
   "jurisdiction": "United States",
   "body": "Food and Drug Administration",
   "actionType": "PUBLIC MEETING",
   "lifecycle": "CURRENT",
   "meetingDate": "2026-08-25",
   "title": "FDA convenes patients on nonhealing chronic wounds — a fixed date, not a policy",
   "instrument": "FDA-led Patient-Focused Drug Development public meeting, 25 August 2026, 10:00 a.m.–4:30 p.m. ET, hybrid; docket FDA-2026-N-5057, written comments to 26 October 2026",
   "what": "FDA hosts a hybrid public meeting to hear from patients and care partners about nonhealing chronic wounds: daily-life effects, current treatment approaches, and what patients weigh before joining a clinical trial. Three sessions, each opening with a patient panel. Written comments run to 26 October.",
   "effect": "Chronic wounds sit at the intersection of diabetes, vascular disease, primary care, podiatry and geriatrics, and the meeting’s output — patient-experience data — feeds endpoint design for future wound-therapy trials. For a family-medicine practice the relevance is who should speak: patients living with these wounds, and the clinicians who can help them register.",
   "limits": "A patient-focused drug development meeting is listening, not deciding. It approves nothing, changes no coverage, and sets no standard of care. Nothing about wound-care therapy changes because the meeting occurs.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "FDA — PFDD public meeting for nonhealing chronic wounds, 25 August 2026",
     "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds"
    },
    {
     "label": "Federal Register — meeting notice and request for comments (docket FDA-2026-N-5057)",
     "url": "https://www.federalregister.gov/documents/2026/05/29/2026-10752/patient-focused-drug-development-for-nonhealing-chronic-wounds-public-meeting-request-for-comments"
    }
   ],
   "related": [
    "/patient-education/understanding-type-2-diabetes/",
    "/policy/clinical-trial-diversity-and-results-transparency/",
    "/policy/patient-reported-outcomes-in-payment-policy/"
   ]
  },
  {
   "id": "mbc-quarterly-meeting-2026-08",
   "date": "2026-08-19",
   "sort": "2026-08-19a",
   "jurisdiction": "California",
   "body": "Medical Board of California",
   "actionType": "PUBLIC MEETING",
   "lifecycle": "EFFECTIVE",
   "title": "Medical Board of California quarterly meetings, 19–21 August: agenda published",
   "instrument": "Bagley-Keene Open Meeting Act, Gov. Code § 11120 et seq.",
   "what": "Licensing Panel A and Panel B meet 19 August; the quarterly Board meeting runs 20 August 9:00 a.m.–5:00 p.m. and 21 August 9:00 a.m.–5:00 p.m. at the UC San Diego Viterbi Family Vision Research Center, 9449 Campus Point Drive, La Jolla, with WebEx access. The Board agenda includes the Enforcement Program Summary (item 5C, covering personnel, the expert reviewer programme and statistics); discussion and possible action on eighteen bills (item 7), among them AB 408 (Berman) on the physician health and wellness programme, four artificial-intelligence measures — AB 1979 (Bonta) and AB 2575 (Ortega) on AI in health care services, SB 903 (Padilla) on AI and mental-health professionals, and SB 1146 (Gonzalez) on digital replicas and synthetic performers in health advertising — SB 1002 (Niello) on a telehealth licence exemption for out-of-state physicians, AB 2386 (Alvarez) on the Licensed Physicians from Mexico Program, AB 1637 (Caloza) on medical records, and SB 849 (Weber Pierson) on reinstatement after surrender for sexual misconduct; legislative proposals for the 2026 Sunset Report (item 8); possible action on requiring continuing medical education on the topics in Business and Professions Code sections 2191, 2191.4, 2191.5, 2191.6 and 2196.9 (item 9); an Interstate Medical Licensure Compact update from the IMLCC executive director (item 12); a licensed-midwife education presentation (item 13); a Maternal Health Task Force update (item 14); and a presentation on artificial intelligence in health care by the Chief Health AI Officer of UC San Diego Health (item 15).",
   "effect": "This is the single densest overlap between a public agenda and this library in 2026: physician wellness, four AI bills, CME mandates, the Compact, telehealth licensure and maternal health all appear on one agenda. Two practical points for a physician who wants to be heard. The written-comment deadline has passed — the agenda set it at Wednesday 12 August — so the remaining route is live comment, limited to three minutes per agenda item with twenty minutes total per item, apportioned between in-person and remote speakers. And the agenda is the boundary: under Bagley-Keene the Board may not act on anything not listed, so an item absent from this agenda cannot be decided this week.",
   "limits": "An agenda establishes what may be discussed, not what will be decided; every item is captioned 'discussion and possible action', and the Board states that times and order may change. Nothing here reports an outcome. A bill on the agenda is a bill, not law — Board support or opposition changes no duty. Follow-up records will be created only for actions the Board actually takes on 20–21 August.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "Medical Board of California — Quarterly Board Meeting agenda, 20–21 August 2026 (PDF)",
     "url": "https://www.mbc.ca.gov/About/Meetings/Agenda/31621/brd-Agenda-20260820.pdf"
    },
    {
     "label": "Medical Board of California — Licensing Panel A agenda, 19 August 2026 (PDF)",
     "url": "https://www.mbc.ca.gov/About/Meetings/Agenda/31607/pa-Agenda-20260819.pdf"
    },
    {
     "label": "Medical Board of California — Licensing Panel B agenda, 19 August 2026 (PDF)",
     "url": "https://www.mbc.ca.gov/About/Meetings/Agenda/31606/pb-Agenda-20260819.pdf"
    },
    {
     "label": "Medical Board of California — Meeting details page",
     "url": "https://www.mbc.ca.gov/about/meetings/details.aspx?id=4097"
    },
    {
     "label": "Medical Board of California — Meetings Index (meeting dates verified)",
     "url": "https://www.mbc.ca.gov/About/Meetings/Index.aspx",
     "readOn": "2026-08-18"
    }
   ],
   "related": [
    "/policy/the-ab-408-post-mortem/",
    "/policy/physician-wellness-programs/",
    "/policy/when-burnout-is-treated-as-misconduct/",
    "/policy/california-and-the-imlc/",
    "/policy/interstate-licensure-limits/",
    "/policy/telemedicine-across-state-lines/",
    "/policy/cme-vs-continuing-certification/",
    "/policy/initial-continuing-and-maintenance-of-certification/",
    "/policy/ai-in-licensing-and-monitoring/",
    "/policy/ai-assisted-diagnosis-and-physician-responsibility/",
    "/policy/generative-ai-in-medical-documentation/",
    "/policy/the-health-quality-investigation-unit/",
    "/policy/the-central-complaint-unit/",
    "/policy/international-medical-graduate-alternative-licensure-pathways/",
    "/policy/imgs-in-the-us-workforce/",
    "/policy/maternal-mortality-review-committees/",
    "/policy/midwifery-licensure-and-birth-setting-regulation/",
    "/policy/how-medical-records-become-regulatory-evidence/",
    "/policy/settlement-and-stipulation/"
   ],
   "discoverabilityNote": "The three agenda PDFs are published but are not linked from the Board's meeting-details page, which on 17 August 2026 still read 'location TBD' and 'this meeting's schedule has yet to be determined'. Anyone verifying from that page alone concludes there is no agenda. The agendas were located from their direct URLs.",
   "eventState": "MEETING CONCLUDED — OFFICIAL OUTCOME RECORD PENDING",
   "materialsState": "PUBLISHED",
   "stateNote": "The scheduled window (Panels A and B 19 August; quarterly Board 20–21 August) has passed. No action summary or approved minutes for the August meeting were located on the record read 24 August 2026. Outcomes populate only from the webcast record, official action summary or approved minutes — never inferred from the agenda.",
   "meetingDate": "2026-08-19",
   "events": [
    {
     "on": "2026-08-15",
     "state": "MATERIALS NOT YET VERIFIED",
     "note": "As published in the 15 August issue — accurate when published."
    },
    {
     "on": "2026-08-17",
     "state": "MATERIALS PUBLISHED — MEETING UPCOMING",
     "note": "Agendas and supporting materials read at mbc.ca.gov."
    },
    {
     "on": "2026-08-19",
     "state": "IN SESSION — NO ACTION RECORDED",
     "note": "Panel A convened 9:00 a.m. Outcomes: PENDING — DO NOT INFER. Populated only from the webcast record, official action summary or approved minutes."
    },
    {
     "on": "2026-08-24",
     "state": "MEETING CONCLUDED — OFFICIAL OUTCOME RECORD PENDING",
     "note": "Meeting window closed 21 August. Disposition of each agenda item: not yet identified in the publicly available record reviewed 24 August. Populated only from the official record."
    },
    {
     "on": "2026-08-25",
     "state": "MEETING CONCLUDED — OFFICIAL OUTCOME RECORD PENDING",
     "note": "Meetings index read 25 August 2026: the August meeting is listed under past meetings; no action summary or approved minutes posted. Every agenda item remains PENDING."
    }
   ]
  },
  {
   "id": "fda-huons-saline-kit-early-alerts-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18z",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "SAFETY ALERT",
   "lifecycle": "CURRENT",
   "title": "FDA Early Alerts: epidural kits (Medical Action Industries) and convenience kits (Becton Dickinson) containing recalled Huons saline",
   "instrument": "FDA Early Alerts — Epidural Kit Issue from Medical Action Industries (customer letter 23 July 2026); Convenience Kit Issue from Becton Dickinson (data as of 29 July 2026)",
   "what": "Kits may contain sodium chloride ampules manufactured by Huons Co., Ltd. and previously recalled. FDA: do not use the ampules; quarantine or remove and destroy the ampule at point of use; remaining kit components may continue to be used. Stated risk if sterility is compromised: microorganisms, endotoxins or foreign matter — systemic inflammatory response, infection, micro-clots, organ failure; for epidural use in proximity to the spine, meningeal infection, abscess, and spinal-root compression injury leading to paralysis or death. No serious injuries or deaths reported as of the source dates.",
   "limits": "An Early Alert is not a final recall classification and not a finding of harm. The stated risks are FDA’s description of potential consequences, not reported events.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "FDA — Early Alert: epidural kit issue, Medical Action Industries",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-epidural-kit-issue-medical-action-industries"
    },
    {
     "label": "FDA — Early Alert: convenience kit issue, Becton Dickinson",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "record": "/weekly/2026-08-24/#fda-huons-saline-kit-early-alerts-2026"
  },
  {
   "id": "doj-goshko-podiatry-fca-intervention-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18y",
   "jurisdiction": "United States",
   "body": "DOJ · U.S. Attorney's Office, N.D. Illinois · with the State of Illinois",
   "actionType": "CIVIL FCA — COMPLAINT IN INTERVENTION",
   "lifecycle": "ALLEGATION",
   "title": "US and Illinois intervene: $5.2 million alleged in podiatry claims billed under other physicians’ names after a Medicaid termination",
   "instrument": "Joint complaint in intervention announced 18 August 2026 (filed in N.D. Ill.), in a qui tam brought by PayrHealth, LLC: Foot & Ankle Health Care Center, Ltd., European Foot & Ankle Surgical Care, Ltd., Dr. Vadim Goshko, Atlantic Wave Holdings, LLC and Atlantic Wave II, LLC",
   "what": "The complaint alleges that after Illinois Medicaid terminated Dr. Goshko as a provider on 1 May 2019, the defendants submitted claims listing other physicians as having performed podiatry services Goshko actually performed, and failed to inform Medicare of the Medicaid exclusion; Medicare and Medicaid allegedly paid more than $5.2 million ($5,215,857.51 per the complaint) to which the defendants were not entitled.",
   "limits": "Allegations only — a complaint in intervention determines no liability. DOJ’s own release states the claims are accusations.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-24",
   "sources": [
    {
     "label": "DOJ — USAO N.D. Illinois, announcement",
     "url": "https://www.justice.gov/usao-ndil/pr/united-states-and-state-illinois-file-complaint-intervention-false-claims-act-lawsuit"
    }
   ],
   "related": [
    "/enforcement/",
    "/policy/fraud-waste-and-abuse-the-enforcement-architecture/"
   ],
   "record": "/enforcement/#chron-2026"
  },
  {
   "id": "health-canada-index-2026-08-17-18",
   "date": "2026-08-18",
   "sort": "2026-08-18q",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "RECALL",
   "lifecycle": "CURRENT",
   "title": "Two more Canadian entries: an endoscopic haemostasis kit recalled, unauthorized drugs seized from a Montreal retailer",
   "instrument": "Government of Canada Recalls, advisories and safety alerts index: Cook Medical Hemospray Kit, health product recall, 17 August 2026; unauthorized drugs seized from Rabais 4Saisons Inc., Montreal, public advisory, 18 August 2026",
   "what": "Two entries joined the Canadian record in the window. A health product recall covers the Cook Medical Hemospray Kit — the powder used endoscopically to stop gastrointestinal bleeding — and a public advisory states that unauthorized drugs seized from a Montreal retailer may pose serious health risks. Both are recorded here at the level at which they were read: the index entry, its notice type and its date. The notices themselves are not summarised, so nothing is stated about affected lots, mechanism or distribution.",
   "effect": "The distinction between the two entries is the whole point of keeping them in one record. A recall of a hospital haemostasis device is a supply-and-substitution question for endoscopy services; an advisory about unauthorized product seized from a retailer is a consumer-exposure question, and the products in that category are the ones a patient brings to a primary-care visit in a bag rather than on a medication list.",
   "limits": "An index entry establishes that a notice exists, its type and its date — nothing more. No lot numbers, no injury finding, and no distribution scope are asserted. A recall is not a finding of harm, and a seizure advisory is not a finding that any individual product caused injury.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "Government of Canada — Recalls, advisories and safety alerts (index carrying both entries)",
     "url": "https://recalls-rappels.canada.ca/en"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "medi-cal-uis-managed-care-to-ffs-2027",
   "date": "2026-08-18",
   "sort": "2026-08-18p",
   "jurisdiction": "California",
   "body": "Department of Health Care Services",
   "vertical": "medi-cal",
   "actionType": "BENEFIT POLICY CHANGE",
   "lifecycle": "FINAL",
   "effectiveDate": "2027-01-01",
   "title": "California moves a whole population out of managed care: unsatisfactory immigration status to fee-for-service, 1 January 2027",
   "instrument": "DHCS implementation of federal policy: Medi-Cal members with unsatisfactory immigration status (UIS) transition from managed care to the Medi-Cal fee-for-service delivery system effective 1 January 2027; provider guidance carried in a managed-care plan alert dated 12 August 2026",
   "what": "Federal guidance issued in 2025 directed every state to move Medicaid members with unsatisfactory immigration status out of risk-based managed care and into fee-for-service by 1 January 2027, on the basis that states may not cover federally eligible emergency Medicaid services for this population through risk-based managed care. California is implementing it: from that date UIS members, including dual-eligible members, receive all covered Medi-Cal services through fee-for-service. DHCS's provider guidance is specific. Providers must be enrolled in Medi-Cal fee-for-service to be paid for treating these patients; those not already enrolled through PAVE must submit an application and be approved by 1 January 2027 to receive fee-for-service rates. Members will no longer be assigned a primary care provider, but an enrolled provider may continue seeing the same patients. Enhanced Care Management and Community Supports are not covered under fee-for-service; DHCS states that care management, care coordination, case management and community health worker services remain billable under existing fee-for-service codes. Providers are advised to have patients refill prescriptions before 1 January 2027. The May Revision scored the change as a reduction of $583.8 million ($471.6 million General Fund) in 2026-27 and $1.5 billion ($1.2 billion General Fund) ongoing; the enacted budget included $39 million General Fund in 2026-27 for care coordination and navigation.",
   "effect": "This is the change most likely to sever an existing doctor-patient relationship in a Central Valley practice, and it does so through an enrollment form rather than a coverage decision. The patient keeps Medi-Cal; what changes is the delivery system, and with it whether the practice can be paid. A physician who sees these patients under a managed-care contract and is not separately enrolled in fee-for-service through PAVE becomes, on 1 January 2027, an unpaid provider to a patient who is still covered — which in practice means the patient is told to go elsewhere. The second-order loss is care management: ECM and Community Supports end for this population, and the substitute is a set of fee-for-service billing codes a small practice has to know how to use. The deadline that matters to a clinic is therefore not January but whenever its PAVE application must be filed to be approved in time.",
   "limits": "The transition changes the delivery system, not eligibility: no one loses Medi-Cal because of it, and it is not the same action as the October 2026 federal immigration-status reclassification or the January 2027 community-engagement requirement, each of which has its own record. It is not a benefit reduction on its face, though ECM and Community Supports do not exist in fee-for-service. The operational detail here is DHCS guidance as carried in a plan alert; it is not a DHCS bulletin read directly, and the code lists DHCS says it will publish had not been published on the record read.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "DHCS — Tracking Federal Impact: Medi-Cal Eligibility (UIS transition to fee-for-service)",
     "url": "https://www.dhcs.ca.gov/tracking-federal-impact-medi-cal-eligibility/"
    },
    {
     "label": "DHCS — Medi-Cal Changes",
     "url": "https://www.dhcs.ca.gov/medi-cal/updates/medi-cal-changes/"
    },
    {
     "label": "DHCS — FY 2026-27 May Revision highlights (PDF)",
     "url": "https://www.dhcs.ca.gov/Budget/Documents/DHCS-FY-2026-27-May-Revise-Highlights.pdf"
    },
    {
     "label": "DHCS — Provider Application and Validation for Enrollment (PAVE)",
     "url": "https://www.dhcs.ca.gov/providers-partners/provider-application-and-validation-for-enrollment/"
    }
   ],
   "related": [
    "/policy/immigrant-eligibility-rules-and-chilling-effects-on-care/",
    "/policy/medi-cal-in-plain-language/",
    "/policy/medi-cal-dental-vision-pharmacy-and-medical-benefits/",
    "/policy/childrens-coverage-continuity/",
    "/policy/language-access-healthcare-infrastructure/"
   ]
  },
  {
   "id": "fda-anda-505b2-draft-guidance-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18n",
   "jurisdiction": "United States",
   "body": "Food and Drug Administration",
   "actionType": "GUIDANCE",
   "lifecycle": "PROPOSED",
   "commentDeadline": "2026-10-19",
   "title": "FDA redraws the map between generic and hybrid drug applications, in draft",
   "instrument": "Draft guidance for industry, Determining Whether to Submit an ANDA or a 505(b)(2) Application; Federal Register notice 2026-16837, 18 August 2026 (91 FR 53418); comments to 19 October 2026",
   "what": "FDA announced the availability of a draft guidance intended as the foundational guidance for choosing between the two abbreviated approval pathways under the FD&C Act — the ANDA route under section 505(j) and the 505(b)(2) route for applications that rely in part on data the applicant does not own. It revises the May 2019 guidance of the same name and, when finalised, will replace it. Written comments are due by 19 October 2026.",
   "effect": "Pathway choice sets a product's evidence burden before any study is run, and one day now closes two FDA windows — this one and the generative-AI device docket, both 19 October. For prescribers the meaning is downstream: the pathway determines what evidence stands behind a generic or hybrid product and how it reaches substitution.",
   "limits": "A draft guidance binds no one — not FDA and not applicants. The May 2019 guidance remains the current version until a final version replaces it, and guidance in any form is not regulation.",
   "desks": [
    "weekly"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "Federal Register — notice 2026-16837, 91 FR 53418 (18 August 2026)",
     "url": "https://www.govinfo.gov/content/pkg/FR-2026-08-18/pdf/2026-16837.pdf"
    }
   ],
   "related": [
    "/policy/accelerated-approval-and-confirmatory-trials/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "mhra-mbmp-position-paper-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18h",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "REGULATORY SCIENCE — POSITION PAPER",
   "lifecycle": "CURRENT",
   "title": "The UK says microbiome medicines need no new law — the existing framework already covers them",
   "instrument": "UK Position Paper on Microbiome-Based Medicinal Products (MBMPs), published 18 August 2026",
   "what": "The MHRA’s position is that microbiome-based medicinal products — medicines that modulate, restore or replace the human microbiome — fall within the existing framework of the Human Medicines Regulations 2012: as biological medicinal products, or in some cases as advanced therapy medicinal products. No MBMP currently holds a UK marketing authorisation. The paper sets out what developers must address — product characterisation, manufacturing consistency, batch-to-batch variability, safety assessment including antimicrobial-resistance risk, and clinical evidence — and leaves existing faecal microbiota transplantation arrangements (clinical trials, unlicensed supply under specials) unchanged.",
   "effect": "For clinicians the near-term meaning is what did not change: FMT for recurrent C. difficile continues under the same arrangements and the same prescriber responsibility. The forward meaning is a licensing route: a class of therapies aimed at antimicrobial resistance now has a stated path to authorisation rather than a regulatory vacuum.",
   "limits": "A position paper is regulatory science, not legislation and not a licence. It approves no product, changes no authorisation, and creates no new obligation. That MBMPs are \"promising\" is the regulator’s framing of a field with, at present, zero UK-authorised products.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "GOV.UK — UK Position Paper on Microbiome-Based Medicinal Products",
     "url": "https://www.gov.uk/government/publications/uk-position-paper-on-microbiome-based-medicinal-products-mbmps"
    },
    {
     "label": "GOV.UK — MHRA sets out position on regulation of microbiome-based medicinal products",
     "url": "https://www.gov.uk/government/news/mhra-sets-out-position-on-regulation-of-microbiome-based-medicinal-products"
    }
   ],
   "related": [
    "/patient-education/antibiotic-stewardship-using-antibiotics-wisely/",
    "/patient-education/antibiotics-when-they-help-resistance/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "mhra-dsi-2026-008-infant-rectal-catheters",
   "date": "2026-08-18",
   "sort": "2026-08-18g",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "SAFETY ALERT — DEVICE SAFETY INFORMATION",
   "lifecycle": "CURRENT",
   "title": "UK: do not use rectal catheters in infants for colic or gas — stop and dispose",
   "instrument": "Device Safety Information DSI/2026/008, issued 18 August 2026, covering all rectal catheters marketed as gas and colic relievers",
   "what": "The MHRA directs that rectal catheters not be used in infants, including for colic, gas-related discomfort or constipation, and that these products be taken out of use immediately and unused devices disposed of. The direction covers the product class, not a single manufacturer or lot.",
   "effect": "This is the rare alert whose action sits with parents as much as clinicians: the products are sold to households. For primary care the task is twofold — asking about use when an infant presents with unexplained abdominal or rectal findings, and being ready with the answer to the question the alert will generate, which is what to do for colic instead.",
   "limits": "A class-wide do-not-use direction is a safety measure about a use, not an adjudication that any specific product caused any specific injury. The alert does not establish what should replace these products; that is a clinical conversation.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "GOV.UK — MHRA publications index carrying DSI/2026/008",
     "url": "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"
    },
    {
     "label": "GOV.UK — DSI/2026/008, all rectal catheters (gas and colic relievers)",
     "url": "https://www.gov.uk/drug-device-alerts/all-rectal-catheters-gas-and-colic-relievers-do-not-use-in-infants-including-for-the-treatment-of-colic-gas-related-discomfort-or-constipation-dsi-slash-2026-slash-008"
    }
   ],
   "related": [
    "/patient-education/infant-feeding-and-colic/",
    "/patient-education/when-to-call-the-pediatrician/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "tga-adm-listed-medicines-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18g",
   "jurisdiction": "Australia",
   "body": "Therapeutic Goods Administration",
   "actionType": "CONSULTATION",
   "lifecycle": "CURRENT",
   "title": "Australia consults on automated decision-making for listed-medicine applications",
   "instrument": "TGA consultation: proposed changes to support automated decision making (ADM) for applications to change listed medicines. Closes 14 September 2026.",
   "what": "The TGA is consulting on letting automated systems process applications to change listed medicines — the low-risk, self-certified tier of Australia’s register, where products enter the ARTG on sponsor certification rather than individual pre-market evaluation. The proposal concerns the agency’s own administrative processing.",
   "effect": "This is government process automation, not clinical AI: no diagnostic tool, no clinical decision support, no patient-facing system is regulated by it. Its interest is comparative — a medicines regulator formalising when its own decisions may be made by a machine, while the same agency regulates AI in medical devices by intended purpose.",
   "limits": "A consultation is not a decision. Nothing about listed-medicine processing changes unless the TGA adopts changes after the window closes. This record does not assert what the automated processing would approve or refuse.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "TGA — consultations index (ADM for applications to change listed medicines, closes 14 September 2026)",
     "url": "https://www.tga.gov.au/therapeutic-goods-administration-tga"
    },
    {
     "label": "TGA Consultation Hub",
     "url": "https://consultations.tga.gov.au/"
    }
   ],
   "related": [
    "/policy/global-ai-standards/",
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/continuous-learning-algorithms/"
   ]
  },
  {
   "id": "consumer-health-ai-google-apple-2026-08",
   "date": "2026-08-18",
   "sort": "2026-08-18f",
   "jurisdiction": "United States",
   "body": "Company material — Google; Apple (reported)",
   "actionType": "COMPANY MATERIAL — NOT A REGULATORY ACTION",
   "lifecycle": "CURRENT",
   "title": "The consumer health-AI layer moves while the device rules are still being written",
   "instrument": "Company product material: Google Health (successor to the Fitbit app, launched 19 May 2026) with a Gemini-based coach and a paid tier; release 5.05, 3 August 2026, adding two-way Apple Health synchronisation and Smart Health Links for sharing data with providers. Apple Health+ with an AI health agent is reported by journalists, not announced by Apple.",
   "what": "Two things happened in the same ten days at opposite ends of the regulatory spectrum. FDA opened a docket asking how generative-AI medical devices should be evaluated. Meanwhile the largest consumer health platforms shipped generative features into hundreds of millions of phones without entering that pathway at all: Google's coach summarises records and answers health questions while the company states it is not designed to diagnose conditions or replace clinicians, and its 3 August release added two-way synchronisation with Apple Health plus a link format for sending data to a provider. Apple's reported Health+ subscription with an AI agent has not been announced by Apple.",
   "effect": "The consequence for a clinician is arriving in the room, not in a rule. A patient now brings a platform-generated summary of their own records and a chatbot's reading of it. Two practical questions follow: whether the summary is complete enough to rely on, and who is accountable for an inference inside it. The general-wellness framing is what keeps these features outside device regulation, and it is the same intended-purpose boundary the TGA regulates by and the FDA is asking about — which is why the boundary, not the product, is the thing to watch.",
   "limits": "Company material establishes only what the company says. Nothing here is a regulatory action, a clearance, an authorisation or a finding: no product named is asserted to be a regulated medical device, and no clinical performance claim is made or accepted. Google's own statement that its coach is not intended to diagnose is recorded as the company's position, not as a verified fact about the software's behaviour. The Apple Health+ item is journalists' reporting of unannounced plans.",
   "forecast": {
    "label": "FORECAST — LOW CONFIDENCE",
    "statement": "An Apple Health+ subscription with an AI agent ships within the next twelve months.",
    "basis": "Sustained reporting through 2025–2026 and a reported reorganisation of the health and fitness team under services.",
    "competing": "Apple ships the AI health features inside the existing free Health app with no subscription, or defers again; Apple has announced neither a product nor a date, and its Siri timeline has already slipped repeatedly."
   },
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "FDA — Considerations for the Regulation of Generative AI-Enabled Medical Devices (the regulatory boundary this sits outside)",
     "url": "https://www.fda.gov/medical-devices/digital-health-center-excellence/considerations-regulation-generative-ai-enabled-medical-devices-discussion-paper-and-request"
    },
    {
     "label": "TGA — AI and medical device software: regulation by intended purpose",
     "url": "https://www.tga.gov.au/how-we-regulate/manufacturing/medical-devices/manufacturer-guidance-specific-types-medical-devices/artificial-intelligence-ai-and-medical-device-software"
    }
   ],
   "related": [
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/continuous-learning-algorithms/",
    "/policy/global-ai-standards/",
    "/policy/ambient-clinical-documentation-benefits-and-risks/",
    "/patient-education/evaluating-online-medical-information/",
    "/patient-education/avoiding-health-misinformation/"
   ]
  },
  {
   "id": "ema-biosimilar-guideline-revision-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18e",
   "jurisdiction": "European Union",
   "body": "European Medicines Agency",
   "actionType": "CONSULTATION",
   "lifecycle": "PROPOSED",
   "commentDeadline": "2026-10-31",
   "title": "EMA opens the revision of its overarching biosimilar guideline for comment",
   "instrument": "EMA/CHMP/BMWP concept paper on revision of the Guideline on similar biological medicinal products (CHMP/437/04 Rev. 1), EMA/CHMP/BMWP/153523/2026 — consultation 22 July to 31 October 2026",
   "what": "EMA has opened consultation on revising the guideline that sets the general principles for biosimilar development — the choice of reference product, the demonstration of biosimilarity, and in particular the necessity and utility of comparative efficacy studies, which the agency's March 2026 reflection paper concluded do not add pivotal information to a biosimilar assessment. The revision would also carry the new legal definitions and data requirements from the European Union's pharmaceutical legislation into the guideline.",
   "effect": "Biosimilar availability is a prescribing question before it is a policy question. If comparative efficacy studies stop being expected where analytical and functional comparability is complete, development time and cost fall, and the practical consequence in a clinic is how quickly a second or third biosimilar of a biologic appears — which is what actually moves price and switching pressure.",
   "limits": "A concept paper is not the revised guideline. Nothing in it changes an existing data requirement, and it does not establish that comparative efficacy studies are no longer needed for any product. EMA has indicated a draft revision for consultation in 2027 and adoption in 2028; both remain proposals.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "EMA — Similar biological medicinal products (scientific guideline page carrying the open consultation)",
     "url": "https://www.ema.europa.eu/en/similar-biological-medicinal-products-scientific-guideline"
    },
    {
     "label": "EMA — concept paper on revision of the biosimilar guideline",
     "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-similar-biological-medicinal-products-chmp-437-04-rev1_en.pdf"
    }
   ],
   "related": [
    "/policy/generic-and-biosimilar-competition/",
    "/policy/accelerated-approval-and-confirmatory-trials/",
    "/policy/medicare-drug-price-negotiation/"
   ]
  },
  {
   "id": "ema-nicotine-dependence-guideline-revision-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18d",
   "jurisdiction": "European Union",
   "body": "European Medicines Agency",
   "actionType": "CONSULTATION",
   "lifecycle": "PROPOSED",
   "commentDeadline": "2026-08-30",
   "title": "EMA consults on extending its smoking-cessation guideline to all forms of nicotine dependence",
   "instrument": "EMA concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking, EMA/112569/2026 — consultation 29 May to 30 August 2026",
   "what": "The existing European guideline governs medicines developed for smoking cessation. EMA's concept paper records that it is neither intended for nor fully applicable to medicines for dependence on non-combustible nicotine products, and that in the absence of any other guideline it is nonetheless the one being applied. The proposal is to adjust the guideline so it covers all forms of nicotine dependence, including inhaled and oromucosal products. A draft CHMP guidance document is planned for release no later than the first quarter of 2027.",
   "effect": "The clinical gap is already in the room: adolescents and young adults presenting with dependence on vapes and nicotine pouches are treated with medicines authorised on smoking-cessation evidence. This consultation is the regulatory acknowledgement that the evidence base was built for a different exposure, and it is the point at which a clinician who sees that population can say so on the record.",
   "limits": "A concept paper is not a guideline and not a decision. It states what EMA proposes to revise and invites comment; no development requirement changes, and no authorised indication is altered by it. A future draft guideline would itself go out for consultation.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "EMA — Development of new medicinal products for the treatment of smoking (scientific guideline page carrying the open consultation)",
     "url": "https://www.ema.europa.eu/en/development-new-medicinal-products-treatment-smoking-scientific-guideline"
    },
    {
     "label": "EMA — concept paper on the need for revision (EMA/112569/2026)",
     "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-development-medicinal-products-treatment-smoking_en.pdf"
    }
   ],
   "related": [
    "/policy/tobacco-endgame-policies/",
    "/policy/accelerated-approval-and-confirmatory-trials/",
    "/policy/vaping-regulation-and-youth-access/"
   ]
  },
  {
   "id": "tga-radiopharmaceutical-consultation-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18c",
   "jurisdiction": "Australia",
   "body": "Therapeutic Goods Administration",
   "actionType": "CONSULTATION",
   "lifecycle": "COMMENT PERIOD CLOSED",
   "commentDeadline": "2026-08-21",
   "title": "TGA consultation on radiopharmaceutical regulation (comment period closed 21 August)",
   "instrument": "TGA public consultation — Radiopharmaceutical regulation in Australia (Medicines Regulation Division), conducted through the TGA Consultation Hub",
   "what": "The TGA is seeking high-level feedback on how the current regulatory settings for radiopharmaceuticals work in practice — the pathways, exemptions and access mechanisms used for medicines that carry small amounts of radioactive material and are used in the diagnosis and treatment of cancer and cardiovascular disease. Both diagnostic and therapeutic products, including theranostics, are in scope. The TGA's own consultation listing carries a closing date of 21 August 2026; the information paper published with the consultation stated an original window of 5 June to 31 July 2026, so the closing date has moved out. Submissions are lodged through the Consultation Hub by 11:59 pm AEST on the closing date.",
   "effect": "This is the layer of regulation a nuclear-medicine service actually operates in: how a hospital-prepared radiopharmaceutical is treated, which exemption a compounded dose relies on, and what a cyclotron or generator-based supply chain must hold. The TGA is asking practitioners rather than only sponsors, and the window is three days from this record.",
   "limits": "A consultation is not a regulatory decision. The TGA states that feedback from this consultation will not of itself result in immediate regulatory change and will inform future targeted consultation. Nothing in it changes a current obligation, a supply pathway or an exemption.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "TGA — Consultation: Radiopharmaceutical regulation in Australia",
     "url": "https://www.tga.gov.au/news/consultations/consultation-radiopharmaceutical-regulation-australia"
    },
    {
     "label": "TGA — What's new (consultation listing carrying the 21 August 2026 closing date)",
     "url": "https://www.tga.gov.au/news/whats-new"
    },
    {
     "label": "TGA Consultation Hub — information paper to support the consultation (May 2026)",
     "url": "https://consultations.tga.gov.au/medicines-regulation-division/radiopharmaceutical-regulation-in-australia-open-p/"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/global-ai-standards/",
    "/policy/essential-medicine-supply-chain-resilience/"
   ],
   "events": [
    {
     "on": "2026-08-21",
     "state": "COMMENT PERIOD CLOSED — OUTCOME PENDING",
     "note": "Window closed 21 August; what the TGA does with comments is a future record. Recorded 24 August 2026."
    }
   ]
  },
  {
   "id": "oig-new-york-parity-pa-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18b",
   "jurisdiction": "United States",
   "body": "HHS Office of Inspector General",
   "actionType": "AUDIT / OVERSIGHT FINDING",
   "lifecycle": "CURRENT",
   "title": "OIG finds New York did not ensure Medicaid managed-care parity compliance on prior authorisation",
   "instrument": "HHS-OIG audit report A-02-24-01011 — New York Did Not Ensure That Selected Medicaid Managed Care Organizations Complied With Mental Health and Substance Use Disorder Parity Requirements Related to Prior Authorization",
   "what": "OIG's public report index carries a second state audit on the same question it put to Kansas eight days earlier: whether the state ensured its Medicaid managed-care organisations applied mental-health and substance-use parity requirements to prior authorisation. New York is the second state named in the series, which locates parity in utilisation management rather than in the coverage document.",
   "effect": "For a treating physician the operative point is where parity is tested. A benefit package can be nominally at parity while the authorisation pathway in front of a behavioural-health referral is slower or more restrictive than the one in front of a medical referral. Two states now have findings addressed to their oversight of exactly that gap, which makes the authorisation record — not the benefit schedule — the document to cite in an appeal.",
   "limits": "An audit finding is not a fraud finding, not a penalty and not an adjudication against any plan's clinical decisions; it is addressed to state oversight. This record establishes the report's number, subject, jurisdiction and presence in OIG's public report index as read on 18 August 2026, and dates the record to that reading. The report's own cover date is not asserted.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "HHS-OIG — What's New (report index carrying A-02-24-01011)",
     "url": "https://oig.hhs.gov/newsroom/whats-new/"
    },
    {
     "label": "HHS-OIG — Kansas parity audit A-07-24-02842, the first report in the series",
     "url": "https://oig.hhs.gov/reports/all/2026/kansas-did-not-ensure-that-its-medicaid-managed-care-organizations-complied-with-mental-health-and-substance-use-disorder-parity-requirements-related-to-prior-authorization/"
    }
   ],
   "related": [
    "/policy/investigating-pa-delays/",
    "/policy/mental-health-parity-enforcement/",
    "/policy/peer-to-peer-review/",
    "/policy/algorithmic-pa-and-human-accountability/"
   ],
   "supersedes": null,
   "extendsRecord": "oig-kansas-parity-pa-2026"
  },
  {
   "id": "fda-genai-device-discussion-paper-2026",
   "date": "2026-08-18",
   "sort": "2026-08-18a",
   "jurisdiction": "United States",
   "body": "FDA — Center for Devices and Radiological Health, Digital Health Center of Excellence",
   "actionType": "DISCUSSION PAPER / REQUEST FOR FEEDBACK",
   "lifecycle": "CURRENT",
   "documentState": "DISCUSSION PAPER",
   "commentWindowState": "OPEN",
   "commentDeadline": "2026-10-19",
   "docket": "FDA-2026-N-7874",
   "title": "FDA opens a public docket on how it might regulate generative-AI medical devices",
   "instrument": "Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback, issued 18 August 2026; docket FDA-2026-N-7874",
   "what": "FDA issued a discussion paper seeking feedback on risk assessment, premarket evaluation and postmarket monitoring of generative-AI-enabled medical devices. It sketches a two-axis risk-assessment framework, a premarket approach built on competency assessment consisting of non-clinical device benchmarking and clinical confirmation, several risk-proportionate postmarket monitoring approaches, and considerations for foundation models and agentic systems. Feedback is due 19 October 2026.",
   "effect": "For a physician using or evaluating a generative-AI tool, nothing changes today. What changes is the shape of the argument: FDA is publicly floating an evaluation model borrowed from how clinicians themselves are credentialled — benchmark first, then confirm in clinical use — which is the frame a future submission, and a future purchasing conversation, will be built around.",
   "limits": "Not a rule. Not draft guidance. Not final guidance. It does not implement or propose policy, and FDA states it does not address whether the approaches discussed fall within existing legal authorities. Nothing in it creates a duty for a manufacturer or a clinician.",
   "desks": [
    "weekly",
    "intelligence",
    "enforcement"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "FDA — news release, 18 August 2026",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices",
     "readOn": "2026-08-18"
    },
    {
     "label": "FDA — discussion paper (Digital Health Center of Excellence)",
     "url": "https://www.fda.gov/medical-devices/digital-health-center-excellence/considerations-regulation-generative-ai-enabled-medical-devices-discussion-paper-and-request",
     "readOn": "2026-08-18"
    },
    {
     "label": "Regulations.gov — docket FDA-2026-N-7874",
     "url": "https://www.regulations.gov/docket/FDA-2026-N-7874",
     "readOn": "2026-08-18"
    }
   ]
  },
  {
   "id": "mhra-natpsa-2026-004-resmed-astral",
   "date": "2026-08-17",
   "sort": "2026-08-17c",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "NATIONAL PATIENT SAFETY ALERT",
   "lifecycle": "CURRENT",
   "title": "UK issues its strongest alert class for ResMed Astral ventilators; FDA carries the same event as an early alert",
   "instrument": "National Patient Safety Alert NatPSA/2026/004/MHRA, issued 17 August 2026, on ResMed Astral 100 and 150 ventilators and printed-circuit-board spare parts manufactured before October 2024; the underlying instrument is ResMed's field safety notice, and FDA published an early alert on the same event on 15 July 2026",
   "what": "A supercapacitor in affected ventilators can leak over time and damage the circuit board, putting the device into a fail-safe state: therapy in progress stops with a maximum-volume alarm, and a device in standby will not start. The MHRA classifies this as a safety-critical and complex National Patient Safety Alert — its strongest alert class — directing every hospital trust, health board and independent provider delivering ventilation care to coordinate implementation at executive level. The stated occurrence rate is 0.1 per cent over the eight-year service life. Replacement boards are under global supply constraint with no definitive timeline; the UK and US positions agree that patients should not stop using the ventilator unless a clinician directs it, and that backup ventilation must be immediately available.",
   "effect": "Astral ventilators support ventilator-dependent adults and children at home as well as in hospital, which is why the alert reaches care-home staff and home-ventilation services, not just critical care. The operative clinical task is the backup plan: confirming that every affected patient has an alternative means of ventilation ready, and that caregivers respond correctly to the fail-safe alarm, during a repair queue whose length nobody can state.",
   "limits": "An alert is not a market withdrawal, and neither regulator directs discontinuation — the risk calculus favours continued use with precautions. Five serious injuries and no deaths had been reported to the firm as of late June; incident reports are not adjudicated causation, and nothing here establishes harm in any specific patient.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "GOV.UK — NatPSA/2026/004/MHRA, ResMed Astral 100 and 150 ventilators",
     "url": "https://www.gov.uk/drug-device-alerts/national-patient-safety-alert-resmed-astral-100-and-150-ventilators-potential-for-patient-harm-due-to-unexpected-interruption-of-ventilation-therapy-natpsa-slash-2026-slash-004-slash-mhra"
    },
    {
     "label": "FDA — early alert and firm correction for Astral ventilators",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/ventilator-correction-resmed-issues-correction-astral-ventilator"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/reporting-on-ai-enabled-devices/",
    "/patient-education/home-oxygen-and-respiratory-equipment-safety/"
   ]
  },
  {
   "id": "health-canada-device-and-fluid-recalls-2026-08",
   "date": "2026-08-17",
   "sort": "2026-08-17b",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "RECALL",
   "lifecycle": "CURRENT",
   "title": "Health Canada posts recalls for an intravenous fluid and a cuffed endotracheal tube",
   "instrument": "Health-product recalls posted to the Government of Canada Recalls and Safety Alerts database: Lactated Ringer's Injection USP (particulate matter), 17 August 2026; Endotracheal Tube, Cuffed, 14 August 2026",
   "what": "Two recalls posted three days apart reach basic hospital and clinic inventory rather than a specialty product line: Lactated Ringer's Injection USP for the presence of particulate matter, and a cuffed endotracheal tube. Both were posted to Canada's central recalls database, which is the authoritative register for reportable health-product recalls.",
   "effect": "Particulate matter in an intravenous solution and a defect in an airway device are the two failure modes that reach a patient fastest, because both are used at the moment there is least time to check a lot number. The operational task is the same for each: identify affected stock before the next use, which in an emergency setting means now rather than at the next inventory cycle.",
   "limits": "These are recalls of specified products and lots. Neither establishes patient harm, and neither is a finding about the manufacturer's conduct. Hazard classification, lot identification and distribution detail live in each database entry; this record does not restate them and does not assign a Type I/II/III classification that Health Canada has not published here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "Government of Canada — Recalls, advisories and safety alerts (Lactated Ringer's Injection USP, 17 August 2026; Endotracheal Tube, Cuffed, 14 August 2026)",
     "url": "https://recalls-rappels.canada.ca/en"
    },
    {
     "label": "Health Canada — Guide for recalling medical devices (GUI-0054)",
     "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/problem-reporting/medical-devices-recall-guide-0054.html"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/reporting-on-ai-enabled-devices/",
    "/patient-education/preparing-for-imaging-or-diagnostic-testing/"
   ]
  },
  {
   "id": "cms-4215-p-comment-close",
   "date": "2026-08-17",
   "sort": "2026-08-17a",
   "jurisdiction": "United States",
   "body": "Centers for Medicare & Medicaid Services",
   "actionType": "PROPOSED RULE — COMMENT PERIOD",
   "lifecycle": "PROPOSED",
   "title": "Medicare Drug Price Negotiation Program proposed rule closes for comment",
   "instrument": "CMS-4215-P, 91 Fed. Reg. (published 16 June 2026), doc. 2026-12059",
   "commentDeadline": "2026-08-17",
   "what": "CMS issued the proposed rule for the Medicare Drug Price Negotiation Program and the Part D benefit programme on 12 June 2026; it published in the Federal Register on 16 June and carried a 60-day comment period that closes today, 17 August 2026. Two revised information collection requests for initial price applicability year 2029 — Negotiation Program Drug Selection, and Drug Price Negotiation — carry the same 17 August due date.",
   "effect": "Today is the last day a physician's objection can be entered on the record for this rule. It is the comment window, not the rule, that closes: nothing in the proposal binds anyone yet. A separate window remains open — CMS's draft guidance on manufacturer effectuation of the maximum fair price in 2028, issued 16 July 2026, takes comments until 18 September 2026 at 11:59 p.m. Pacific, by email rather than through regulations.gov.",
   "limits": "A proposed rule is not law. No duty, payment change or dispensing obligation arises from CMS-4215-P today, and the 2028 effectuation guidance is draft guidance rather than regulation.",
   "desks": [
    "weekly",
    "intelligence",
    "enforcement"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "CMS — Medicare Drug Price Negotiation Program: Regulations, Guidance and Policy Documents",
     "url": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/regulations-guidance-policy-documents"
    },
    {
     "label": "Federal Register — CMS-4215-P (16 June 2026)",
     "url": "https://www.federalregister.gov/documents/2026/06/16/2026-12059/medicare-drug-price-negotiation-program-and-medicare-prescription-drug-benefit-program"
    },
    {
     "label": "Regulations.gov — IPAY 2029 information collection comments",
     "url": "https://www.regulations.gov/document/CMS-2026-2080-0001"
    }
   ],
   "related": [
    "/policy/medicare-drug-price-negotiation/",
    "/policy/pharmacy-benefit-managers-rebates-and-transparency/",
    "/policy/formulary-design-and-patient-access/",
    "/policy/public-participation-in-regulation/"
   ],
   "instrumentState": "PROPOSED",
   "commentWindowState": "CLOSED",
   "eventHistory": [
    {
     "date": "2026-08-17",
     "event": "Comment period closed.",
     "verifiedOn": "2026-08-18"
    }
   ],
   "stateNote": "The comment window is closed. The rule itself remains PROPOSED and is not final."
  },
  {
   "id": "health-canada-pregabalin-sertraline-2026",
   "date": "2026-08-15",
   "sort": "2026-08-15b",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "RECALL — PUBLIC ADVISORY",
   "lifecycle": "CURRENT",
   "title": "Two lots of Teva-Pregabalin 150 mg recalled in Canada for cross-contamination with sertraline",
   "instrument": "Health Canada public advisory and health-product recall, posted to the Government of Canada Recalls and Safety Alerts database",
   "what": "Health Canada posted a public advisory on 15 August 2026 recalling two lots of Teva-Pregabalin 150 mg capsules because of cross-contamination with sertraline, a different medicine entirely — an SSRI antidepressant rather than a gabapentinoid.",
   "effect": "Cross-contamination between two unrelated actives is a different problem from a potency or particulate defect: a patient taking a recalled capsule may be receiving a serotonergic drug nobody prescribed. That matters most where a patient is already on a serotonergic agent, a triptan or tramadol, and it matters clinically in the other direction too — an unexplained new symptom in a pregabalin patient now has a mechanism worth asking about. The action for a practice is to identify which patients hold the recalled lots, not to change pregabalin prescribing.",
   "limits": "A recall establishes that specified lots must be removed from supply. It does not establish that any patient was harmed, that every capsule in the lots is contaminated, or that pregabalin or sertraline is unsafe as authorised. Lot numbers and the affected quantity are held in Health Canada's own database entry and are not restated here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "Government of Canada — Recalls, advisories and safety alerts (Teva-Pregabalin 150 mg, 15 August 2026)",
     "url": "https://recalls-rappels.canada.ca/en"
    },
    {
     "label": "Health Canada — Advisories, warnings and recalls: drugs and health products",
     "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/advisories-warnings-recalls.html"
    }
   ],
   "related": [
    "/patient-education/common-medication-interactions/",
    "/patient-education/safe-medication-storage-disposal/",
    "/policy/drug-shortage-reporting-and-accountability/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "ab1979-senate-dopass-2026",
   "date": "2026-08-13",
   "sort": "2026-08-13z",
   "jurisdiction": "California",
   "body": "Legislature",
   "actionType": "LEGISLATIVE ACTION",
   "lifecycle": "ACTIVE — SENATE FLOOR PENDING",
   "title": "AB 1979 (health care AI, Bonta): Senate committee reports Do Pass; not yet enrolled",
   "instrument": "AB 1979 (2025–2026 Reg. Sess.), read at LegiScan's official-source-linked action history: 13 August 2026 Senate — Do pass (5–2), following 3 August placed on suspense file",
   "what": "Verified floor history stops at the 13 August committee report. No Senate third-reading vote, Assembly concurrence in Senate amendments, or enrollment was located.",
   "effect": "The bill that would regulate AI in the delivery of health care services is alive and unresolved days from the end-of-session deadline.",
   "limits": "Do not describe this bill as enrolled, passed, or operative. The California floor-passage deadline is 31 August; the next verifiable event is a Senate floor vote.",
   "desks": [
    "weekly",
    "policy"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "LegiScan — AB 1979 action history",
     "url": "https://legiscan.com/CA/bill/AB1979/2025"
    }
   ],
   "related": [
    "/intelligence/medical-board-august-2026/",
    "/intelligence/california-legislature-2026/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "tga-device-information-sharing-2026",
   "date": "2026-08-13",
   "sort": "2026-08-13a",
   "jurisdiction": "Australia",
   "body": "Therapeutic Goods Administration",
   "actionType": "CONSULTATION",
   "lifecycle": "PROPOSED",
   "commentDeadline": "2026-10-02",
   "title": "TGA consults on releasing more medical-device safety and performance information",
   "instrument": "Proposed amendments to disclosure powers under s 61, Therapeutic Goods Act 1989 (Cth)",
   "what": "The TGA opened a consultation running from 13 August to 2 October 2026 on expanding what it may lawfully release about medical devices under section 61 of the Therapeutic Goods Act 1989, so that more information reaches the public following post-market reviews and investigations — particularly where findings concern a device's safety, quality, performance or use. The proposal is framed as implementing the intent of An Action Plan for Medical Devices.",
   "effect": "If adopted, the post-market record becomes visible rather than inferable. Australian clinicians would be able to see that a device they use has been through a review and what the review found, which is information that currently reaches prescribers only through recalls and safety alerts.",
   "limits": "This is a consultation on a proposal, not a regulatory change. Nothing is required of any sponsor or clinician, no disclosure obligation exists yet, and the outcome will be published after the closing date.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "TGA — Consultation on sharing more information about medical devices",
     "url": "https://www.tga.gov.au/news/consultations/sharing-more-information-about-medical-devices"
    },
    {
     "label": "TGA — Consultation on improving the sharing of information about medical devices",
     "url": "https://www.tga.gov.au/news/news-articles/consultation-improving-sharing-information-about-medical-devices"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/global-ai-standards/",
    "/policy/cybersecurity-in-connected-devices/",
    "/policy/reporting-on-ai-enabled-devices/"
   ]
  },
  {
   "id": "cms-rapid-coverage-pathway-2026",
   "date": "2026-08-11",
   "sort": "2026-08-11b",
   "jurisdiction": "United States",
   "body": "Centers for Medicare & Medicaid Services with the Food and Drug Administration",
   "actionType": "PROCEDURAL NOTICE — COMMENT PERIOD",
   "lifecycle": "PROPOSED · OPEN FOR COMMENT",
   "commentDeadline": "2026-10-13",
   "title": "Medicare proposes same-day coverage review for breakthrough devices: the RAPID pathway",
   "instrument": "Proposed procedural notice, Medicare Program: Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway (CMS-3487-NC), Federal Register 2026-16368, published 11 August 2026",
   "what": "CMS proposes to align its national coverage process with FDA review for eligible Breakthrough Devices: Class II devices participating in FDA's Total Product Life Cycle Advisory Program and Class III Breakthrough Devices regardless of TAP participation. CMS would join manufacturer engagement from the investigational-device-exemption pre-submission stage, and for devices completing the pathway a proposed national coverage determination would issue the same day as FDA market authorisation, opening the statutory 30-day comment period, with a final NCD targeted about 60 days after authorisation for Class II and about 90 for Class III. The Transitional Coverage for Emerging Technologies pathway is paused for new candidates while RAPID is implemented. Comments on the procedural notice close 13 October 2026.",
   "effect": "The practical stake for a clinician is the gap this addresses: FDA authorisation has not meant Medicare coverage, and the wait between the two has run a year or more. Same-day proposed coverage would change when a newly authorised device is actually orderable for a Medicare patient. The structural change is earlier: coverage evidence expectations would be negotiated during trial design, which shapes what endpoints sponsors study.",
   "limits": "A procedural notice is not a coverage decision, and RAPID is proposed, not operative — the pathway takes effect only on publication of a final notice after comments are considered. No device is covered, proposed for coverage, or eligible today because of this notice, and a Breakthrough designation alone does not put a device in the pathway.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "Federal Register — CMS-3487-NC, RAPID Coverage Pathway (2026-16368), comments to 13 October 2026",
     "url": "https://www.federalregister.gov/documents/2026/08/11/2026-16368/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway"
    },
    {
     "label": "CMS fact sheet — RAPID Coverage Pathway procedural notice (CMS-3487-NC)",
     "url": "https://www.cms.gov/newsroom/fact-sheets/regulatory-alignment-predictable-immediate-device-coverage-pathway-cms-3487-nc-procedural-notice"
    },
    {
     "label": "CMS/FDA joint announcement, 23 April 2026",
     "url": "https://www.cms.gov/newsroom/press-releases/cms-fda-announce-rapid-coverage-pathway-accelerate-patient-access-life-changing-medical-devices"
    }
   ],
   "related": [
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/medicare-drug-price-negotiation/",
    "/policy/accelerated-approval-and-confirmatory-trials/"
   ]
  },
  {
   "id": "eo-14420-childhood-vaccine-recommendations-2026",
   "date": "2026-08-10",
   "sort": "2026-08-10z",
   "jurisdiction": "United States",
   "body": "The White House",
   "actionType": "EXECUTIVE ORDER",
   "lifecycle": "EFFECTIVE",
   "title": "An executive order states federal childhood vaccine recommendations — and directs a plan to split the MMR",
   "instrument": "Executive Order 14420 of 10 August 2026, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, published at 91 FR 53173–53175 on 14 August 2026",
   "what": "The order recognises a set of \"Gold Standard Childhood Vaccine Recommendations\" informed by three distinct categories of childhood immunization recommendation identified in an HHS scientific assessment. That assessment was completed under the executive order of 5 December 2025 on aligning United States core childhood vaccine recommendations with best practices from peer, developed countries; it identified a set of consensus vaccines consistently recommended in all peer countries and found that the United States recommends more childhood vaccines than any peer nation, including more than twice as many doses as some European nations. The accompanying White House fact sheet describes the recommendations as covering 11 diseases, a decrease from the 18 it says CDC recommended in 2024, with immunizations no longer recommended for all children moved to shared clinical decision-making. On the combination measles, mumps and rubella vaccine the order states that MMR should be administered as three separate single-disease shots once such products are domestically available, and that to the maximum extent feasible all childhood immunizations should be administered at separate medical visits. It directs the HHS Task Force on Safer Childhood Vaccines to present plans to the President, within 90 days, to offer options to administer core childhood vaccines — starting with MMR — as single vaccines rather than combination products. By its own terms the order is implemented consistent with applicable law and subject to the availability of appropriations, and creates no right or benefit enforceable at law or in equity.",
   "effect": "For a family-medicine practice the operative question is not what the order recommends but what a parent will ask about it, and the honest answer has two halves. The single-antigen route the order prefers for MMR does not exist to prescribe: the order conditions it on such products being domestically available, and directs planning toward that availability rather than establishing it. Separate-visit administration, by contrast, is a scheduling question a practice can already be asked to accommodate, and it multiplies visits for the same protection — which is a conversation about access, transport and missed school and work, not only about immunology. The 90-day plan date is the next thing that actually produces a document.",
   "limits": "An executive order stating recommendations is not the childhood immunization schedule. By its terms this order does not amend any CDC schedule, any ACIP recommendation, any Vaccines for Children resolution, or any licensure; it creates no enforceable right or benefit; and it licenses no product. The MMR provision is conditional on single-disease products becoming domestically available and is a direction to plan, not an available option. Nothing in it changes a state school-entry requirement, which is state law. The 11-versus-18 comparison is the White House's characterisation of its own action, not an independent finding of this record.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "Federal Register — Executive Order 14420 (91 FR 53173, 14 August 2026)",
     "url": "https://www.federalregister.gov/documents/2026/08/14/2026-16730/delivering-gold-standard-childhood-vaccine-recommendations-for-americans"
    },
    {
     "label": "The White House — EO 14420, full text (PDF)",
     "url": "https://www.whitehouse.gov/wp-content/uploads/2026/08/eo-14420.pdf"
    },
    {
     "label": "The White House — fact sheet accompanying the order",
     "url": "https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-delivers-gold-standard-childhood-vaccine-recommendations-for-americans/"
    }
   ],
   "related": [
    "/policy/vaccine-mandates-exemptions-and-institutional-authority/",
    "/policy/school-vaccination-requirements-and-exemption-design/",
    "/policy/vaccine-procurement-injury-compensation-and-public-trust/",
    "/patient-education/hpv-and-adolescent-immunizations/",
    "/patient-education/understanding-immunizations-guide-vaccines-adults-/"
   ]
  },
  {
   "id": "mhra-dsi-2026-007-conformity-2026",
   "date": "2026-08-10",
   "sort": "2026-08-10b",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "SAFETY ALERT — DEVICE SAFETY INFORMATION",
   "lifecycle": "CURRENT",
   "title": "MHRA orders devices supplied without valid UKCA/CE certification out of use and into quarantine",
   "instrument": "Device Safety Information DSI/2026/007, issued under the UK Medical Device Regulations 2002; devices also assessed against Regulation (EU) 2017/745",
   "what": "The MHRA identified medical devices supplied on the UK market without the conformity markings and supporting certification required for lawful supply. Healthcare organisations are told to stop using and supplying the listed devices, retain them pending further advice, notify the MHRA at devices.compliance@mhra.gov.uk quoting DSI/2026/007, and assist with traceability; distributors are to cease further supply and inform customers who may hold affected stock. The device categories reach ordinary clinical work: blood collection and infusion, surgical and biopsy procedures, wound management, and skin preparation and disinfection. One named product is a bone marrow biopsy needle manufactured by Meditech Devices Pvt. Ltd.",
   "effect": "This is a regulatory-status failure rather than a device failure, and it lands differently for that reason. There is no lot-specific defect to look for and no clinical sign to watch: the action is an inventory and procurement question, and the exposure is that conformity assessment, quality-management, sterility and performance assurance were never established for stock already in use.",
   "limits": "The MHRA states expressly that it has not identified any specific defect, performance issue, quality issue or safety signal associated with these products. Nothing here establishes that any patient was harmed, that any listed device malfunctioned, or that any device is unsafe — only that the assurance required for lawful UK supply is absent. It is a Device Safety Information notice, not a recall of a defective product.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "GOV.UK — DSI/2026/007, devices supplied without valid UKCA/CE conformity markings or certification",
     "url": "https://www.gov.uk/drug-device-alerts/devices-supplied-without-valid-ukca-slash-ce-conformity-markings-or-certification-remove-from-use-and-place-in-quarantine-dsi-slash-2026-slash-007"
    },
    {
     "label": "GOV.UK — MHRA advises quarantine of medical devices supplied without appropriate conformity markings",
     "url": "https://www.gov.uk/government/news/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-markings"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/reporting-on-ai-enabled-devices/",
    "/policy/cybersecurity-in-connected-devices/",
    "/policy/how-the-fda-reviews-ai-enabled-devices/"
   ]
  },
  {
   "id": "oig-kansas-parity-pa-2026",
   "date": "2026-08-10",
   "sort": "2026-08-10a",
   "jurisdiction": "United States",
   "body": "HHS Office of Inspector General",
   "actionType": "AUDIT / OVERSIGHT FINDING",
   "lifecycle": "CURRENT",
   "title": "OIG finds Kansas did not ensure Medicaid managed-care parity compliance on prior authorisation",
   "instrument": "OIG audit report A-07-24-02842",
   "what": "OIG reported that Kansas did not ensure its Medicaid managed-care organisations complied with mental-health and substance-use-disorder parity requirements as those requirements apply to prior authorisation.",
   "effect": "Parity is usually litigated as a coverage question; this report locates it in utilisation management, where the physician actually meets it. A prior-authorisation protocol that is more restrictive for behavioural health than for medical or surgical care is a parity problem in its own right, independent of whether the benefit is covered at all.",
   "limits": "The finding is directed at state oversight of its managed-care plans. It is not a penalty, not a finding against any plan's clinical staff, and not a determination about any individual authorisation decision.",
   "desks": [
    "weekly",
    "intelligence",
    "enforcement"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "HHS OIG — What's New (report A-07-24-02842)",
     "url": "https://oig.hhs.gov/newsroom/whats-new/"
    }
   ],
   "related": [
    "/policy/mental-health-parity-enforcement/",
    "/policy/claim-denials-and-the-appeals-ladder/",
    "/policy/peer-to-peer-review/",
    "/policy/ai-in-utilization-management/",
    "/policy/public-reporting-of-pa-metrics/"
   ]
  },
  {
   "id": "mhra-dsi-2026-006-belzer-update-2026",
   "date": "2026-08-06",
   "sort": "2026-08-06b",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "SAFETY ALERT — SUPERSEDING UPDATE",
   "lifecycle": "CURRENT",
   "supersedes": "DSI/2023/005",
   "title": "UK closes a transplant-fluid safety chapter: the 2023 Belzer advice is superseded and sales resume",
   "instrument": "Device Safety Information DSI/2026/006, published 6 August 2026, replacing DSI/2023/005. Products: Belzer UW Cold Storage Solution and Belzer MPS (UW Machine Perfusion Solution), manufactured by Carnamedica; UK responsible person Bridge to Life",
   "what": "The MHRA updated its advice on Belzer organ-preservation solutions, where defects — leakage and discolouration producing potentially contaminated fluid — had posed a risk of significant patient harm and led to the 2023 advice and a suspension of sales. Corrective action by Carnamedica and Bridge to Life has been accepted; the sales suspension is lifted; DSI/2023/005 is replaced and should no longer be followed. The MHRA’s review of its data found no safety signals arising from the earlier defect period. The audience list shows the reach: critical care, general surgery, transplantation and immunosuppression, renal medicine, cardiac and vascular surgery, paediatrics and neonatology.",
   "effect": "For transplant services this is the resolution state of a two-and-a-half-year safety file: the fluid that flushes and stores donated organs returns to normal supply under updated instructions. The record-keeping point is the lifecycle: the 2023 advice is not deleted, it is superseded by a named successor — following the old advice is now itself the error.",
   "limits": "Lifting a suspension establishes that corrective action satisfied the regulator, not that the original defect never mattered and not a finding about any past transplant outcome. The operative instructions are those in DSI/2026/006; this record does not restate handling detail that belongs to the notice itself.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "GOV.UK — MHRA device safety information and alerts index (DSI/2026/006, 6 August 2026)",
     "url": "https://www.gov.uk/drug-device-alerts"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "fda-tudriqev-accelerated-approval-2026",
   "date": "2026-08-06",
   "sort": "2026-08-06a",
   "jurisdiction": "United States",
   "body": "Food and Drug Administration",
   "actionType": "MARKETING AUTHORISATION — ACCELERATED APPROVAL",
   "lifecycle": "CURRENT",
   "excludeFromEnforcement": true,
   "title": "FDA grants accelerated approval to Tudriqev for anti-PD-1 refractory advanced melanoma",
   "instrument": "Accelerated approval, 21 C.F.R. pt. 601 subpt. E; BLA granted to Replimune, Inc.",
   "what": "On 6 August 2026 the FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified HSV-1 oncolytic viral therapy, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma that progressed on a PD-1-blocking antibody regimen. The open-label single-arm trial enrolled 140 patients and evaluated 91; 24 per cent achieved an objective response, with a median duration of 14.1 months. The product is injected intratumourally every two weeks for eight doses, with nivolumab from week three. The application held Breakthrough Therapy and Priority Review designations and went before the Cellular, Tissue, and Gene Therapies Advisory Committee on 30 July 2026.",
   "effect": "For primary care the relevance is not prescribing but explanation: patients will ask what an accelerated approval means. It means the evidence supporting approval is a response rate and its duration in a single-arm trial, not a survival advantage over an alternative, and that continued approval is contingent on confirmatory trials. Safety counselling includes the risk of transmitting herpes infection to close contacts and of herpes reactivation in the patient.",
   "limits": "This is a marketing authorisation, not an institutional enforcement action, and it is deliberately excluded from the enforcement ledger so that taxonomy keeps its meaning. Clinical benefit has not been verified; the approval may be withdrawn if confirmatory trials do not confirm it.",
   "desks": [
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "FDA — FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma (6 Aug 2026)",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma"
    }
   ],
   "related": [
    "/policy/accelerated-approval-and-confirmatory-trials/",
    "/policy/real-world-evidence-in-regulatory-decisions/",
    "/policy/clinical-trial-diversity-and-results-transparency/",
    "/patient-education/cancer-screening-when-and-what-tests-you-need/"
   ]
  },
  {
   "id": "mhra-dsi-2026-005-atlan-ventilator-2026",
   "date": "2026-08-04",
   "sort": "2026-08-04b",
   "jurisdiction": "United Kingdom",
   "body": "Medicines and Healthcare products Regulatory Agency",
   "actionType": "SAFETY ALERT — DEVICE SAFETY INFORMATION",
   "lifecycle": "CURRENT",
   "title": "UK: anaesthesia workstations with a piston-ventilator defect stay in service — under permanent supervision",
   "instrument": "Device Safety Information DSI/2026/005, published 4 August 2026, following Dräger’s April 2026 Field Safety Notice expanding an October 2024 FSN",
   "what": "Dräger’s April 2026 Field Safety Notice expanded the population of Atlan anaesthesia workstations affected by a manufacturing defect that can cause piston ventilator failure before or during use; the FSN extends one issued in October 2024 for the same issue. The MHRA directs sites to identify affected devices from the FSN listing, have Dräger replace the motor assemblies, and until replacement use affected devices only with permanent supervision per the instructions for use. If mechanical ventilation fails — the device alarms with a ventilator-error message — the direction is immediate transition to manual or spontaneous ventilation.",
   "effect": "Atlan workstations deliver anaesthesia and ventilation for adults, children and neonates. The operational weight of this alert is the mitigation, not a removal: an affected theatre keeps its equipment running but must staff for continuous supervision and be ready to hand-ventilate. That is a rota and training question for every site on the FSN list, and it lasts until Dräger completes the motor-assembly replacements.",
   "limits": "As of 29 July 2026 the manufacturer reports no confirmed patient injuries or deaths associated with the issue. A Device Safety Information notice with mitigations is not a recall from service and not a finding of harm; it is a managed correction of a manufacturing deviation, with interim use permitted under stated conditions.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "sources": [
    {
     "label": "GOV.UK — DSI/2026/005: Dräger Atlan anaesthesia workstations, risk of ventilator failure",
     "url": "https://www.gov.uk/drug-device-alerts/drager-atlan-anaesthesia-workstations-risk-of-ventilator-failure-dsi-slash-2026-slash-005"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/cybersecurity-in-connected-devices/"
   ]
  },
  {
   "id": "fda-bd-intraosseous-early-alert-2026",
   "date": "2026-08-04",
   "sort": "2026-08-04a",
   "jurisdiction": "United States",
   "body": "FDA — Center for Devices and Radiological Health",
   "actionType": "DEVICE SAFETY — EARLY ALERT / FIRM-INITIATED RECALL",
   "lifecycle": "CURRENT",
   "documentState": "EARLY ALERT",
   "recallClassificationState": "NOT YET CLASSIFIED IN FDA RECALL DATABASE AT DATE OF READING",
   "title": "Intraosseous needle sets recalled after reports the stylet can lock in place during insertion",
   "instrument": "FDA Early Alert: Intraosseous Needle Set Issue from Becton Dickinson, 4 August 2026; BD customer letter 30 July 2026; BD recall announcement 31 July 2026",
   "what": "Certain BD Intraosseous Vascular Access System Needle Sets (five powered-driver needle kits, 15Ga, 15–55mm) were manufactured with out-of-tolerance dimensions, allowing the obturator (stylet) to rotate and lock into the needle hub during insertion. FDA reports that as of 22 July BD had reported 45 serious injuries and four deaths associated with the issue. Affected lots were distributed between 30 September 2024 and 12 June 2026. The powered driver itself is not affected.",
   "effect": "This is an insertion-phase failure in a device used when intravenous access cannot be obtained — out-of-hospital cardiac arrest, severe trauma. Affected lots are to be identified and destroyed, not returned to stock. FDA states that a needle already placed and functioning needs no additional step, and that unsuccessful IO placement does not exhaust vascular access options: additional peripheral attempts or central access remain available on clinical judgement.",
   "limits": "FDA issued this as an Early Alert, which FDA uses to notify the public of a potentially high-risk device issue while it is still reviewing information. At the date of reading, an Early Alert plus a firm-initiated recall is what the record establishes; a Class I designation for this 2026 event was not located in FDA’s device-recall database and is therefore not asserted here. An earlier 2022 BD intraosseous recall (Z-1397-2022) was separately classified Class I and is a different event.",
   "desks": [
    "weekly",
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-18",
   "sources": [
    {
     "label": "FDA — Early Alert: Intraosseous Needle Set Issue from Becton Dickinson",
     "url": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intraosseous-needle-set-issue-becton-dickinson",
     "readOn": "2026-08-18"
    },
    {
     "label": "FDA — BD recall announcement, 31 July 2026",
     "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bd-issues-nationwide-recall-specific-lots-bdr-intraosseous-vascular-access-system-needle-sets-due",
     "readOn": "2026-08-18"
    },
    {
     "label": "FDA — affected lot list",
     "url": "https://www.fda.gov/media/194047/download?attachment",
     "readOn": "2026-08-18"
    }
   ]
  },
  {
   "id": "ab539-suspense-cleared-2026",
   "date": "2026-08-03",
   "sort": "2026-08-03z",
   "jurisdiction": "California",
   "body": "Legislature",
   "actionType": "LEGISLATIVE ACTION",
   "lifecycle": "ACTIVE — SENATE FLOOR PENDING",
   "title": "AB 539 (prior authorization, Schiavo): cleared the Senate Appropriations suspense file, heads to the floor",
   "instrument": "AB 539 (2025–2026 Reg. Sess.): 3 August 2026 Senate — placed on suspense file (7–0), following 1 July do pass as amended and re-refer to Appropriations",
   "what": "The bill would require health-plan and insurer prior authorizations to remain valid for at least one year. No third-reading vote was located.",
   "effect": "A one-year validity rule would remove the most common friction in chronic-disease management: re-authorising a therapy the payer already approved.",
   "limits": "No current payer obligation arises from this bill. Not enrolled and not law.",
   "desks": [
    "weekly",
    "policy"
   ],
   "verifiedOn": "2026-08-29",
   "sources": [
    {
     "label": "LegiScan — AB 539 action history",
     "url": "https://legiscan.com/CA/bill/AB539/2025"
    }
   ],
   "related": [
    "/policy/prior-authorization/",
    "/intelligence/california-legislature-2026/"
   ],
   "record": "/weekly/#updates-0829"
  },
  {
   "id": "oig-si-joint-injections-2026",
   "date": "2026-08-03",
   "sort": "2026-08-03a",
   "jurisdiction": "United States",
   "body": "HHS Office of Inspector General",
   "actionType": "AUDIT / OVERSIGHT FINDING",
   "lifecycle": "CURRENT",
   "title": "OIG estimates $15.2 million in improper Medicare payments for sacroiliac-joint injections",
   "instrument": "OIG national audit report, issued 3 August 2026",
   "what": "OIG reviewed sacroiliac-joint injection sessions billed to Medicare between 1 October 2023 and 30 September 2024. From a sample of 100 sessions it found 72 did not comply with Medicare requirements, and it projected that 134,526 of the 186,842 sessions in its review universe were improperly paid, an estimated $15.2 million. A large share of the errors involved therapeutic injections billed as though they were diagnostic. OIG recommended that CMS expand contractor education and consider greater national consistency in local coverage rules; CMS concurred with two of the three recommendations.",
   "effect": "The exposure here is coding and documentation, not fraud. Because the error pattern is diagnostic-versus-therapeutic classification and local coverage determinations differ between contractors, a physician can bill identically in two jurisdictions and be compliant in one. The recommendation for national consistency is the part to watch: if CMS acts on it, the coverage rule a practice relies on may change without any new statute.",
   "limits": "An audit finding is not an enforcement action. OIG made no allegation of fraud, named no physician, and established no violation by any individual clinician. The recommendations run to CMS, not to providers, and remain open and unimplemented.",
   "desks": [
    "weekly",
    "intelligence",
    "enforcement"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "HHS OIG — Medicare Improperly Paid Physicians an Estimated $15.2 Million for Sacroiliac Joint Injections",
     "url": "https://oig.hhs.gov/reports/all/2026/medicare-improperly-paid-physicians-an-estimated-152-million-for-sacroiliac-joint-injections/"
    }
   ],
   "related": [
    "/policy/interpreting-enforcement-statistics/",
    "/policy/why-enforcement-data-need-context/",
    "/policy/inspectors-general-and-gao-in-health-oversight/",
    "/policy/the-false-claims-act-in-healthcare/",
    "/policy/quality-measures-and-gaming/"
   ]
  },
  {
   "id": "eu-art50",
   "date": "2026-08-02",
   "sort": "2026-08-02b",
   "jurisdiction": "European Union",
   "body": "European Commission",
   "actionType": "REGULATION",
   "lifecycle": "EFFECTIVE",
   "title": "EU AI Act Article 50 transparency obligations begin to apply",
   "instrument": "Regulation (EU) 2024/1689 (AI Act), Article 50",
   "what": "Article 50's transparency duties apply from 2 August 2026: disclosure that a person is interacting with an AI system, machine-readable marking of synthetic content, and disclosure of emotion-recognition and biometric-categorisation use.",
   "effect": "The high-risk obligations most relevant to clinical devices are deferred to a later date; the transparency layer is not. A European deployment of an ambient scribe or triage chatbot carries a disclosure duty now, independent of whether the system is ultimately classified high-risk.",
   "limits": "Deferral of the high-risk timetable did not defer Article 50, and no health-sector carve-out applies.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "European Commission — guidelines on Article 50 transparency obligations",
     "url": "https://digital-strategy.ec.europa.eu/en/library/guidelines-transparency-obligations-providers-and-deployers-ai-systems"
    }
   ],
   "record": "/weekly/2026-08-15/#eu-art50",
   "related": [
    "/policy/global-ai-standards/",
    "/policy/regulatory-framework-across-the-ai-lifecycle/"
   ]
  },
  {
   "id": "caita-operative",
   "date": "2026-08-02",
   "sort": "2026-08-02a",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "STATUTE",
   "lifecycle": "EFFECTIVE",
   "title": "California AI Transparency Act becomes operative",
   "instrument": "Bus. & Prof. Code ch. 25 (SB 942, 2024, as amended by AB 853, 2025)",
   "what": "The Act's first tranche of duties became operative. Covered generative-AI providers must offer detection tooling and attach provenance disclosures to content they generate; large online platform and capture-device duties follow on later dates set in the amended statute.",
   "effect": "A physician using a generative tool inside documentation or patient communication is a deployer, not a provider, and the Act does not transfer the provider's disclosure duty onto the clinician. What it does change is the evidentiary picture: provenance metadata now travels with generated text, which is discoverable.",
   "limits": "Nothing in the Act addresses clinical standard of care or malpractice exposure.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "California Legislative Information — AB 853 text",
     "url": "https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202520260AB853"
    }
   ],
   "record": "/weekly/2026-08-15/#caita",
   "related": [
    "/policy/generative-ai-in-medical-documentation/",
    "/policy/ai-assisted-diagnosis-and-physician-responsibility/"
   ]
  },
  {
   "id": "health-canada-bundibugyo-mrna-trial-2026",
   "date": "2026-07-30",
   "sort": "2026-07-30b",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "CLINICAL TRIAL AUTHORIZATION",
   "lifecycle": "CURRENT",
   "title": "Canada authorises a first-in-human trial of an mRNA vaccine against Bundibugyo Ebola",
   "instrument": "Health Canada clinical trial authorization, 30 July 2026: Phase I study of Moderna’s candidate mRNA vaccine (mRNA-1469) against Ebola disease caused by Bundibugyo virus",
   "what": "Health Canada authorised a Phase I trial of an mRNA vaccine candidate against Bundibugyo virus — the Ebola species driving the current outbreak in the Democratic Republic of the Congo, for which no licensed vaccine or treatment exists. Canada is the second country to authorise a Phase I Bundibugyo vaccine trial, after the UK. The study assesses safety, dose range and side effects in healthy participants. The company announced first vaccinations on 4 August; that is company material.",
   "effect": "Nothing changes in any clinic. The record’s value is exactly what a Phase I authorization is: the earliest human-evidence stage, in a disease where the outbreak is outpacing the toolkit. If the candidate advances, later phases and any authorisation each require their own decision.",
   "limits": "A clinical trial authorization is not a vaccine approval, not a finding of efficacy, and not evidence the candidate works. Phase I measures safety and immune response in small numbers of healthy volunteers. No product is available to patients on this record, in Canada or anywhere else.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-19",
   "frontier": true,
   "sources": [
    {
     "label": "Health Canada — news release, 30 July 2026 authorization",
     "url": "https://www.canada.ca/en/health-canada/news/2026/08/health-canada-authorizes-vaccine-clinical-trial-for-ebola-disease-caused-by-the-bundibugyo-virus.html"
    }
   ],
   "related": [
    "/policy/clinical-trial-diversity-and-results-transparency/",
    "/patient-education/understanding-immunizations-guide-vaccines-adults-/",
    "/policy/accelerated-approval-and-confirmatory-trials/"
   ]
  },
  {
   "id": "cms-2452-p",
   "date": "2026-07-23",
   "sort": "2026-07-23",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROPOSED RULE",
   "lifecycle": "PROPOSED",
   "title": "CMS proposes to replace the 6 percent provider-tax threshold with state-specific ceilings",
   "instrument": "CMS-2452-P, 91 FR (2026-14897) — Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes; released 21 July 2026, published 23 July 2026",
   "what": "The rule would implement section 71115 of Public Law 119-21 by replacing the long-standing 6 percent indirect hold-harmless threshold with thresholds based on taxes enacted and imposed as of 4 July 2025, effective 1 October 2026, with a phase-down for most permissible classes in Medicaid expansion states from 1 October 2027. It would also add services of health insurers as a new permissible class and create new reporting requirements. Comments are due 21 September 2026. The CMS Office of the Actuary estimates the rule would reduce federal expenditures by $246 billion over ten years.",
   "effect": "This is a financing rule with clinical consequences: provider taxes fund a large share of the non-federal Medicaid share, and a state that loses that revenue adjusts provider rates, eligibility processing, or managed-care capitation — not its statutory obligations. For a physician seeing Medi-Cal patients, the exposure is rate and access pressure two budget cycles out, not a compliance duty.",
   "limits": "Proposed. The 1 October 2026 statutory date belongs to section 71115, not to this rule; nothing in the proposal binds a state or a provider until a final rule issues.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "Federal Register — CMS-2452-P (23 July 2026)",
     "url": "https://www.federalregister.gov/documents/2026/07/23/2026-14897/medicaid-program-amending-the-indirect-hold-harmless-threshold-of-health-care-related-taxes"
    },
    {
     "label": "CMS — CMS-2452-P fact sheet",
     "url": "https://www.cms.gov/newsroom/fact-sheets/amending-indirect-hold-harmless-threshold-health-care-related-taxes-proposed-rule-cms-2452-p"
    }
   ],
   "related": [
    "/policy/medicaid-financing-mechanics-provider-taxes-and-state-directed-payments/",
    "/policy/public-participation-in-regulation/",
    "/policy/medicaid-financing-mechanics-provider-taxes-and-state-directed-payments/"
   ]
  },
  {
   "id": "medi-cal-orp",
   "date": "2026-07-23",
   "sort": "2026-07-23",
   "jurisdiction": "California",
   "body": "Department of Health Care Services",
   "actionType": "AGENCY GUIDANCE",
   "lifecycle": "EFFECTIVE",
   "title": "Medi-Cal ordering, referring and prescribing enrollment bulletin takes effect",
   "instrument": "DHCS provider bulletin; 42 C.F.R. § 455.410(b); Welf. & Inst. Code §§ 14043.1, 14043.26",
   "what": "DHCS updated the forms and procedures for ordering/referring/prescribing-only (ORP) enrollment. The bulletin is effective; the enforcement date for claim denials tied to an unenrolled ORP provider is phased and, on the record read, not fixed.",
   "effect": "A physician who never bills Medi-Cal but writes prescriptions or referrals for Medi-Cal patients is inside the enrollment requirement. The exposure is not to the physician's own billing but to the pharmacy's or laboratory's claim, which is the party that gets denied.",
   "limits": "The requirement is the record; no dated DHCS notice fixing an enforcement commencement date forms part of it.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "DHCS — updated Medi-Cal requirements for ORP provider forms and procedures",
     "url": "https://www.dhcs.ca.gov/updated-medi-cal-requirements-for-ordering-referring-prescribing-provider-forms-and-procedures/"
    },
    {
     "label": "DHCS — ORP-only enrollment information",
     "url": "https://www.dhcs.ca.gov/providers-partners/ordering-referring-prescribing-only-enrollment-information/"
    }
   ],
   "record": "/weekly/2026-08-15/#medi-cal-orp",
   "related": [
    "/policy/how-medi-cal-managed-care-plans-coordinate-care/"
   ]
  },
  {
   "id": "cms-california-medicaid-deferral-2026",
   "date": "2026-07-21",
   "sort": "2026-07-21a",
   "jurisdiction": "United States",
   "body": "HHS / Centers for Medicare & Medicaid Services",
   "vertical": "docket",
   "actionType": "PROGRAM INTEGRITY — PAYMENT DEFERRAL",
   "lifecycle": "CURRENT",
   "title": "CMS defers approximately $867.5 million in federal Medicaid payments to California",
   "instrument": "HHS press release, 21 July 2026; CMS focused financial review",
   "what": "CMS deferred approximately $867.5 million in federal Medicaid payments to California and $199 million to Minnesota after focused financial reviews identified claims requiring additional review before federal matching funds are released. For California, CMS reviewed claims for certain in-home care programmes after identifying spending growth it described as far exceeding national trends. HHS stated in the same announcement that these are payment deferrals and not permanent funding cuts, and that both states may provide documentation showing the claims meet federal Medicaid requirements. HHS also described continued use of exclusion authorities.",
   "effect": "The clinically relevant consequence is not fiscal but operational. California reimburses continuously, so a prolonged hold on matching funds for in-home care can reach caregiver payroll and service scheduling well before it reaches any policy document — meaning the first sign of it in practice is a patient whose home-care hours become unreliable. Treat it as a discharge-planning risk.",
   "limits": "A deferral is not a permanent cut, not a fraud adjudication, not a disallowance, and not a finding against any individual provider or beneficiary. It operates on federal matching funds to the state and does not change any patient's eligibility or benefits.",
   "desks": [
    "weekly",
    "intelligence",
    "enforcement"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "HHS — HHS Defers More Than $1 Billion in Medicaid Payments to California, Minnesota Pending Review of High-Risk Claims",
     "url": "https://www.hhs.gov/press-room/hhs-defers-medicaid-payments-california-minnesota-fraud-review.html"
    }
   ],
   "related": [
    "/policy/medicaid-financing-mechanics-provider-taxes-and-state-directed-payments/",
    "/policy/home-and-community-based-services-vs-institutional-bias/",
    "/policy/interpreting-enforcement-statistics/",
    "/policy/why-enforcement-data-need-context/",
    "/policy/the-direct-care-workforce-pay-training-and-retention/"
   ]
  },
  {
   "id": "cms-mfp-effectuation-guidance-2028",
   "date": "2026-07-16",
   "sort": "2026-07-16a",
   "jurisdiction": "United States",
   "body": "Centers for Medicare & Medicaid Services",
   "vertical": "medicare-cms",
   "actionType": "DRAFT GUIDANCE — COMMENT PERIOD",
   "lifecycle": "PROPOSED",
   "title": "CMS draft guidance on manufacturer effectuation of the 2028 maximum fair price",
   "instrument": "Draft guidance, Medicare Drug Price Negotiation Program, issued 16 July 2026",
   "commentDeadline": "2026-09-18",
   "what": "CMS issued draft guidance addressing how manufacturers are to effectuate the maximum fair price for initial price applicability year 2028. Comments are due by 11:59 p.m. Pacific on 18 September 2026 and are submitted by email rather than through regulations.gov.",
   "effect": "Sets out the agency’s proposed expectations for manufacturer effectuation; it is the second open window on the negotiation programme after CMS-4215-P closed on 17 August 2026.",
   "limits": "Draft guidance is not a regulation. It creates no duty for any physician, pharmacy or manufacturer while in draft, and the submission route is email, which is a common cause of missed comment deadlines.",
   "desks": [
    "medicare-cms"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "CMS — Medicare Drug Price Negotiation Program, regulations, guidance and policy documents",
     "url": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/regulations-guidance-policy-documents"
    }
   ],
   "related": [
    "cms-4215-p-comment-close"
   ]
  },
  {
   "id": "cms-1848-p",
   "date": "2026-07-16",
   "sort": "2026-07-16",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROPOSED RULE",
   "lifecycle": "PROPOSED",
   "title": "CY 2027 Physician Fee Schedule proposed rule published",
   "instrument": "CMS-1848-P, 91 FR 43842 — CY 2027 Payment Policies under the Physician Fee Schedule",
   "what": "Placed on public display 14 July 2026 and published 16 July 2026; comments close 14 September 2026. Finalized policies would generally take effect 1 January 2027.",
   "effect": "Two conversion factors and an efficiency adjustment carry forward as proposals for a second year, which means the CY 2026 structure is not a one-year experiment. Comment is the only stage at which a physician's operational objection is on the record.",
   "limits": "No obligation arises until a final rule issues; the 2027 dates in the proposal are not duties.",
   "desks": [
    "weekly",
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "CMS — CMS-1848-P regulation notice",
     "url": "https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1848-p"
    },
    {
     "label": "CMS — CY 2027 PFS fact sheet",
     "url": "https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule"
    }
   ],
   "record": "/enforcement/#pfs-2027",
   "related": [
    "/policy/telehealth-payment-after-temporary-flexibilities/",
    "/policy/value-based-payment-and-the-risk-of-undertreatment/"
   ],
   "commentDeadline": "2026-09-14"
  },
  {
   "id": "hr3514-markup",
   "date": "2026-07-15",
   "sort": "2026-07-15",
   "jurisdiction": "United States",
   "body": "House Committee on Ways and Means",
   "actionType": "LEGISLATION IN PROGRESS",
   "lifecycle": "PROPOSED",
   "title": "Ways and Means advances the Medicare Advantage prior-authorization bill to the full House",
   "instrument": "H.R. 3514, Improving Seniors' Timely Access to Care Act; full-committee markup, 15 July 2026",
   "what": "The committee marked up a health package including H.R. 3514 and reported it out; the bill advances to the full House. As introduced, it would require an electronic prior-authorization programme and enrollee-protection standards for plan years beginning on or after 1 January 2028, with transparency requirements from 1 January 2027.",
   "effect": "This is the legislative track running alongside the CMS interoperability rules. If it passes in this form, the API duties CMS built by rule acquire a statutory floor and a real-time-decision definition that a rule alone can revise.",
   "limits": "A reported bill is not law. Nothing in it binds any plan today, and committee approval does not schedule a floor vote.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-16",
   "sources": [
    {
     "label": "House Ways and Means — full-committee markup notice, 15 July 2026",
     "url": "https://waysandmeans.house.gov/event/markup-of-h-r-9641-h-r-3108-h-r-9642-h-r-9468-h-r-3514-h-r-9644-and-h-r-9645/"
    },
    {
     "label": "Congress.gov — H.R. 3514 (119th Congress)",
     "url": "https://www.congress.gov/bill/119th-congress/house-bill/3514"
    }
   ],
   "related": [
    "/policy/electronic-pa-and-cms-interoperability-rules/",
    "/policy/investigating-pa-delays/",
    "/policy/fhir-apis-and-coverage-decisions/"
   ]
  },
  {
   "id": "sb164-hha-moratorium-2026",
   "date": "2026-06-29",
   "sort": "2026-06-29z",
   "jurisdiction": "California",
   "body": "Legislature · CDPH",
   "actionType": "STATUTE",
   "lifecycle": "EFFECTIVE",
   "title": "California closed home health agency licensing on enactment: SB 164 and the unmet-need exception",
   "instrument": "Senate Bill 164 (2025–2026 Reg. Sess.), effective on enactment 29 June 2026; Health and Safety Code § 1728.9 (moratorium) and § 1728.95 (exception); § 1734 (regulation-making authority)",
   "what": "Section 1728.9 bars the department from issuing a new home health agency licence, or approving a new branch office on an existing licence, during a moratorium. Section 1728.95 permits an exception where the department makes a written finding that an applicant — including an applicant whose application was pending when the section took effect — has demonstrated an unmet need for home health services in the proposed service area, judged on the concentration of existing services. Section 1734 carries the department's authority to adopt implementing regulations.",
   "effect": "California has now used the same instrument on hospice and on home health: freeze entry, then write the regulations the freeze was meant to buy time for. The market-structure question — who may enter and who may own a home health agency — is being decided through licensure capacity rather than through payment or quality rules.",
   "limits": "The chapter number, the outer end date of the moratorium, and the operational requirements CDPH has set out in All Facilities Letter 26-28 are not stated: the chaptered text and the AFL have not been read at source. Nothing here states a filing deadline for an existing agency.",
   "desks": [
    "policy",
    "weekly"
   ],
   "verifiedOn": "2026-08-30",
   "verifyBeforePublication": [
    "CDPH AFL 26-28 full text",
    "chapter number",
    "moratorium end date"
   ],
   "sources": [
    {
     "label": "California Department of Finance — trailer bill text adding HSC §§ 1728.9, 1728.95 and amending § 1734",
     "url": "https://trailerbill.dof.ca.gov/public/trailerBill/pdf/1481"
    }
   ],
   "related": [
    "/policy/home-based-care-and-provider-market-entry/",
    "/policy/change-of-ownership-review/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "medi-cal-dental-delay-2027",
   "date": "2026-06-29",
   "sort": "2026-06-29a",
   "jurisdiction": "California",
   "body": "Department of Health Care Services",
   "vertical": "medi-cal",
   "actionType": "BENEFIT CHANGE — DELAYED",
   "lifecycle": "CORRECTED",
   "effectiveDate": "2027-07-01",
   "title": "Medi-Cal adult dental elimination delayed from 1 July 2026 to 1 July 2027",
   "instrument": "California 2026-27 State Budget, signed 29 June 2026; DHCS Medi-Cal Dental Benefit Changes notice",
   "what": "The scheduled elimination of routine adult dental benefits for Medi-Cal members aged 19 and older who do not qualify for federally funded full-scope Medi-Cal was moved from 1 July 2026 to 1 July 2027. Discontinuation of Proposition 56 supplemental payments and removal of Prospective Payment System per-visit rates for specified clinic encounters not eligible for federal financial participation were delayed on the same schedule. From 1 July 2027 eligibility verification returns DENTAL BENEFITS LIMITED TO EMERGENCY SERVICES ONLY, and affected members in a Dental Managed Care plan may be disenrolled from that plan.",
   "effect": "There is an eleven-month window in which affected adults still have full dental benefits, and most public commentary written from the original budget describes the benefit as already gone. Protected regardless of immigration status: anyone under 19, pregnant members through one year postpartum, and foster or former foster youth under 26 who were in care on their 18th birthday. Emergency dental — severe pain, infection, extraction — continues after the change.",
   "limits": "The delay changes a date, not the policy. Nothing here restores a benefit permanently, and nothing changes eligibility for any other Medi-Cal benefit. Eligibility is determined by the county on individual circumstances.",
   "desks": [
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "DHCS — Medi-Cal Dental Benefit Changes",
     "url": "https://www.dhcs.ca.gov/services/medi-cal-dental-benefit-changes/"
    },
    {
     "label": "Medi-Cal Adult Dental Information — 2026-27 budget delay",
     "url": "https://dental.dhcs.ca.gov/Members/Dental_Managed_Care/Managed_Care_Resources/MediCalAdultDentalInformation"
    },
    {
     "label": "DHCS — Immigration Status and Changes to Medi-Cal Eligibility",
     "url": "https://www.dhcs.ca.gov/immigration-status-and-changes-to-medi-cal-eligibility/"
    }
   ],
   "related": [
    "/policy/medi-cal-in-plain-language/",
    "/policy/medi-cal-dental-vision-pharmacy-and-medical-benefits/",
    "/policy/immigrant-eligibility-rules-and-chilling-effects-on-care/",
    "/policy/dental-therapy-and-oral-health-access/"
   ]
  },
  {
   "id": "carbon-health",
   "date": "2026-06-26",
   "sort": "2026-06-26",
   "jurisdiction": "California",
   "body": "Attorney General",
   "actionType": "CIVIL SETTLEMENT",
   "lifecycle": "CURRENT",
   "title": "Carbon Health settlement: structural remedy and individual liability in a friendly-PC structure",
   "instrument": "California Attorney General settlement with Carbon Health Technologies, Inc., affiliated professional medical corporations, and its co-founder and former chief executive",
   "what": "Announced 26 June 2026. The settlement reaches the corporate entity, the affiliated professional corporations, and an individual.",
   "effect": "The naming of an individual is the part that changes planning. A structure that recites physician ownership on paper does not insulate the person who exercised the disputed control.",
   "limits": "A negotiated resolution, ordinarily without admission of liability. The amount is not a measure of proven harm and creates no precedent.",
   "desks": [
    "enforcement"
   ],
   "verifiedOn": "2026-08-14",
   "sources": [
    {
     "label": "California Department of Justice — Office of the Attorney General",
     "url": "https://oag.ca.gov/news"
    }
   ],
   "record": "/enforcement/#carbon-health",
   "related": [
    "/policy/professional-corporations-and-msos/",
    "/policy/who-employs-the-physician/"
   ]
  },
  {
   "id": "dmhc-blue-shield",
   "date": "2026-06-23",
   "sort": "2026-06-23b",
   "jurisdiction": "California",
   "body": "Department of Managed Health Care",
   "actionType": "ADMINISTRATIVE ENFORCEMENT",
   "lifecycle": "CURRENT",
   "title": "DMHC fines Blue Shield of California $300,000 over denied newborn-care payments",
   "instrument": "DMHC enforcement action announced 23 June 2026; Knox-Keene Health Care Service Plan Act",
   "what": "The Department announced a $300,000 administrative penalty against Blue Shield of California for denying payments for newborn care.",
   "effect": "Newborn care is the recurring pattern in this line of enforcement: the infant is a new enrollee whose eligibility posts after the encounter, so the claim is denied on enrollment grounds for care the plan must cover. A denial in that shape is a plan-side defect worth escalating rather than writing off.",
   "limits": "An administrative penalty against a plan is not a finding about any physician or any individual claim, and it does not itself reopen denied claims.",
   "desks": [
    "enforcement",
    "weekly"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "DMHC — press releases index",
     "url": "https://www.dmhc.ca.gov/Resources/Newsroom/PressReleases.aspx"
    },
    {
     "label": "DMHC — Enforcement Actions Database",
     "url": "https://www.dmhc.ca.gov/LawsRegulations/EnforcementActions.aspx"
    }
   ],
   "related": [
    "/policy/grievances-exhaustion-and-clinical-complaints/",
    "/policy/investigating-pa-delays/"
   ]
  },
  {
   "id": "doj-takedown-2026",
   "date": "2026-06-23",
   "sort": "2026-06-23",
   "jurisdiction": "United States",
   "body": "Department of Justice",
   "actionType": "CRIMINAL CHARGE",
   "lifecycle": "CURRENT",
   "title": "2026 National Health Care Fraud Takedown: 455 defendants charged",
   "instrument": "DOJ 2026 National Health Care Fraud Takedown, announced 23 June 2026",
   "what": "DOJ announced charges against 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving over $6.5 billion in alleged false claims. Cases were brought in 56 federal districts across 45 states and territories, with all 50 state Medicaid Fraud Control Units participating, and over $182 million in assets seized. Alongside the charges, CMS suspended 1,079 providers and revoked billing privileges for 1,403.",
   "effect": "The administrative half is the part physicians underestimate. A payment suspension or revocation lands before any adjudication and does not wait for a plea, a verdict, or a licensing decision — which is why the CMS numbers, not the defendant count, are the operational risk.",
   "limits": "Every charge is an allegation. No finding of guilt exists until conviction or plea, and dispositions will be added to this record as they issue rather than replacing it.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-16",
   "sources": [
    {
     "label": "Justice Department — takedown announcement, 23 June 2026",
     "url": "https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-455-defendants-charged-connection-over-65"
    },
    {
     "label": "HHS-OIG — 2026 National Health Care Fraud Takedown case index",
     "url": "https://oig.hhs.gov/fraud/enforcement/2026-national-health-care-fraud-takedown/"
    }
   ],
   "related": [
    "/policy/the-false-claims-act-in-healthcare/",
    "/policy/interpreting-enforcement-statistics/",
    "/policy/complaint-is-not-finding/"
   ]
  },
  {
   "id": "fda-mqsa-monterey-2026",
   "date": "2026-06-22",
   "sort": "2026-06-22z",
   "jurisdiction": "United States",
   "body": "FDA · CDRH",
   "actionType": "SAFETY NOTIFICATION",
   "lifecycle": "CURRENT",
   "title": "FDA: mammograms at a Monterey, California facility may be of poor quality — and the facility has not sent the notices it was ordered to send",
   "instrument": "FDA Safety Notification — Mammography Problems at Mammography Center of Monterey; Patient and Provider Notification order required 22 June 2026 under the Mammography Quality Standards Act, 42 U.S.C. § 263b",
   "what": "FDA required the facility to notify patients examined on or after 22 December 2023, and their referring providers, of possible problems with the quality of their mammograms. As at the posting of the notification the facility had not complied with that order. The facility is not accredited, does not hold an active MQSA certificate, and may not lawfully perform mammography. FDA's advice to a patient who has not since had a mammogram at another MQSA-certified facility is to obtain her images and reports and have them reviewed at a certified facility.",
   "effect": "This is California, it is patient-facing, and the ordinary safety net failed twice: the facility lost its certification and then did not send the letters. A woman who had a mammogram in Monterey since December 2023 may have been reassured by an image nobody qualified has since read.",
   "limits": "An MQSA certification and notification action. Not a recall, not a finding that any individual patient was misdiagnosed, and not a criminal or civil proceeding.",
   "desks": [
    "enforcement",
    "weekly",
    "patient"
   ],
   "verifiedOn": "2026-08-30",
   "sources": [
    {
     "label": "FDA — Mammography Problems at Mammography Center of Monterey: Safety Notification",
     "url": "https://www.fda.gov/radiation-emitting-products/mqsa-reports-and-safety-notifications/mammography-problems-mammography-center-monterey-monterey-california-fda-safety-notification"
    }
   ],
   "related": [
    "/patient-education/cancer-screening-when-and-what-tests-you-need/",
    "/patient-education/preparing-for-imaging-or-diagnostic-testing/",
    "/patient-education/organizing-medical-records/"
   ],
   "record": "/weekly/#updates-0830"
  },
  {
   "id": "cms-0062-comments",
   "date": "2026-06-15",
   "sort": "2026-06-15",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROPOSED RULE",
   "lifecycle": "PROPOSED",
   "title": "Comment period closes on the drug prior-authorization proposal",
   "instrument": "CMS-0062-P — Interoperability Standards and Prior Authorization for Drugs",
   "what": "The comment period closed 15 June 2026. A final rule was pending as of this record's date.",
   "effect": "Comment is now closed, so the practical question shifts from what to say to what to prepare for: proposed compliance dates in October 2027 for most provisions.",
   "limits": "Proposed only. The October 2027 dates are not current duties and may change or disappear in a final rule.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "CMS — CMS-0062-P proposed rule",
     "url": "https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p"
    }
   ],
   "record": "/enforcement/#cms-0062",
   "related": [
    "/policy/electronic-pa-and-cms-interoperability-rules/"
   ]
  },
  {
   "id": "oig-ma-prior-auth",
   "date": "2026-06-11",
   "sort": "2026-06-11",
   "jurisdiction": "United States",
   "body": "HHS Office of Inspector General",
   "actionType": "AUDIT / OVERSIGHT FINDING",
   "lifecycle": "CURRENT",
   "title": "OIG finds post-acute prior-authorization denial rates far above the all-services rate",
   "instrument": "OEI-09-24-00331 (skilled nursing facilities) and OEI-09-24-00330 (long-term care hospitals and inpatient rehabilitation facilities), completed 8 June 2026, posted 11 June 2026",
   "what": "Reviewing June 2024 data from the 19 largest Medicare Advantage organizations, OIG found 12 percent of SNF admission requests denied, with plan-level rates from 0.4 to 23 percent; 18 percent of SNF denials were appealed, and 95 percent of appealed denials were overturned in the enrollee's favour. Denial rates reached 65 percent for long-term care hospital requests and 54 percent for inpatient rehabilitation, with the three largest organizations among the highest.",
   "effect": "A 95 percent overturn rate is an argument about initial determinations, not about appeals working. For the discharging physician it means a denial of post-acute placement is worth appealing on the clinical record you already have, and that the delay itself — days in an acute bed — is the harm to document.",
   "limits": "An audit finding is not an enforcement action and establishes no violation by any named plan. OIG's data cannot separate denials that should never have issued from approvals granted on later documentation.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-16",
   "sources": [
    {
     "label": "HHS-OIG — MAOs overturned nearly all appealed SNF prior-authorization denials (OEI-09-24-00331)",
     "url": "https://oig.hhs.gov/reports/all/2026/medicare-advantage-organizations-overturned-nearly-all-appealed-prior-authorization-denials-for-skilled-nursing-facility-admission-raising-concerns-about-initial-denials/"
    },
    {
     "label": "HHS-OIG — work-plan record for the post-acute prior-authorization reviews",
     "url": "https://oig.hhs.gov/reports/work-plan/browse-work-plan-projects/srs-e-26-004/"
    }
   ],
   "related": [
    "/policy/investigating-pa-delays/",
    "/policy/peer-to-peer-review/",
    "/policy/medicare-advantage-risk-coding-integrity/",
    "/policy/grievances-exhaustion-and-clinical-complaints/"
   ]
  },
  {
   "id": "ohca-ab1415-regs",
   "date": "2026-05-15",
   "sort": "2026-05-15",
   "jurisdiction": "California",
   "body": "Office of Health Care Affordability (HCAI)",
   "actionType": "PROPOSED REGULATION",
   "lifecycle": "PROPOSED",
   "title": "OHCA proposes the regulations that implement AB 1415's notice regime",
   "instrument": "Proposed revisions to the material change transaction and cost-and-market-impact-review regulations (Cal. Code Regs., tit. 22, div. 7, ch. 11.5), text dated May 2026, implementing AB 1415 (Ch. 641, Stats. 2025)",
   "what": "OHCA published proposed regulatory text for informal comment and accepted comments until 11 June 2026. The text extends the notice framework to noticing entities — private equity groups, hedge funds, newly created entities and certain management services organizations — and carries the 90-day advance filing requirement across to them. Until regulations are enacted, OHCA's own FAQ states that noticing entities must at a minimum provide written notice under Health and Safety Code section 127507(c)(2)(A).",
   "effect": "This answers the question the statute left open on 1 January: an MSO transaction closing now is already inside the notice duty, and the interim standard is written notice rather than the full filing package. Waiting for final regulations is not a compliance position.",
   "limits": "Proposed and, on the record read, not adopted. The definitions and ownership thresholds in the draft may change before adoption, and no compliance date attaches to the draft itself.",
   "desks": [
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "HCAI — Laws & Regulations (OHCA rulemaking to implement AB 1415; comments to 11 June 2026)",
     "url": "https://hcai.ca.gov/about/laws-regulations/"
    },
    {
     "label": "HCAI — proposed CMIR regulation text for informal comment, May 2026",
     "url": "https://hcai.ca.gov/wp-content/uploads/2026/05/CMIR-Regulations-May-2026-Proposed-Text-for-Informal-Comment.pdf"
    },
    {
     "label": "HCAI — AB 1415 frequently asked questions",
     "url": "https://hcai.ca.gov/affordability/ohca/assess-market-consolidation/mcn-cmir-faqs/ab-1415-frequently-asked-questions-faq/"
    }
   ],
   "related": [
    "/policy/hospital-consolidation-and-antitrust-enforcement/",
    "/policy/private-equity-and-the-practice/",
    "/policy/certificate-of-need-laws/"
   ]
  },
  {
   "id": "mhra-2026-regs",
   "date": "2026-05-08",
   "sort": "2026-05-08",
   "datePrecision": "day",
   "jurisdiction": "United Kingdom",
   "body": "MHRA",
   "actionType": "PROPOSED REGULATION",
   "lifecycle": "PROPOSED",
   "title": "MHRA publishes the draft Medical Devices (Amendment) Regulations 2026 for Great Britain",
   "instrument": "Draft Medical Devices (Amendment) Regulations 2026, notified on the World Trade Organisation portal 8 May 2026; stakeholder impact survey closed 19 June 2026",
   "what": "The draft statutory instrument sets new pre-market requirements for medical devices and in vitro diagnostics entering the Great Britain market, replacing requirements carried over from the retained EU directives. MHRA invited comment from WTO members and, separately, from industry, approved bodies, healthcare providers and patients through a survey that closed at 23:59 on 19 June 2026.",
   "effect": "For a clinician the consequence is downstream and practical: an instrument that changes classification and conformity assessment changes which devices and diagnostic software reach a British clinic, and on what evidence. Healthcare providers were named as consultees, which means the clinical view of a device's real-world performance was solicited at the drafting stage rather than after adoption.",
   "limits": "A draft statutory instrument. It creates no duty, and adoption requires Parliament; the timetable reported for adoption and entry into force is not part of the notified draft and is not verified here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "GOV.UK — MHRA invites views on proposed changes to medical device regulation",
     "url": "https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation"
    }
   ],
   "related": [
    "/policy/global-ai-standards/",
    "/policy/how-the-fda-reviews-ai-enabled-devices/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ]
  },
  {
   "id": "aspen-dental",
   "date": "2026-05-07",
   "sort": "2026-05-07",
   "jurisdiction": "California",
   "body": "Attorney General",
   "actionType": "CIVIL SETTLEMENT",
   "lifecycle": "CURRENT",
   "title": "Aspen Dental settlement pairs corporate practice with a false-advertising count",
   "instrument": "California Attorney General settlement with Aspen Dental Management, Inc.",
   "what": "Announced 7 May 2026, joining a corporate-practice theory to an advertising claim.",
   "effect": "The pairing matters more than either count alone: how a practice describes itself to patients becomes evidence about who actually controls it.",
   "limits": "Negotiated resolution, ordinarily without admission of liability.",
   "desks": [
    "enforcement"
   ],
   "verifiedOn": "2026-08-14",
   "sources": [
    {
     "label": "California Department of Justice — Office of the Attorney General",
     "url": "https://oag.ca.gov/news"
    }
   ],
   "record": "/enforcement/#aspen-dental",
   "related": [
    "/policy/how-physicians-should-describe-certification-accurately/",
    "/policy/fee-splitting/"
   ]
  },
  {
   "id": "eu-ir-2026-977",
   "date": "2026-05-04",
   "sort": "2026-05-04",
   "datePrecision": "month",
   "jurisdiction": "European Union",
   "body": "European Commission",
   "actionType": "REGULATION",
   "lifecycle": "EFFECTIVE",
   "title": "Uniform procedural requirements imposed on notified bodies under MDR and IVDR",
   "instrument": "Commission Implementing Regulation (EU) 2026/977 — uniform requirements for conformity assessment and notified bodies (MDR/IVDR, Annex VII), adopted May 2026",
   "what": "The Implementing Regulation sets standardised procedural requirements for the conformity assessment activities of notified bodies under the Medical Devices Regulation and the In Vitro Diagnostic Regulation. It sits alongside, and is separate from, the Commission's targeted simplification proposal for MDR and IVDR published on 16 December 2025 (COM(2025) 1023 final), which remains in the ordinary legislative procedure before the Parliament and Council.",
   "effect": "Certification delay is the mechanism by which European device rules reach a clinic: a diagnostic or software device that cannot get through a notified body does not arrive. Standardising quotation, timeline and audit practice is aimed at that bottleneck, and it is in force now, unlike the larger revision.",
   "limits": "An implementing regulation binds notified bodies, not clinicians, and it does not change the substantive safety and performance requirements of MDR or IVDR. The December 2025 simplification proposal is a proposal only; nothing in it applies. The exact adoption date within May 2026 is not verified here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "European Commission — medical devices, new regulations (lists Implementing Regulation (EU) 2026/977 and the 16 December 2025 proposal)",
     "url": "https://health.ec.europa.eu/medical-devices-new-regulations/overview_en"
    },
    {
     "label": "European Commission — COM(2025) 1023 final (proposal text)",
     "url": "https://health.ec.europa.eu/document/download/25e7ea7c-cab3-40cf-86d9-d11f5e7744d8_en?filename=md_com_2025-1023_act_en.pdf"
    }
   ],
   "related": [
    "/policy/global-ai-standards/",
    "/policy/pre-market-vs-post-market-surveillance/",
    "/policy/regulatory-framework-across-the-ai-lifecycle/"
   ]
  },
  {
   "id": "cms-0062-p",
   "date": "2026-04-14",
   "sort": "2026-04-14",
   "jurisdiction": "United States",
   "body": "CMS / HHS",
   "actionType": "PROPOSED RULE",
   "lifecycle": "PROPOSED",
   "title": "CMS proposes to extend electronic prior authorization to drugs",
   "instrument": "CMS-0062-P — Interoperability Standards and Prior Authorization for Drugs, published 14 April 2026",
   "what": "The proposal would extend the framework built by CMS-0057-F to drugs under both the medical and pharmacy benefit, require impacted payers to report API endpoints and usage metrics, and adopt certain HL7 FHIR standards under HIPAA Administrative Simplification.",
   "effect": "Drug prior authorization is where most practices lose the most staff time. The proposal's usage-metric reporting is the part with teeth, because it makes plan behaviour comparable rather than anecdotal.",
   "limits": "Proposed only; no duty arises from publication.",
   "desks": [
    "weekly",
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-15",
   "sources": [
    {
     "label": "CMS — CMS-0062-P proposed rule",
     "url": "https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p"
    }
   ],
   "record": "/enforcement/#cms-0062",
   "related": [
    "/policy/fhir-apis-and-coverage-decisions/",
    "/policy/electronic-pa-and-cms-interoperability-rules/"
   ]
  },
  {
   "id": "health-canada-mlmd",
   "date": "2026-04-01",
   "sort": "2026-04-01",
   "datePrecision": "month",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "AGENCY GUIDANCE",
   "lifecycle": "CURRENT",
   "title": "Health Canada publishes pre-market guidance for machine-learning-enabled medical devices",
   "instrument": "Health Canada, Pre-market guidance for machine learning-enabled medical devices (Class II–IV), April 2026",
   "what": "The guidance sets Health Canada's expectations for machine-learning-enabled devices: the medical purpose must be stated for any Class II, III or IV device; predetermined change control plans provide a route to pre-authorise planned model changes that address a known risk; and manufacturers are expected to apply SGBA Plus, collecting and analysing disaggregated data on sub-populations across training, test and clinical data. Health Canada adopts the IMDRF terms and definitions for these devices.",
   "effect": "The disaggregated-data expectation is the part a physician can use. A device authorised in Canada should be able to say how it performed in the populations a clinic actually serves, and the guidance makes that a documented submission element rather than a courtesy.",
   "limits": "Guidance states current thinking and is not binding law; it imposes no new statutory obligation and may be revised. Dated April 2026 on the departmental page; the exact publication day is not verified here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "Health Canada — Pre-market guidance for machine learning-enabled medical devices",
     "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/pre-market-guidance-machine-learning-enabled-medical-devices.html"
    },
    {
     "label": "Health Canada — guidance document (PDF)",
     "url": "https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/medical-devices/application-information/guidance-documents/pre-market-guidance-machine-learning-enabled-medical-devices/pre-market-guidance-machine-learning-enabled-medical-devices.pdf"
    }
   ],
   "related": [
    "/policy/continuous-learning-algorithms/",
    "/policy/regulatory-framework-across-the-ai-lifecycle/",
    "/policy/global-ai-standards/"
   ]
  },
  {
   "id": "art-center",
   "date": "2026-03-30",
   "sort": "2026-03-30",
   "jurisdiction": "California",
   "body": "Attorney General / Court of Appeal",
   "actionType": "AGENCY POSITION",
   "lifecycle": "CURRENT",
   "title": "Attorney General files amicus brief on the power to replace a physician-owner",
   "instrument": "Amicus curiae brief of the California Attorney General, Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625 (Cal. Ct. App., 2d Dist., Div. Three), filed 30 March 2026",
   "what": "The Attorney General filed an amicus brief in an appeal from a 2024 Los Angeles Superior Court decision (No. 24SMCV01185) that had found the unlicensed practice of medicine where a management party held the discretion to move control of the practice from one physician to another of its choosing. The brief argues that a contractual right to replace a professional corporation's physician-owner gives the lay entity control over physician employment and, through it, the practice. The California Medical Association filed a competing brief on 15 April 2026 urging a facts-and-circumstances test rather than a categorical rule.",
   "effect": "This is the view a practice will be litigating against, and it targets a clause that appears in a great many management agreements as boilerplate succession language.",
   "limits": "An amicus position is persuasive, not binding, and two amici disagree on the standard. The appeal was pending on the record read; no appellate ruling has issued.",
   "desks": [
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "California Attorney General — announcement of the amicus filing",
     "url": "https://oag.ca.gov/news/press-releases/attorney-general-bonta-files-amicus-brief-defense-california%E2%80%99s-ban-corporate"
    },
    {
     "label": "California Medical Association — amicus brief, No. B338625 (filed 15 April 2026)",
     "url": "https://www.cmadocs.org/Portals/CMA/files/public/CMA%20Amicus%20Brief%20(Art%20Center%20Holdings%20v.%20WCE).pdf"
    }
   ],
   "record": "/enforcement/#art-center",
   "related": [
    "/policy/who-controls-clinical-judgment/",
    "/policy/employment-agreement-clauses/"
   ]
  },
  {
   "id": "tga-ai-guidance",
   "date": "2026-02-05",
   "sort": "2026-02-05",
   "datePrecision": "month",
   "jurisdiction": "Australia",
   "body": "Therapeutic Goods Administration",
   "actionType": "AGENCY GUIDANCE",
   "lifecycle": "CURRENT",
   "title": "TGA guidance: AI is regulated by intended purpose, including generative clinical decision support",
   "instrument": "TGA guidance, Artificial intelligence (AI) and medical device software regulation, updated February 2026",
   "what": "The guidance states that regulation is triggered by the manufacturer's intended purpose rather than by the presence of AI, and it names clinical decision support tools that use generative AI to give diagnostic or treatment recommendations as regulated devices. Devices must be included in the Australian Register of Therapeutic Goods unless excluded or exempt, and synthetic data will generally not substitute for clinical data in meeting clinical evidence requirements.",
   "effect": "Intended purpose is the operative concept, so a tool marketed as an assistant is regulated on what it is for, not what it is called. Where a practice deploys a generative tool for a purpose outside its registered intended purpose, the guidance's own remedy is to cease supply or revise the purpose and re-submit — which makes off-label deployment the deploying organisation's exposure.",
   "limits": "Guidance interprets the Therapeutic Goods Act framework; it is not itself legislation. The exact date of the February 2026 update, and the listing of software as a medical device among the TGA's stated compliance priorities for 2026–2027, are not verified here.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "TGA — Artificial intelligence (AI) and medical device software regulation",
     "url": "https://www.tga.gov.au/products/medical-devices/software-and-artificial-intelligence-ai/manufacturing/artificial-intelligence-ai-and-medical-device-software-regulation"
    },
    {
     "label": "TGA — overview of software and artificial intelligence",
     "url": "https://www.tga.gov.au/products/medical-devices/software-and-artificial-intelligence-ai/overview"
    }
   ],
   "related": [
    "/policy/ai-assisted-diagnosis-and-physician-responsibility/",
    "/policy/generative-ai-in-medical-documentation/",
    "/policy/global-ai-standards/"
   ]
  },
  {
   "id": "dmhc-health-net",
   "date": "2026-02-04",
   "sort": "2026-02-04",
   "jurisdiction": "California",
   "body": "Department of Managed Health Care",
   "actionType": "ADMINISTRATIVE ENFORCEMENT",
   "lifecycle": "CURRENT",
   "title": "DMHC fines Health Net plans $1.3 million for mishandling provider payment disputes",
   "instrument": "DMHC enforcement action announced 4 February 2026; Knox-Keene Act provider dispute resolution requirements",
   "what": "The Department announced penalties totalling $1.3 million against Health Net plans for mishandling provider payment disputes.",
   "effect": "Provider dispute resolution has acknowledgment and resolution deadlines, and a plan's pattern of missing them is itself the violation — separate from whether any individual claim was payable. A practice that documents dispute dates is documenting the element the Department enforces on.",
   "limits": "A penalty against a plan resolves no individual dispute and makes no finding about any provider's billing. The per-plan allocation of the total was not read at source.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "DMHC — press releases index",
     "url": "https://www.dmhc.ca.gov/Resources/Newsroom/PressReleases.aspx"
    },
    {
     "label": "DMHC — Enforcement Actions Database",
     "url": "https://www.dmhc.ca.gov/LawsRegulations/EnforcementActions.aspx"
    }
   ],
   "related": [
    "/policy/grievances-exhaustion-and-clinical-complaints/",
    "/policy/peer-to-peer-review/"
   ]
  },
  {
   "id": "caa-2026",
   "date": "2026-02-03",
   "sort": "2026-02-03",
   "jurisdiction": "United States",
   "body": "Congress",
   "actionType": "STATUTE",
   "lifecycle": "EFFECTIVE",
   "title": "Consolidated Appropriations Act, 2026 extends Medicare telehealth flexibilities through 2027",
   "instrument": "H.R. 7148, Consolidated Appropriations Act, 2026 (119th Cong.), signed 3 February 2026",
   "what": "The Act funds federal departments for the remainder of FY2026 and extends expiring programmes and authorities, including the Medicare telehealth flexibilities that had lapsed days earlier. The extension runs through 31 December 2027 and was applied retroactively across the gap.",
   "effect": "Geographic and originating-site relief, the expanded practitioner list, audio-only coverage and the deferral of the in-person requirement for tele-behavioural care all continue — but on a date certain, not permanently. Any 2028 schedule built on them is built on an authority that expires first.",
   "limits": "An appropriations extension is not permanence. The same provisions have now lapsed and been restored twice in four months.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-16",
   "sources": [
    {
     "label": "Congress.gov — H.R. 7148, Consolidated Appropriations Act, 2026",
     "url": "https://www.congress.gov/bill/119th-congress/house-bill/7148"
    },
    {
     "label": "GovInfo — enrolled text of H.R. 7148",
     "url": "https://www.govinfo.gov/app/details/BILLS-119hr7148enr"
    }
   ],
   "related": [
    "/policy/telehealth-payment-after-temporary-flexibilities/"
   ]
  },
  {
   "id": "telehealth-lapse",
   "date": "2026-01-31",
   "sort": "2026-01-31",
   "jurisdiction": "United States",
   "body": "Congress / CMS",
   "actionType": "AUTHORITY LAPSE",
   "lifecycle": "HISTORICAL",
   "title": "Medicare telehealth flexibilities lapse for three days",
   "instrument": "Expiry of the extension enacted by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (H.R. 5371), signed 12 November 2025, which carried the flexibilities to 30 January 2026; gap closed retroactively by H.R. 7148",
   "what": "The extension in force through 30 January 2026 expired, and the flexibilities lapsed until the 3 February 2026 Act restored them retroactively.",
   "effect": "Claims for services furnished in the gap were payable in the end, but only after the fact. The operational lesson is the one practices keep re-learning: hold rather than cancel, because a retroactive fix cannot recreate a cancelled appointment.",
   "limits": "Recorded as historical: accurate as of its date, superseded in effect by the 3 February statute. The record states the lapse and its dates, not a pinpoint section designation within H.R. 5371.",
   "desks": [
    "weekly",
    "enforcement"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "Congress.gov — H.R. 5371 (119th Congress), signed 12 November 2025",
     "url": "https://www.congress.gov/bill/119th-congress/house-bill/5371/text"
    },
    {
     "label": "Congress.gov — H.R. 7148, Consolidated Appropriations Act, 2026",
     "url": "https://www.congress.gov/bill/119th-congress/house-bill/7148"
    }
   ],
   "related": [
    "/policy/telehealth-payment-after-temporary-flexibilities/"
   ]
  },
  {
   "id": "dmhc-anthem",
   "date": "2026-01-30",
   "sort": "2026-01-30",
   "jurisdiction": "California",
   "body": "Department of Managed Health Care",
   "actionType": "ADMINISTRATIVE ENFORCEMENT",
   "lifecycle": "CURRENT",
   "title": "DMHC fines Anthem Blue Cross $15 million over member-complaint failures",
   "instrument": "DMHC enforcement action announced 30 January 2026; Knox-Keene Act grievance and complaint requirements",
   "what": "The Department announced a $15 million penalty against Anthem Blue Cross for what it described as longstanding and widespread failures in handling member complaints.",
   "effect": "It is the largest California plan penalty of the year to date and it is about grievance handling, not medical necessity. Where a patient's grievance goes unanswered, the physician's clinical record is often the only contemporaneous account of the request — which is what makes the chart the evidence in a complaint case.",
   "limits": "An administrative penalty is not a judicial finding and does not establish that any particular enrollee's care was wrongly denied.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "DMHC — press releases index",
     "url": "https://www.dmhc.ca.gov/Resources/Newsroom/PressReleases.aspx"
    },
    {
     "label": "DMHC — Enforcement Actions Database",
     "url": "https://www.dmhc.ca.gov/LawsRegulations/EnforcementActions.aspx"
    }
   ],
   "related": [
    "/policy/grievances-exhaustion-and-clinical-complaints/",
    "/policy/complaint-is-not-finding/"
   ]
  },
  {
   "id": "dea-fourth-extension",
   "date": "2026-01-01",
   "sort": "2026-01-01e",
   "datePrecision": "day",
   "jurisdiction": "United States",
   "body": "DEA / HHS",
   "actionType": "FINAL RULE",
   "lifecycle": "EFFECTIVE",
   "title": "Telemedicine prescribing of controlled substances continues through 2026, on a temporary rule",
   "instrument": "Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR (2025-24123), published 31 December 2025; effective 1 January 2026 through 31 December 2026",
   "what": "DEA, jointly with HHS, extended the pandemic-era telemedicine prescribing flexibilities for a fourth time. A DEA-registered practitioner may prescribe a Schedule II–V controlled substance following a telemedicine encounter without a prior in-person evaluation, provided the conditions in the temporary rule are met. HHS announced the extension on 2 January 2026 and stated that it buys time to finalise the proposed Special Registration for Telemedicine.",
   "effect": "The date is the whole point: this authority ends on 31 December 2026, and it is the fourth time it has been extended by temporary rule rather than replaced by a permanent framework. A practice that treats tele-prescribing of controlled substances as settled policy is scheduling into an authority with a fixed expiry and no successor in force.",
   "limits": "A temporary rule. It changes nothing about the requirement that prescriptions issue for a legitimate medical purpose by a licensed practitioner in compliance with federal and state law, and it does not create the special registration that would replace it.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-17",
   "sources": [
    {
     "label": "Federal Register — Fourth Temporary Extension (31 December 2025)",
     "url": "https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled"
    },
    {
     "label": "HHS — announcement of the extension, 2 January 2026",
     "url": "https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html"
    }
   ],
   "related": [
    "/policy/telehealth-payment-after-temporary-flexibilities/",
    "/policy/remote-prescribing-of-controlled-substances/"
   ]
  },
  {
   "id": "cms-0057-f-2026",
   "date": "2026-01-01",
   "sort": "2026-01-01d",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "FINAL RULE",
   "lifecycle": "EFFECTIVE",
   "title": "Prior-authorization decision timeframes and denial-reason duties begin",
   "instrument": "CMS-0057-F — Interoperability and Prior Authorization final rule",
   "what": "From 1 January 2026 impacted payers must meet decision timeframes and give specific denial reasons; the four required FHIR APIs follow on 1 January 2027.",
   "effect": "A denial without a specific reason is now a compliance failure as well as a clinical obstacle, which changes what a practice should demand in writing before starting an appeal.",
   "limits": "In force for timeframes and denial reasons only; the API obligations are not yet due.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-14",
   "sources": [
    {
     "label": "CMS — Interoperability and Prior Authorization final rule (CMS-0057-F)",
     "url": "https://www.cms.gov/priorities/key-initiatives/burden-reduction/interoperability/policies-and-regulations/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f"
    }
   ],
   "record": "/enforcement/#cms-0057-f",
   "related": [
    "/policy/electronic-pa-and-cms-interoperability-rules/",
    "/policy/fhir-apis-and-coverage-decisions/"
   ]
  },
  {
   "id": "ab-1415-effective",
   "date": "2026-01-01",
   "sort": "2026-01-01c",
   "jurisdiction": "California",
   "body": "California Legislature / OHCA",
   "actionType": "STATUTE",
   "lifecycle": "EFFECTIVE",
   "title": "AB 1415 takes effect: management organizations enter the pre-transaction notice regime",
   "instrument": "Assembly Bill 1415, Ch. 641, Stats. 2025, effective 1 January 2026",
   "what": "The Office of Health Care Affordability's notice jurisdiction extends to management services organizations and similar entities, bringing transactions that previously sat outside the regime within it.",
   "effect": "Deal timelines lengthen for the entities most often used to assemble physician practices, and a transaction that was structured to avoid notice may no longer avoid it.",
   "limits": "In force. The statute is the operative authority stated here; no implementing regulation forms part of this record.",
   "desks": [
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-14",
   "sources": [
    {
     "label": "AB 1415 (California Legislative Information)",
     "url": "https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202520260AB1415"
    }
   ],
   "record": "/enforcement/#ab-1415",
   "related": [
    "/policy/hospital-consolidation-and-antitrust-enforcement/",
    "/policy/certificate-of-need-laws/"
   ]
  },
  {
   "id": "sb-351-effective",
   "date": "2026-01-01",
   "sort": "2026-01-01b",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "STATUTE",
   "lifecycle": "EFFECTIVE",
   "title": "SB 351 takes effect: private-equity control of clinical judgment becomes a statutory violation",
   "instrument": "Senate Bill 351, Ch. 409, Stats. 2025, effective 1 January 2026",
   "what": "California codified its corporate-practice doctrine as applied to private-equity groups and hedge funds holding interests in physician and dental practices, drawing an express line around clinical decision-making, billing determinations and clinical staffing, with injunctive relief, equitable remedies and fees for the Attorney General.",
   "effect": "The conduct is now named in statute rather than inferred from a line of authority, and the fee award changes enforcement economics. Read a management agreement for three powers specifically: override of a clinical decision, control of billing policy, and productivity-based staffing.",
   "limits": "In force. Enforcement to date has proceeded by settlement, so no judicial construction of the new sections exists yet.",
   "desks": [
    "enforcement",
    "intelligence"
   ],
   "verifiedOn": "2026-08-14",
   "sources": [
    {
     "label": "SB 351 (California Legislative Information)",
     "url": "https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202520260SB351"
    }
   ],
   "record": "/enforcement/#sb-351",
   "related": [
    "/policy/private-equity-and-the-practice/",
    "/policy/who-controls-clinical-judgment/"
   ]
  },
  {
   "id": "cy2026-pfs",
   "date": "2026-01-01",
   "sort": "2026-01-01a",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "FINAL RULE",
   "lifecycle": "EFFECTIVE",
   "title": "CY 2026 Physician Fee Schedule takes effect with two conversion factors",
   "instrument": "CY 2026 Medicare Physician Fee Schedule final rule, 90 FR (2025-19787), effective 1 January 2026",
   "what": "For the first time Medicare pays under two conversion factors: $33.5675 for qualifying participants in advanced alternative payment models and $33.4009 for everyone else. The rule also applied an efficiency adjustment of −2.5 percent to the work RVUs of non-time-based services and made virtual direct supervision permanent.",
   "effect": "A headline increase and a code-level cut arrive together, so the net effect depends entirely on a practice's mix: procedural, non-time-based work absorbs the efficiency adjustment while time-based codes do not. The APM differential also converts model participation from a bonus question into a rate question.",
   "limits": "In force. The 2.5 percent statutory increase inside the conversion factors is a one-year addition, not a new baseline.",
   "desks": [
    "enforcement",
    "weekly",
    "intelligence"
   ],
   "verifiedOn": "2026-08-16",
   "sources": [
    {
     "label": "Federal Register — CY 2026 Physician Fee Schedule final rule",
     "url": "https://www.federalregister.gov/documents/2025/11/05/2025-19787/medicare-and-medicaid-programs-cy-2026-payment-policies-under-the-physician-fee-schedule-and-other"
    },
    {
     "label": "CMS — Physician Fee Schedule",
     "url": "https://www.cms.gov/medicare/payment/fee-schedules/physician"
    }
   ],
   "related": [
    "/policy/value-based-payment-and-the-risk-of-undertreatment/",
    "/policy/productivity-targets-and-independence/",
    "/policy/quality-measures-and-gaming/"
   ]
  },
  {
   "id": "ab1979-concurrence-2026-08-27",
   "date": "2026-08-27",
   "sort": "2026-08-27b",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "PASSED LEGISLATURE — ENGROSSING/ENROLLING",
   "title": "AB 1979 (health care AI) completes legislative passage: Senate 26 August, Assembly concurrence 66–10 on 27 August",
   "what": "Assembly concurred in Senate amendments 66–10 after Senate third-reading passage on 26 August; the bill moved to engrossing and enrolling. Not law; not operative; Governor action pending.",
   "sources": [
    {
     "label": "LegiScan — AB 1979 action history",
     "url": "https://legiscan.com/CA/bill/AB1979/2025"
    }
   ],
   "related": [
    "/bills/ab-1979/",
    "/reform/ai-and-the-practice-of-medicine/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/bills/ab-1979/"
  },
  {
   "id": "ab539-concurrence-2026-08-26",
   "date": "2026-08-26",
   "sort": "2026-08-26b",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "PASSED LEGISLATURE — ENGROSSING/ENROLLING",
   "title": "AB 539 (prior authorization duration) completes legislative passage: Senate 25 August, Assembly concurrence 64–4 on 26 August",
   "what": "Would require a plan’s or insurer’s prior authorization to remain valid for at least one year. Passage complete; no payer obligation until enactment and operative date.",
   "sources": [
    {
     "label": "LegiScan — AB 539 action history",
     "url": "https://legiscan.com/CA/bill/AB539/2025"
    }
   ],
   "related": [
    "/bills/ab-539/",
    "/reform/proposals/prior-authorization-duration-and-algorithmic-denial/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/bills/ab-539/"
  },
  {
   "id": "ab2575-third-reading-sequence-2026-08-28-30",
   "date": "2026-08-30",
   "sort": "2026-08-30b",
   "jurisdiction": "California",
   "body": "California Senate",
   "actionType": "FLOOR ACTION",
   "lifecycle": "ACTIVE — THIRD READING",
   "title": "AB 2575: passage refused 18–10 and reconsideration granted 40–0 on 28 August; amended on third reading; ordered back to third reading 30 August",
   "what": "The chamber history now establishes the 28 August sequence — third reading, passage refused 18–10, reconsideration granted 40–0, read third time and amended, ordered to second reading — followed by second reading and re-ordering to third reading on 30 August. Recorded action outranks the calendar: the earlier text-freeze expectation is superseded.",
   "sources": [
    {
     "label": "LegiScan — AB 2575 action history",
     "url": "https://legiscan.com/CA/bill/AB2575/2025"
    }
   ],
   "related": [
    "/bills/ab-2575/",
    "/reform/proposals/ai-medical-record-integrity/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/bills/ab-2575/"
  },
  {
   "id": "ca-final-session-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31x",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "SESSION MILESTONE",
   "lifecycle": "IN PROGRESS AT SNAPSHOT",
   "title": "Final passage day: Senate floor session In Progress at the 8:40 PM snapshot",
   "what": "31 August is the last day for each house to pass bills. The Senate’s official event page showed the 11:00 AM floor session In Progress at 20:40 PT; final-day dispositions are recorded only as chamber histories establish them, never inferred from the calendar.",
   "sources": [
    {
     "label": "California Senate — daily file/events, 31 August 2026",
     "url": "https://www.senate.ca.gov/"
    }
   ],
   "related": [
    "/bills/",
    "/calendar/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/records/california-final-passage-day-2026-08-31/"
  },
  {
   "id": "sb903-passage-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "PASSED LEGISLATURE — GOVERNOR ACTION PENDING",
   "title": "SB 903 passes: AI systems barred from providing or advertising \"therapy\" if enacted",
   "what": "Per the author’s Senate release, the Legislature passed SB 903, addressing AI and mental-health practice — prohibiting AI algorithms from providing or advertising therapy and setting standards for professionals’ use of AI. Not law; Governor action pending. Raises the boundary question: when does an AI tool begin performing a regulated healing-art function?",
   "sources": [
    {
     "label": "California Senate — author’s release, 31 August 2026",
     "url": "https://legiscan.com/CA/bill/SB903/2025"
    }
   ],
   "related": [
    "/bills/",
    "/reform/ai-and-the-practice-of-medicine/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/bills/sb-903/"
  },
  {
   "id": "sb1023-passage-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31w",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "PASSED LEGISLATURE — GOVERNOR ACTION PENDING",
   "title": "SB 1023 passes: injectable PrEP reimbursement through the outpatient drug benefit",
   "what": "Would require plans already covering injectable PrEP to offer reimbursement through the outpatient prescription-drug benefit, addressing buy-and-bill barriers for community clinics. Illustrates the coverage-is-not-access problem: nominal coverage defeated by benefit design.",
   "sources": [
    {
     "label": "California Senate — author’s release, 31 August 2026",
     "url": "https://legiscan.com/CA/bill/SB1023/2025"
    }
   ],
   "related": [
    "/bills/",
    "/policy/formulary-design-and-patient-access/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "sb942-passage-2026-08-27",
   "date": "2026-08-27",
   "sort": "2026-08-27c",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "PASSED LEGISLATURE — GOVERNOR ACTION PENDING",
   "title": "SB 942 passes: health, safety and dignity standards for civil immigration detention",
   "what": "Per Senator Caballero’s office, establishes detention health and safety standards enforceable by the Attorney General. Carries an urgency clause if enacted — final text controls; nothing operative today.",
   "sources": [
    {
     "label": "Senator Caballero — release, 27 August 2026",
     "url": "https://legiscan.com/CA/bill/SB942/2025"
    }
   ],
   "related": [
    "/bills/",
    "/policy/the-constitutional-floor-for-correctional-health-care/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "gov-signing-package-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31y",
   "jurisdiction": "California",
   "body": "Governor of California",
   "actionType": "GUBERNATORIAL ACTION",
   "lifecycle": "SIGNED — CHAPTERING PENDING",
   "title": "Governor signs AB 1760 (Dental Practice Act) and AB 2503 (pupil exertional heat illness) in the 31 August package",
   "what": "Signed is not automatically effective: chapter numbers and operative dates are recorded when the chaptered texts are. AB 1760 amends the Dental Practice Act; AB 2503 addresses exertional heat illness guidance for pupil athletes.",
   "sources": [
    {
     "label": "Governor of California — signing announcement, 31 August 2026",
     "url": "https://www.gov.ca.gov/"
    }
   ],
   "related": [
    "/bills/",
    "/policy/statute-vs-regulation-vs-guidance/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/records/ca-governor-signing-package-2026-08-31/"
  },
  {
   "id": "cms-rhtp-arkansas-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31v",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROGRAM IMPLEMENTATION",
   "lifecycle": "ANNOUNCED",
   "title": "CMS announces $149.3 million for Arkansas under the Rural Health Transformation Program",
   "what": "Package spans telehealth, specialty care, preventive screening, remote monitoring, imaging, ambulance upgrades, emergency teleconsultation and rural infrastructure — joining Virginia, Georgia, Alaska and Ohio in the state implementation record. Grant implementation, not rulemaking and not enforcement.",
   "sources": [
    {
     "label": "CMS — Rural Health Transformation announcement, 31 August 2026",
     "url": "https://www.cms.gov/newsroom"
    }
   ],
   "related": [
    "/policy/rural-emergency-hospitals/",
    "/policy/global-budgets-for-rural-hospitals/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/records/cms-rhtp-arkansas-2026-08-31/"
  },
  {
   "id": "hhs-samhsa-77m-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31u",
   "jurisdiction": "United States",
   "body": "HHS / SAMHSA",
   "actionType": "PROGRAM IMPLEMENTATION",
   "lifecycle": "ANNOUNCED",
   "title": "HHS announces $77 million in behavioral-health grants, including $9.4 million for suicide-prevention and 988 follow-up",
   "what": "Grants span substance-use prevention, treatment and recovery, community mental health, and crisis services, including 988 crisis-center follow-up. Raises the measurement question KPSGILL tracks with AB 1956: systems should be judged by what happens after a crisis contact, not only answer rates.",
   "sources": [
    {
     "label": "HHS — grant announcement, 31 August 2026",
     "url": "https://www.hhs.gov/press-room"
    }
   ],
   "related": [
    "/policy/the-988-crisis-line-and-the-crisis-care-continuum/",
    "/bills/ab-1956/"
   ],
   "verifiedOn": "2026-08-31",
   "recordUrl": "/records/hhs-samhsa-behavioral-health-grants-2026-08-31/"
  },
  {
   "id": "fda-icmra-endotoxin-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31t",
   "jurisdiction": "International",
   "body": "FDA / ICMRA (EMA lead)",
   "actionType": "REGULATORY CONVERGENCE",
   "lifecycle": "COLLABORATIVE ASSESSMENT COMPLETED",
   "title": "FDA and ICMRA partners complete a collaborative assessment of recombinant endotoxin testing, reducing reliance on horseshoe-crab blood",
   "what": "FDA, TGA, Health Canada, PMDA and Swissmedic participated with EMA as lead authority; FDA reports aligned decisions within days under the collaborative-assessment pilot. A working test of international regulatory reliance without surrendered national decision authority.",
   "sources": [
    {
     "label": "FDA — ICMRA collaborative assessment announcement, 31 August 2026",
     "url": "https://www.fda.gov/news-events"
    }
   ],
   "related": [
    "/policy/real-world-evidence-in-regulatory-decisions/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "who-ihr-committee-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31s",
   "jurisdiction": "Global",
   "body": "WHO",
   "actionType": "GOVERNANCE MILESTONE",
   "lifecycle": "FIRST MEETING IN PROGRESS",
   "title": "WHO convenes the first States Parties Committee on IHR implementation",
   "what": "Mandate: review implementation, identify obstacles, share practice and support States Parties, with priorities in country-level implementation, measurable progress, equity and interoperability. Not a new treaty and not an IHR amendment — implementation architecture for the rules that already bind.",
   "sources": [
    {
     "label": "WHO — States Parties Committee first meeting, 31 August 2026",
     "url": "https://www.who.int/news"
    }
   ],
   "related": [
    "/policy/cross-border-outbreak-notification-and-the-international-health-regulations/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "who-rare-disease-gap-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31n",
   "jurisdiction": "Global",
   "body": "WHO",
   "actionType": "POLICY PROCESS OPENED",
   "lifecycle": "PROCESS — NOT A FINAL PLAN",
   "title": "WHO publishes the process for a ten-year Global Action Plan on Rare Diseases",
   "what": "Discussion paper expected Q4 2026, first draft early 2027, Executive Board review 2028, World Health Assembly consideration May 2028. A development process, not an adopted plan; planning dates are not effective dates.",
   "sources": [
    {
     "label": "WHO — rare diseases action plan process, 31 August 2026",
     "url": "https://www.who.int/news"
    }
   ],
   "related": [
    "/policy/orphan-drug-incentives-and-evidence/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "eu-dsa-chatgpt-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31r",
   "jurisdiction": "European Union",
   "body": "European Commission",
   "actionType": "DESIGNATION",
   "lifecycle": "DESIGNATED — OBLIGATIONS DUE END NOVEMBER",
   "title": "Commission designates ChatGPT a Very Large Online Search Engine under the DSA",
   "what": "Alongside VLOP designations for Reddit and Roblox. Additional DSA obligations — systemic-risk assessment and mitigation touching minors, physical and mental well-being and fundamental rights — fall due by end November 2026. Platform governance, not medical-device regulation; tracked for patient-facing AI at population scale.",
   "sources": [
    {
     "label": "European Commission — DSA designations, 31 August 2026",
     "url": "https://ec.europa.eu/commission/presscorner/"
    }
   ],
   "related": [
    "/reform/ai-and-the-practice-of-medicine/",
    "/policy/countering-health-misinformation-without-censorship-overreach/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "nhs-pharmacy-cvd-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31p",
   "jurisdiction": "United Kingdom",
   "body": "NHS England",
   "actionType": "PROGRAM PILOT",
   "lifecycle": "ANNOUNCED — PILOT FROM AUTUMN",
   "title": "NHS England: ~100 pharmacies to pilot rapid cholesterol checks with pharmacist-prescriber consultation",
   "what": "Eligible people aged 40–84 receive a finger-prick lipid profile, blood-pressure assessment and consultation; runs to spring 2027. The earlier north-London model found roughly one in five tested at high ten-year cardiovascular risk. Comparative evidence for pharmacy-based prevention and scope-of-practice policy.",
   "sources": [
    {
     "label": "NHS England — announcement, 31 August 2026",
     "url": "https://www.england.nhs.uk/news/"
    }
   ],
   "related": [
    "/policy/pharmacist-prescriptive-authority/",
    "/policy/primary-care-capacity/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "tga-udi-implementation-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31o",
   "jurisdiction": "Australia",
   "body": "TGA",
   "actionType": "GUIDANCE / IMPLEMENTATION MATERIAL",
   "lifecycle": "PUBLISHED",
   "title": "TGA expands healthcare implementation material for Unique Device Identification",
   "what": "Australia’s UDI framework requires manufacturers to assign identifiers, label them and submit records to the Australian UDI Database; the new material maps device identity from supply through clinical use and patient records including My Health Record. Comparative model for implant traceability into the EHR.",
   "sources": [
    {
     "label": "TGA — UDI healthcare implementation, 31 August 2026",
     "url": "https://www.tga.gov.au/"
    }
   ],
   "related": [
    "/policy/cybersecurity-in-connected-devices/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "mexico-youth-mental-health-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31m",
   "jurisdiction": "Mexico",
   "body": "Presidency / Secretaría de Salud",
   "actionType": "PROGRAM LAUNCH",
   "lifecycle": "NATIONAL PROGRAM — NOT A STATUTORY ENTITLEMENT",
   "title": "Mexico launches \"El ABC de las emociones\", a national youth mental-health strategy",
   "what": "A preventive, community and territorial strategy for ages 14–18 centred on secondary and upper-secondary schools. Comparative counterpoint to crisis-line-centred policy: prevention before the crisis contact.",
   "sources": [
    {
     "label": "Presidencia de México — 31 August 2026",
     "url": "https://www.gob.mx/presidencia"
    }
   ],
   "related": [
    "/bills/ab-1956/",
    "/policy/the-988-crisis-line-and-the-crisis-care-continuum/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "russia-order-662-effective-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31q",
   "jurisdiction": "Russia",
   "body": "Roszdravnadzor",
   "actionType": "FINAL RULE",
   "lifecycle": "EFFECTIVE",
   "title": "Roszdravnadzor Order 662 takes effect: inspection checklists for medical-device circulation oversight",
   "what": "Order No. 662 of 22 July 2026, registered with the Ministry of Justice 19 August as No. 87896, official publication 0001202608200005, effective 31 August. Checklists span testing, clinical use, manufacture, service, transport, storage and sale. Meets the Russia rule: order number, signing date, MinJust registration, publication identity and effective date all established.",
   "sources": [
    {
     "label": "pravo.gov.ru — publication 0001202608200005",
     "url": "http://publication.pravo.gov.ru/document/0001202608200005"
    },
    {
     "label": "Roszdravnadzor — Order 662 listing",
     "url": "https://roszdravnadzor.gov.ru/"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "ema-prac-meeting-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31l",
   "jurisdiction": "European Union",
   "body": "EMA — PRAC",
   "actionType": "COMMITTEE MEETING",
   "lifecycle": "MEETING IN PROGRESS — OUTCOMES NOT YET AVAILABLE",
   "title": "EMA pharmacovigilance committee meets 31 August – 3 September; agenda published, outcomes pending",
   "what": "Agenda items are questions before the committee, not recommendations. Outcomes are checked from 3 September; a committee recommendation is itself distinct from EMA or Commission final action.",
   "sources": [
    {
     "label": "EMA — PRAC agenda, 31 August 2026",
     "url": "https://www.ema.europa.eu/en/committees/prac"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "verifiedOn": "2026-08-31"
  },
  {
   "id": "ab2575-senate-passage-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z1",
   "jurisdiction": "California",
   "body": "California Senate",
   "actionType": "FLOOR ACTION",
   "lifecycle": "SENATE PASSED — RETURNED TO ASSEMBLY FOR CONCURRENCE",
   "title": "AB 2575 passes the Senate 21–10 on 31 August and is ordered to the Assembly for concurrence in the 28 August amendments",
   "what": "The Senate read the bill a third time and passed it, AYES 21 NOES 10, on the amended 28 August text. Because the Senate amended the bill after Assembly passage, the Assembly must concur before legislative passage is complete. Passed Senate and passed Legislature are not synonyms. The Assembly concurrence roll call is not established on the record read at the 1 September snapshot.",
   "sources": [
    {
     "label": "California Legislative Information — AB 2575 bill history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260AB2575"
    }
   ],
   "related": [
    "/bills/ab-2575/",
    "/california/governors-desk/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/bills/ab-2575/"
  },
  {
   "id": "ca-session-concluded-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z0",
   "jurisdiction": "California",
   "body": "California Legislature",
   "actionType": "SESSION MILESTONE",
   "lifecycle": "FINAL PASSAGE PERIOD CONCLUDED",
   "title": "California 2025–2026 Regular Session: final passage period concluded; enrollment and gubernatorial phase underway",
   "what": "The last day for each house to pass bills has passed. Adjournment decides no individual measure: each bill carries only the state its own newest authoritative action establishes, from failed through chaptered.",
   "sources": [
    {
     "label": "California Legislature — session calendar",
     "url": "https://www.senate.ca.gov/"
    }
   ],
   "related": [
    "/california/governors-desk/",
    "/calendar/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/california/governors-desk/"
  },
  {
   "id": "sb942-presented-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z2",
   "jurisdiction": "California",
   "body": "California Legislature / Governor",
   "actionType": "ENROLLMENT AND PRESENTMENT",
   "lifecycle": "ENROLLED AND PRESENTED TO GOVERNOR",
   "title": "SB 942 (civil detainees: bill of rights) enrolled and presented to Governor Newsom at 6:00 PM on 31 August",
   "what": "The enrolled bill contains an urgency provision providing for immediate effect if enacted. Urgency describes what happens on enactment; it does not make an unsigned bill operative. Not law unless and until gubernatorial action occurs.",
   "sources": [
    {
     "label": "California Legislative Information — SB 942 (2025–2026) history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260SB942"
    }
   ],
   "related": [
    "/bills/sb-942/",
    "/california/governors-desk/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/bills/sb-942/"
  },
  {
   "id": "sb503-presented-2026-08-30",
   "date": "2026-08-30",
   "sort": "2026-08-30z1",
   "jurisdiction": "California",
   "body": "California Legislature / Governor",
   "actionType": "ENROLLMENT AND PRESENTMENT",
   "lifecycle": "ENROLLED AND PRESENTED TO GOVERNOR",
   "title": "SB 503 (health care services: artificial intelligence) enrolled and presented to the Governor at 6:00 PM on 30 August",
   "what": "The bill addresses identification, mitigation, monitoring and reporting duties for AI systems used in clinical decision-making or health-care resource allocation with known or reasonably foreseeable risks of biased outputs. The enrolled text has not been read at this snapshot; duty-by-duty analysis is withheld until it is.",
   "sources": [
    {
     "label": "California Legislative Information — SB 503 history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260SB503"
    }
   ],
   "related": [
    "/bills/sb-503/",
    "/reform/ai-and-the-practice-of-medicine/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/bills/sb-503/"
  },
  {
   "id": "sb1023-presented-2026-08-30",
   "date": "2026-08-30",
   "sort": "2026-08-30z0",
   "jurisdiction": "California",
   "body": "California Legislature / Governor",
   "actionType": "ENROLLMENT AND PRESENTMENT",
   "lifecycle": "ENROLLED AND PRESENTED TO GOVERNOR",
   "title": "SB 1023 (injectable PrEP reimbursement) enrolled and presented to the Governor at 6:00 PM on 30 August",
   "what": "Would require plans already covering injectable HIV pre-exposure prophylaxis to offer reimbursement through the outpatient prescription-drug benefit. Presentment starts the gubernatorial clock and creates no plan obligation.",
   "sources": [
    {
     "label": "California Legislative Information — SB 1023 history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260SB1023"
    }
   ],
   "related": [
    "/bills/sb-1023/",
    "/reform/policy-lab/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/bills/sb-1023/"
  },
  {
   "id": "who-bdbv-ervebo-guidance-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01z",
   "jurisdiction": "Global",
   "body": "WHO",
   "actionType": "EMERGENCY NORMATIVE GUIDANCE",
   "lifecycle": "GUIDANCE ISSUED — RESEARCH-PROTOCOL USE RECOMMENDED",
   "title": "WHO: evidence insufficient to establish clinically meaningful Ervebo protection against Bundibugyo virus; off-label use recommended only within research protocols",
   "what": "WHO issued updated emergency normative guidance on potential use of licensed Ervebo during Bundibugyo virus disease outbreaks. Its conclusion is that available evidence is insufficient to establish clinically meaningful protection in humans against BDBV. WHO therefore recommends off-label use only within research protocols, alongside generating efficacy evidence through a ring randomised controlled trial, continuing proven outbreak-control measures, communicating uncertainty, and accelerating BDBV-specific vaccines and therapeutics. Ervebo is a licensed Ebola vaccine; licensure for one orthoebolavirus is not established efficacy against another.",
   "sources": [
    {
     "label": "WHO — emergency normative guidance on Ervebo use in Bundibugyo virus disease outbreaks, 1 September 2026",
     "url": "https://www.who.int/publications"
    }
   ],
   "related": [
    "/intelligence/outbreak-state/",
    "/policy/real-world-evidence-in-regulatory-decisions/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/who-bundibugyo-ervebo-guidance-2026-09-01/"
  },
  {
   "id": "who-drc-ebola-trials-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01y",
   "jurisdiction": "Global",
   "body": "WHO",
   "actionType": "OUTBREAK R&D BRIEFING",
   "lifecycle": "CLINICAL INVESTIGATION UNDERWAY",
   "title": "WHO Member States briefing: three vaccines and three therapeutics reported in trials in the DRC Ebola response",
   "what": "Trial activity is not established efficacy and not product availability. The outbreak state, the PHEIC state, licensed countermeasures, off-label research use, vaccine trials, therapeutic trials and the WHO recommendation are tracked as separate dimensions precisely so research activity is never read as an available product.",
   "sources": [
    {
     "label": "WHO — high-level Member States briefing, 1 September 2026",
     "url": "https://www.who.int/news"
    }
   ],
   "related": [
    "/intelligence/outbreak-state/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/who-drc-ebola-trials-2026-09-01/"
  },
  {
   "id": "who-europe-responsible-ai-report-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01x",
   "jurisdiction": "European Region",
   "body": "WHO/Europe",
   "actionType": "EVIDENCE REPORT",
   "lifecycle": "PUBLISHED — NOT BINDING",
   "title": "WHO/Europe publishes the Report of the Knowledge Community on Responsible AI in Health",
   "what": "The report identifies persistent barriers: fragmented datasets, biased datasets, governance gaps, unclear accountability and AI-literacy deficits. Its central proposition is that governance readiness, rather than speed of deployment, should be the measure of responsible AI progress. A normative evidence report, not a regulation and not a binding standard.",
   "sources": [
    {
     "label": "WHO/Europe — Report of the Knowledge Community on Responsible AI in Health, 1 September 2026",
     "url": "https://www.who.int/europe/publications"
    }
   ],
   "related": [
    "/reform/ai-governance-readiness/",
    "/reform/ai-and-the-practice-of-medicine/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/who-europe-responsible-ai-health-2026-09-01/"
  },
  {
   "id": "uk-mhra-health-bill-amendments-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01w",
   "jurisdiction": "United Kingdom",
   "body": "UK Government / MHRA",
   "actionType": "GOVERNMENT AMENDMENTS TABLED",
   "lifecycle": "AMENDMENTS TABLED — PARLIAMENTARY SCRUTINY PENDING",
   "title": "UK Government tables three Health Bill amendments affecting the MHRA statutory framework",
   "what": "The amendments concern medicines and device information-sharing powers, making medicines and device legislation easier to update, and authority supporting development of a future medical-device licensing regime. Tabled government amendments are not enacted law: no regulation is in force and no device licensing regime is established.",
   "sources": [
    {
     "label": "UK Parliament — Health Bill amendment paper, 1 September 2026",
     "url": "https://bills.parliament.uk/"
    }
   ],
   "related": [
    "/intelligence/uk-mhra-health-bill/",
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/uk-mhra-health-bill-amendments-2026-09-01/"
  },
  {
   "id": "cms-rhtp-hawaii-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01v",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "PROGRAM IMPLEMENTATION",
   "lifecycle": "ANNOUNCED — GRANT AWARD",
   "title": "CMS announces $58 million for Hawaii under the Rural Health Transformation Program",
   "what": "The award is described as supporting ambulance replacement, emergency communications, healthcare workforce, infrastructure, technology and rural access. Grant implementation, not rulemaking and not enforcement. Hawaii joins Arkansas, Virginia, Georgia, Alaska and Ohio in the state implementation record.",
   "sources": [
    {
     "label": "CMS — Rural Health Transformation Program announcement, 1 September 2026",
     "url": "https://www.cms.gov/newsroom"
    }
   ],
   "related": [
    "/intelligence/rural-health-transformation/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/cms-rhtp-hawaii-2026-09-01/"
  },
  {
   "id": "hhs-live-real-life-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01u",
   "jurisdiction": "United States",
   "body": "HHS",
   "actionType": "PUBLIC-HEALTH GUIDANCE / EDUCATION",
   "lifecycle": "PUBLISHED — EDUCATIONAL, NOT A BINDING CLINICAL GUIDELINE",
   "title": "HHS holds the Live Real Life symposium on children’s screen use and announces clinician continuing education",
   "what": "HHS announced clinician continuing education carrying 1.5 AMA PRA Category 1 Credits for the advisory and 1 additional credit for the toolkit, with family-facing educational materials. Educational and implementation material: it is not characterised here as a binding clinical guideline, and no KPSGILL recommendation is derived from it without evidence review.",
   "sources": [
    {
     "label": "HHS — Live Real Life symposium and clinician education materials, 1 September 2026",
     "url": "https://www.hhs.gov/press-room"
    }
   ],
   "related": [
    "/reform/policy-lab/",
    "/patient-education/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/hhs-child-screen-use-2026-09-01/"
  },
  {
   "id": "fda-pfas-devices-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01t",
   "jurisdiction": "United States",
   "body": "FDA",
   "actionType": "SCIENTIFIC / REGULATORY COMMUNICATION",
   "lifecycle": "COMMUNICATION UPDATED — NO RECALL, NO NEW RULE",
   "title": "FDA updates its PFAS-in-medical-devices material and adds a new FAQ",
   "what": "FDA distinguishes fluoropolymers used in medical devices from the PFAS compounds commonly discussed in environmental contamination, and states that fluoropolymers are important in devices including catheters, cardiovascular implants, tubing and wound dressings. Not a recall, not a new approval, not a prohibition and not a final rule.",
   "sources": [
    {
     "label": "FDA — PFAS in medical devices, updated 1 September 2026",
     "url": "https://www.fda.gov/medical-devices"
    }
   ],
   "related": [
    "/policy/pfas-and-medical-devices/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/fda-pfas-medical-devices-2026-09-01/"
  },
  {
   "id": "australia-health-literacy-framework-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01s",
   "jurisdiction": "Australia",
   "body": "Australian Government",
   "actionType": "NATIONAL POLICY FRAMEWORK",
   "lifecycle": "PUBLISHED — FRAMEWORK, NOT STATUTE",
   "title": "Australia launches its first National Health Literacy Framework",
   "what": "The framework addresses people’s ability to find, understand, evaluate and use health information and to interact effectively with health systems, and expressly links low health literacy with delayed care, greater hospital use, poor chronic-disease management, medication errors and avoidable hospitalisation. A strategy framework, not a statute or regulation.",
   "sources": [
    {
     "label": "Australian Government Department of Health — National Health Literacy Framework, 1 September 2026",
     "url": "https://www.health.gov.au/"
    }
   ],
   "related": [
    "/policy/health-literacy-as-infrastructure/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/australia-national-health-literacy-framework-2026-09-01/"
  },
  {
   "id": "nhs-flu-campaign-phase1-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01r",
   "jurisdiction": "United Kingdom",
   "body": "NHS England",
   "actionType": "PROGRAM IMPLEMENTATION",
   "lifecycle": "IN EFFECT — PHASE ONE",
   "title": "NHS England begins phase one of the 2026 flu vaccination campaign",
   "what": "Initial eligible groups include children, pregnant women and certain at-risk children; additional adult groups begin primarily on 1 October. Implementation of a national vaccination programme, not a legislative reform.",
   "sources": [
    {
     "label": "NHS England — 2026 flu campaign, 1 September 2026",
     "url": "https://www.england.nhs.uk/news/"
    }
   ],
   "related": [
    "/patient-education/understanding-immunizations-guide-vaccines-adults-/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/nhs-england-flu-campaign-2026-09-01/"
  },
  {
   "id": "australia-iqhp-orientation-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01q",
   "jurisdiction": "Australia",
   "body": "Australian Government",
   "actionType": "IMPLEMENTATION MATERIAL",
   "lifecycle": "PUBLISHED",
   "title": "Australia publishes orientation resources for internationally qualified health professionals and their supervisors",
   "what": "Material on orientation to the Australian health system for internationally qualified practitioners. Tracked as workforce and licensure comparison, not as a regulatory change.",
   "sources": [
    {
     "label": "Australian Government Department of Health — IQHP orientation resources, 1 September 2026",
     "url": "https://www.health.gov.au/"
    }
   ],
   "related": [
    "/policy/interstate-licensure-limits/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/australia-iqhp-orientation-2026-09-01/"
  },
  {
   "id": "tga-respiratory-device-list-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01p",
   "jurisdiction": "Australia",
   "body": "TGA",
   "actionType": "POST-MARKET SAFETY MONITORING UPDATE",
   "lifecycle": "LIST UPDATED",
   "title": "TGA adds eight ARTG entries to its list of ventilator, CPAP and BiPAP devices unaffected by foam-material concerns",
   "what": "A list of devices reported as unaffected, not a recall of the listed products. Post-market surveillance record connected to the Philips foam history.",
   "sources": [
    {
     "label": "TGA — ventilator, CPAP and BiPAP devices unaffected list, updated 1 September 2026",
     "url": "https://www.tga.gov.au/"
    }
   ],
   "related": [
    "/policy/pre-market-vs-post-market-surveillance/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T13:36:00-07:00",
   "recordUrl": "/records/tga-respiratory-devices-2026-09-01/"
  },
  {
   "id": "ab2575-assembly-concurrence-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z9",
   "jurisdiction": "California",
   "body": "California Assembly",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "LEGISLATIVE PASSAGE COMPLETE",
   "recordUrl": "/records/ab2575-assembly-concurrence-2026-08-31/",
   "title": "AB 2575 completes legislative passage: Assembly concurs in Senate amendments 43–12 after Senate passage 21–10",
   "what": "The Assembly took the measure without reference to file and concurred in the 28 August Senate amendments, 43–12. Combined with Senate passage 21–10 the same day, legislative passage is complete. In four days the bill moved from a refused passage vote through reconsideration, amendment, Senate passage and concurrence — enrollment and presentment are the next recorded states, and neither is established here.",
   "sources": [
    {
     "label": "California Legislative Information — AB 2575 history and Assembly floor record",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260AB2575"
    }
   ],
   "related": [
    "/bills/ab-2575/",
    "/california/governors-desk/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "ab1199-assembly-concurrence-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z8",
   "jurisdiction": "California",
   "body": "California Assembly",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "LEGISLATIVE PASSAGE COMPLETE",
   "recordUrl": "/records/ab1199-assembly-concurrence-2026-08-31/",
   "title": "AB 1199 (health care provider credentialing) completes legislative passage: Assembly concurrence 62–0",
   "what": "The Assembly concurred in Senate amendments 62–0, following a 13–0 Health Committee recommendation on 27 August. The unresolved concurrence recorded at the earlier snapshots is now resolved. Not law; enrollment and presentment are the next recorded states.",
   "sources": [
    {
     "label": "California Legislative Information — AB 1199 history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260AB1199"
    }
   ],
   "related": [
    "/bills/ab-1199/",
    "/reform/credentialing-modernization/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "sb903-senate-concurrence-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z7",
   "jurisdiction": "California",
   "body": "California Senate",
   "actionType": "LEGISLATIVE PASSAGE",
   "lifecycle": "LEGISLATIVE PASSAGE COMPLETE",
   "recordUrl": "/records/sb903-senate-concurrence-2026-08-31/",
   "title": "SB 903 (AI and the practice of therapy) completes legislative passage: Senate concurrence 40–0, ordered to enrolling",
   "what": "The Senate concurred in Assembly amendments 40–0 and ordered the measure to engrossing and enrolling. The exact state is legislative passage complete with enrolling underway — not presented to the Governor, which is a separate recorded event.",
   "sources": [
    {
     "label": "California Legislative Information — SB 903 history",
     "url": "https://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml?bill_id=202520260SB903"
    }
   ],
   "related": [
    "/bills/sb-903/",
    "/reform/ai-and-the-practice-of-medicine/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "canada-generic-review-prioritization-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01z9",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "REGULATORY PROCESS REFORM",
   "lifecycle": "ANNOUNCED — IN EFFECT FOR REVIEW ORDER",
   "recordUrl": "/records/canada-generic-review-prioritization-2026-09-01/",
   "title": "Health Canada restructures generic-drug review: prioritisation for access and shortage relevance, capped response extensions, and targeted backlog flexibility",
   "what": "Health Canada states it is not meeting performance standards for some generic submissions because of volume and complexity, and announced three coordinated changes: prioritisation of submissions that improve access, reduce supply disruption, address shortage-related harms or introduce a first generic; a capped extension process for deficiency responses (90 days, one extension request, maximum 90 further days, 180 total); and targeted flexibility for certain Review-2 submissions already beyond performance targets. The agency states expressly that scientific standards, regulatory requirements and approval criteria are unchanged — prioritisation changes review order only.",
   "sources": [
    {
     "label": "Health Canada — notices on generic drug submission prioritisation, extension policy and Review 2 flexibility, 1 September 2026",
     "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products.html"
    }
   ],
   "related": [
    "/records/canada-generic-review-prioritization-2026-09-01/",
    "/policy/generic-drug-regulatory-capacity/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "canada-domestic-manufacturing-pilot-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01z8",
   "jurisdiction": "Canada",
   "body": "Health Canada",
   "actionType": "CONSULTATION OPENED",
   "lifecycle": "CONSULTATION — PILOT PROPOSED, NOT ESTABLISHED",
   "recordUrl": "/records/canada-domestic-manufacturing-pilot-2026-09-01/",
   "title": "Health Canada consults on a pilot prioritising certain generic submissions involving domestic manufacturing",
   "what": "A consultation on review-order priority, not a new approval route. The agency states expressly that the proposed pilot does not create a separate approval pathway and does not lower regulatory requirements. The policy question it raises is whether supply-chain resilience should affect regulatory review priority when the scientific standard is identical.",
   "sources": [
    {
     "label": "Health Canada — consultation on domestic manufacturing prioritisation pilot, 1 September 2026",
     "url": "https://www.canada.ca/en/health-canada/programs.html"
    }
   ],
   "related": [
    "/records/canada-domestic-manufacturing-pilot-2026-09-01/",
    "/policy/generic-drug-regulatory-capacity/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "doj-fraud-division-healthcare-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01z7",
   "jurisdiction": "United States",
   "body": "U.S. Department of Justice",
   "actionType": "ENFORCEMENT ORGANISATION",
   "lifecycle": "DIVISION OPERATING — PRIORITIES STATED",
   "recordUrl": "/records/doj-fraud-division-healthcare-2026-09-01/",
   "title": "DOJ restates the national Fraud Division’s enforcement priorities, health care among them",
   "what": "A 1 September release references the national Fraud Division and identifies health care as an enforcement priority alongside public trust and financial integrity, internal revenue, global trade and corporate misconduct. The division’s creation is an earlier event: the action date is the controlling launch date, and 1 September is only the date this restatement was discovered. Stated organisational priority is not evidence of wrongdoing by any provider.",
   "sources": [
    {
     "label": "U.S. Department of Justice — release referencing the national Fraud Division, 1 September 2026",
     "url": "https://www.justice.gov/news"
    }
   ],
   "related": [
    "/records/doj-fraud-division-healthcare-2026-09-01/",
    "/enforcement/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "cms-home-health-comments-closed-2026-08-31",
   "date": "2026-08-31",
   "sort": "2026-08-31z6",
   "jurisdiction": "United States",
   "body": "CMS",
   "actionType": "COMMENT PERIOD CLOSED",
   "lifecycle": "COMMENT PERIOD CLOSED",
   "recordUrl": "/records/cms-home-health-comments-closed-2026-08-31/",
   "title": "CY 2027 Home Health PPS proposed rule: comment period closed 5:00 PM EDT, 31 August",
   "what": "The rule required comments no later than 5:00 PM EDT on 31 August 2026. At the 1 September snapshot the window is closed; the rule proceeds to final rulemaking. The row moves to concluded and leaves the open-window count — it is not deleted.",
   "sources": [
    {
     "label": "Federal Register — CY 2027 Home Health Prospective Payment System proposed rule",
     "url": "https://www.federalregister.gov/"
    }
   ],
   "related": [
    "/calendar/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  },
  {
   "id": "russia-orders-effective-2026-09-01",
   "date": "2026-09-01",
   "sort": "2026-09-01z6",
   "jurisdiction": "Russia",
   "body": "Ministry of Health / Roszdravnadzor",
   "actionType": "FINAL RULE EFFECTIVE",
   "lifecycle": "EFFECTIVE",
   "recordUrl": "/records/russia-orders-effective-2026-09-01/",
   "title": "Previously verified Russian health orders 434н and 540н take effect 1 September 2026",
   "what": "Both instruments reach their stated effective date. The lifecycle transitions from pending-effective to effective; no compliance consequence beyond the terms of each order is inferred. Order 696н remains a separate 1 October transition on the verified record.",
   "sources": [
    {
     "label": "pravo.gov.ru — official publication records",
     "url": "http://publication.pravo.gov.ru/"
    }
   ],
   "related": [
    "/intelligence/global-regulatory-operations/"
   ],
   "verifiedOn": "2026-09-01",
   "snapshot": "2026-09-01T21:00:00-07:00"
  }
 ],
 "lastExtended": "2026-08-19",
 "standingApproval": {
  "desk": "enforcement",
  "grantedBy": "Kanwar Partap Singh Gill, MD",
  "grantedOn": "2026-08-17",
  "scope": "Enforcement-desk records may publish live on verification to primary source, with approved:true, without a per-record approval step. Corrections to already-published records are noted inline as corrections.",
  "limits": "Does not extend to patient-education articles or to policy articles, which remain per-article approvals in the portal."
 },
 "medicalBoardRule": {
  "effectiveFrom": "2026-01-01",
  "instruction": "Owner instruction, 17 August 2026: select Medical Board of California actions may be included in weekly updates for events from 1 January 2026 onward.",
  "selectionCriteria": [
   "Only actions the Board itself has posted: accusation, decision, suspension order, public letter of reprimand.",
   "The document type is named in the record; an accusation is labelled an allegation and never reported as discipline.",
   "Aggregate counts only from a Board report or agenda item, never assembled by counting website entries.",
   "Petitions to revoke probation and interim suspension orders are recorded as pending, with their disposition appended when it issues.",
   "Public letters of reprimand are removed from the Board's site ten years after the effective date under Bus. & Prof. Code § 2027; a record citing one notes the removal date."
  ],
  "sources": [
   {
    "label": "Medical Board of California — Enforcement",
    "url": "https://www.mbc.ca.gov/Enforcement/"
   },
   {
    "label": "Medical Board of California — Enforcement documents and document types",
    "url": "https://www.mbc.ca.gov/Enforcement/Enforcement-Documents.aspx"
   },
   {
    "label": "Medical Board of California — disciplinary process",
    "url": "https://www.mbc.ca.gov/Enforcement/Disciplinary-Process.aspx"
   },
   {
    "label": "Medical Board of California — disciplinary action alerts subscription",
    "url": "https://www.mbc.ca.gov/Resources/Publications/Alerts.aspx"
   }
  ],
  "status": "Rule published 17 August 2026. No individual Board action appears here: an action enters this record only from a document the Board itself has posted."
 },
 "horizon": {
  "note": "Dates already fixed beyond the window. Published so a reader can see what is scheduled without treating a schedule as a present duty.",
  "items": [
   {
    "date": "2026-09-03",
    "what": "TGA consultation on proposed changes to the Therapeutic Goods Advertising Code closes",
    "jurisdiction": "Australia",
    "source": {
     "label": "TGA — consultation listing",
     "url": "https://www.tga.gov.au/news/whats-new"
    }
   },
   {
    "date": "2026-09-04",
    "what": "TGA consultation on the Required Advisory Statements for Medicine Labels (RASML) closes",
    "jurisdiction": "Australia",
    "source": {
     "label": "TGA — consultation listing",
     "url": "https://www.tga.gov.au/news/whats-new"
    }
   },
   {
    "date": "2026-09-11",
    "what": "TGA consultation on adopting 11 international scientific guidelines closes",
    "jurisdiction": "Australia",
    "source": {
     "label": "TGA — consultation listing",
     "url": "https://www.tga.gov.au/news/whats-new"
    }
   },
   {
    "date": "2026-09-14",
    "what": "TGA consultation on automated decision-making for changes to listed medicines closes",
    "jurisdiction": "Australia",
    "source": {
     "label": "TGA — consultation listing",
     "url": "https://www.tga.gov.au/news/whats-new"
    }
   },
   {
    "date": "2026-12-04",
    "what": "NPDB merges One-Time Query and Continuous Query into NPDB Query",
    "jurisdiction": "United States",
    "source": {
     "label": "NPDB — query merger",
     "url": "https://npdb.hrsa.gov/hcorg/queryMerge.jsp"
    }
   },
   {
    "date": "2027-01-01",
    "what": "CMS-0057-F: four FHIR APIs required of impacted payers",
    "jurisdiction": "United States",
    "source": {
     "label": "CMS — CMS-0057-F",
     "url": "https://www.cms.gov/priorities/key-initiatives/burden-reduction/interoperability/policies-and-regulations/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f"
    }
   },
   {
    "date": "2027-01-01",
    "what": "CY 2027 Physician Fee Schedule policies would take effect if finalised",
    "jurisdiction": "United States",
    "source": {
     "label": "CMS — CMS-1848-P",
     "url": "https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1848-p"
    }
   },
   {
    "date": "2027-03-26",
    "what": "European Health Data Space: general date of application; Commission implementing acts due",
    "jurisdiction": "European Union",
    "source": {
     "label": "European Commission — Regulation (EU) 2025/327",
     "url": "https://health.ec.europa.eu/publications/regulation-eu-2025327-european-health-data-space-and-amending-directive-201124eu-and-regulation-eu_en"
    }
   },
   {
    "date": "2027-10-01",
    "what": "CMS-0062-P proposed compliance date for drug prior-authorization duties (proposal only)",
    "jurisdiction": "United States",
    "source": {
     "label": "CMS — CMS-0062-P",
     "url": "https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p"
    }
   },
   {
    "date": "2027-12-01",
    "what": "EU AI Act high-risk obligations apply",
    "jurisdiction": "European Union",
    "source": {
     "label": "European Commission — Article 50 guidelines",
     "url": "https://digital-strategy.ec.europa.eu/en/library/guidelines-transparency-obligations-providers-and-deployers-ai-systems"
    }
   },
   {
    "date": "2027-12-31",
    "what": "Medicare telehealth flexibilities expire absent further legislation",
    "jurisdiction": "United States",
    "source": {
     "label": "Congress.gov — H.R. 7148",
     "url": "https://www.congress.gov/bill/119th-congress/house-bill/7148"
    }
   },
   {
    "date": "2029-03-26",
    "what": "EHDS: secondary-use rules and cross-border exchange of patient summaries and ePrescriptions apply",
    "jurisdiction": "European Union",
    "source": {
     "label": "European Commission — Regulation (EU) 2025/327",
     "url": "https://health.ec.europa.eu/publications/regulation-eu-2025327-european-health-data-space-and-amending-directive-201124eu-and-regulation-eu_en"
    }
   },
   {
    "date": "2031-03-26",
    "what": "EHDS: imaging, laboratory results and discharge reports join the exchange obligation",
    "jurisdiction": "European Union",
    "source": {
     "label": "European Commission — Regulation (EU) 2025/327",
     "url": "https://health.ec.europa.eu/publications/regulation-eu-2025327-european-health-data-space-and-amending-directive-201124eu-and-regulation-eu_en"
    }
   }
  ],
  "asOf": "2026-08-18"
 },
 "jurisdictions": [
  "California",
  "United States",
  "Canada",
  "United Kingdom",
  "European Union",
  "Australia"
 ],
 "statusChecks": {
  "note": "Things a reader may assume changed in 2026, which did not. Each is verified to the instrument's own record, and each is a reason not to plan against a headline.",
  "asOf": "2026-08-18",
  "items": [
   {
    "subject": "HIPAA Security Rule overhaul",
    "state": "PROPOSED",
    "detail": "The notice of proposed rulemaking published in the Federal Register on 6 January 2025 (comments closed 7 March 2025) has not been finalised. HHS states that while the rulemaking is under way, the current Security Rule remains in effect. Encryption of ePHI, multi-factor authentication and the other headline controls are proposals, not duties.",
    "sources": [
     {
      "label": "Federal Register — HIPAA Security Rule NPRM (6 January 2025)",
      "url": "https://www.federalregister.gov/documents/2025/01/06/2024-30983/hipaa-security-rule-to-strengthen-the-cybersecurity-of-electronic-protected-health-information"
     },
     {
      "label": "HHS — NPRM fact sheet",
      "url": "https://www.hhs.gov/hipaa/for-professionals/security/hipaa-security-rule-nprm/factsheet/index.html"
     }
    ]
   },
   {
    "subject": "EU MDR and IVDR targeted revision",
    "state": "PROPOSED",
    "detail": "The Commission's simplification proposal of 16 December 2025 is before the Parliament and Council. Nothing in it — including the proposed treatment of AI-enabled devices under sectoral rules rather than the AI Act's high-risk regime — applies today.",
    "sources": [
     {
      "label": "European Commission — medical devices, new regulations",
      "url": "https://health.ec.europa.eu/medical-devices-new-regulations/overview_en"
     }
    ]
   },
   {
    "subject": "Great Britain device regime",
    "state": "PROPOSED",
    "detail": "The draft Medical Devices (Amendment) Regulations 2026 are a draft statutory instrument. UKCA and the existing recognition arrangements continue until Parliament acts.",
    "sources": [
     {
      "label": "GOV.UK — MHRA invites views",
      "url": "https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation"
     }
    ]
   },
   {
    "subject": "Medicare Advantage prior-authorization legislation",
    "state": "PROPOSED",
    "detail": "H.R. 3514 was reported out of committee on 15 July 2026. A reported bill is not law and no plan year duty arises from it.",
    "sources": [
     {
      "label": "Congress.gov — H.R. 3514",
      "url": "https://www.congress.gov/bill/119th-congress/house-bill/3514"
     }
    ]
   }
  ],
  "lastSweep": "2026-08-17",
  "sweepWindow": "2026-08-07 to 2026-08-17",
  "sweepNote": "Ten-day sweep run 17 Aug 2026. Seven records added, all seven verified to primary source. One external claim was rejected and later resolved: the Medical Board agenda could not be confirmed from the Board's meeting-details page (which still reads 'schedule yet to be determined') and was only verified once the owner supplied the direct agenda PDF URLs. The lesson is recorded on the record itself.",
  "scopeExpansion": "Six verticals adopted 17 August 2026. Architecture and taxonomy in place; records enter only on primary-source verification. Approximately 60 candidate claims queued above — none published on the strength of the recommendation memo."
 },
 "counts": {
  "records": 147
 },
 "verticals": {
  "note": "Six standing intelligence verticals adopted 17 August 2026 by owner command. Every record carries one or more vertical tags; pages are views over this array, never separate stores.",
  "adopted": "2026-08-17",
  "list": [
   {
    "id": "medi-cal",
    "title": "Medi-Cal Change Ledger",
    "scope": "Eligibility, immigration-status populations, benefits, pharmacy, dental, asset limits, ECM and Community Supports, Prop 35, MCO tax, effective dates.",
    "depth": "deepest state layer"
   },
   {
    "id": "medicare-cms",
    "title": "Medicare / CMS Deadline and Payment Tracker",
    "scope": "Physician fee schedule, MA, Part D, prior authorisation, drug price negotiation, home health, ACOs, provider enrollment, No Surprises Act IDR."
   },
   {
    "id": "clinical-frontier",
    "title": "FDA Clinical Frontier",
    "scope": "Only approvals that introduce a new modality, mechanism or meaningful clinical shift — not routine approvals.",
    "note": "Kept structurally separate from the enforcement ledger so the institutional-action taxonomy keeps its meaning."
   },
   {
    "id": "trial-radar",
    "title": "Trial Radar",
    "scope": "Prime and base editing, CAR-T in autoimmunity, in-vivo CAR-T, xenotransplantation, stem-cell replacement, mRNA cancer vaccines, regenerative neurology, individualised therapeutics.",
    "rule": "Investigational status stated on every record. No investigational agent is described as therapy."
   },
   {
    "id": "ai-atlas",
    "title": "AI Specialty Impact Atlas",
    "scope": "Every major specialty: 2026 baseline, rolling 2029 and 2031 forecast, liability question, human role that remains.",
    "rule": "Forecasts are labelled forecasts and never rendered as established fact."
   },
   {
    "id": "docket",
    "title": "Health-Care Litigation and Enforcement Docket",
    "scope": "Criminal, civil FCA, OIG audit, CMS program integrity, state AG, board action, coverage, Medicaid, FDA, research-funding, corporate-practice and AI/privacy litigation.",
    "rule": "Procedural posture on every entry. Charge is not conviction; settlement is not admission; improper payment is not fraud; deferral is not disallowance."
   }
  ]
 },
 "lifecycleModel": {
  "standard": "editorial/global-monitoring-standard-2026-08-17.md",
  "adopted": "2026-08-17",
  "states": [
   "WATCHING",
   "PROPOSED",
   "OPEN FOR COMMENT",
   "COMMENT PERIOD CLOSED",
   "FINAL",
   "EFFECTIVE",
   "CURRENT",
   "DELAYED",
   "STAYED",
   "ENJOINED",
   "VACATED",
   "SUPERSEDED",
   "WITHDRAWN",
   "CLOSED",
   "HISTORICAL",
   "CORRECTED"
  ],
  "rule": "Exactly one current state per record. State changes are appended with dates, never overwritten."
 },
 "actionTaxonomy": {
  "adopted": "2026-08-17",
  "types": [
   "PROPOSED RULE",
   "FINAL RULE",
   "GUIDANCE",
   "LEGISLATION",
   "COURT FILING",
   "COURT ORDER",
   "INJUNCTION",
   "APPELLATE DECISION",
   "CRIMINAL CHARGE",
   "GUILTY PLEA",
   "CONVICTION",
   "ACQUITTAL",
   "CIVIL COMPLAINT",
   "FALSE CLAIMS ACT SETTLEMENT",
   "ADMINISTRATIVE ACTION",
   "BOARD DISCIPLINE",
   "AUDIT",
   "PROGRAM-INTEGRITY FINDING",
   "PAYMENT DEFERRAL",
   "DISALLOWANCE",
   "WARNING LETTER",
   "RECALL",
   "SAFETY COMMUNICATION",
   "FDA APPROVAL",
   "ACCELERATED APPROVAL",
   "CLINICAL TRIAL RESULT",
   "RESEARCH POLICY",
   "FUNDING ACTION",
   "PUBLIC MEETING",
   "CONSULTATION",
   "BENEFIT POLICY CHANGE",
   "ELIGIBILITY CHANGE"
  ],
  "neverCollapse": [
   "audit is not fraud",
   "charge is not conviction",
   "settlement is not admission",
   "proposal is not law",
   "guidance is not statute",
   "society recommendation is not government requirement",
   "deferral is not disallowance",
   "improper payment is not fraud"
  ]
 },
 "priorityModel": {
  "adopted": "2026-08-17",
  "levels": [
   "P0 URGENT",
   "P1 LEAD",
   "P2 IMPORTANT",
   "P3 WATCH",
   "P4 ARCHIVE"
  ],
  "axes": [
   "physicianImpact",
   "patientImpact",
   "californiaRelevance",
   "nationalRelevance",
   "clinicalImportance",
   "financialImportance",
   "regulatoryImportance",
   "immediacy",
   "novelty",
   "futureSignificance"
  ],
  "note": "Scores are internal. Priority may govern placement on a live page; the score itself is never published."
 },
 "cadence": {
  "adopted": "2026-08-17",
  "runs": {
   "A": "Monday — comprehensive reset",
   "B": "Wednesday — delta only",
   "C": "Friday — enforcement, litigation, research",
   "D": "Sunday — reconciliation and global horizon"
  }
 },
 "generated": "2026-08-30",
 "snapshotCutoff": "2026-09-01T21:00:00-07:00",
 "previousSnapshot": "2026-09-01T13:36:00-07:00",
 "linkRule": "recordUrl is the canonical destination for this event and is what every current surface links to. related[] holds secondary analysis links and is never used as the primary destination where recordUrl exists. recordUrl is stored explicitly and never derived from the record id — several ids diverge from their record slugs."
}